**EMORY UNIVERSITY SCHOOL OF MEDICINE**

Revised: 6/26/22

# 1. Name: Laurence S. Sperling, MD, FACC, FACP, FAHA, FASPC

### 2. Current Emory Office Address: The Emory Clinic

Center for Heart Disease Prevention

Executive Park

### 1605 Chantilly Drive, NE

### Atlanta, Georgia 30324

Telephone: (404)778-2722 Fax: (404)325-2796

3. E-mail Address: lsperli@emory.edu

4. Citizenship: U.S.

5. Current Titles and Affiliations:

1. Academic appointments:

1. Primary appointments:

2009-present Professor of Medicine, Division of Cardiology

Emory University School of Medicine

2018-present endowed Katz Professor in Preventive Cardiology

2. Joint (Secondary) Appointment:

2014-present Professor of Global Health

Hubert Department of Global Health

Rollins School of Public Health at Emory University

3. Visiting Professorship:

December 2, 2016- January 5, 2017

National Heart and Lung Institute

The Faculty of Medicine at Imperial College, London, UK

b. Clinical appointments:

1997-present Founder of the Center for Heart Disease Prevention, Emory Healthcare

1997-2019 Director of the Center for Heart Disease Prevention, Emory Healthcare

2019-present Founder and Director of Emory Cardiovascular Prevention Network

c. Other administrative appointments:

1997-2014 Founder and Director of the HeartWise Risk Reduction Program

1999-2011 Associate Director, Cardiovascular Disease Fellowship Program at Emory

2003-present Founder and Co-Director of LDL Apheresis Program, Emory University Hospital

2007-2019 Appointed by the Dean as Society Advisor for Medical Student Education – Emory University School of Medicine

2011-2018 Appointed by the Dean to Emory Center for Experiential Learning Advisory Group (ExCEL advisory group for medical education)

2019- Million Hearts Executive Director, Division for Heart Disease and Stroke Prevention, Centers for Disease Control and Prevention, Center for Medicare and Medicaid Services

(Intergovernmental Personnel Act Agreement)

6. Previous Academic and Professional Appointments:

1994-1997 Coordinator of House Physicians, Wesley Woods Hospital, Atlanta, GA

1994-1995 Substitute Physician, Occupational Health Clinic, Center for Disease Control, Atlanta, GA

1997-2004 Assistant Professor of Medicine, Division of Cardiology, Emory University

2004-2009 Associate Professor of Medicine, Division of Cardiology,

Emory University

## 2000-2006 Medical Director, *Staying Aloft* Cardiovascular Risk Program for Delta pilots

2000-2007 Medical Director, *Intervent Atlanta*

2003-2004 Appointment to the Research Participation Program at the Centers for Disease Control and Prevention, National Immunization Program administered by the Oak Ridge Institute for Science and Education - related to investigation of cardiovascular complications of smallpox vaccine

7. Licensures/Boards:

Medical License Georgia, 1990

8. Specialty Boards:

1992 Diplomate of American Board of Internal Medicine

1998 Diplomate of ABIM (Cardiovascular Disease)

2008 Recertification in ABIM CV Disease

2018 Recertification in ABIM CV Disease

# 9. Education:

#### 1985 Emory College, Atlanta, GA BA, Psychology

1989 Emory University School of Medicine MD, Medicine

10. Postgraduate Training:

1989-1990 Intern in Medicine Emory University

Juha Kokko, MD, PhD

1990-1992 Resident in Medicine Emory University

Juha Kokko, MD, PhD

1992-1993 Chief Resident in Medicine Emory University Hospital

Juha Kokko, MD, PhD

1993-1995 Vascular Biology Research Emory University

Fellow Marschall Runge, MD, PhD

Patrick Delafontaine, MD

1995-1997 Clinical Cardiology Fellow Emory University

R. Wayne Alexander, MD, PhD

1997 Coronary EBCT Certification LifeTech, Nashville, TN

Tracy Callister, MD

2008 Graduate of the Woodruff Leadership Academy

Emory Healthcare (mentor: Dean Tom Lawley)

2016 Cognitively-Based Compassion Training (through Emory-Tibet Partnership) Geshe Lobsang Tenzin Negi, PhD

2019 Cognitively-Based Compassion Training Intensive, Drepung Loseling Monastery, Geshe Lobsang Tenzin Negi, PhD

11. Committee Memberships:

a. National and International:

2003 Leaders of Emerging Science of Lipid Management, Co-Chair of Mid-Atlantic Working Group

2003-2006 Appointed to the American College of Cardiology (ACC) Education Strategic Directions Committee (Working Group on Live Programs)

2006-2010 Member of the AHA Clinical Council in Cardiology (Membership/ Communications committee Council on Clinical Cardiology)

2008-present ACC Strategic Directions Committee focusing on the convergence of Type 2 Diabetes and Cardiovascular Disease

2009-2012 ACC Prevention of Cardiovascular Disease Committee

2009-2010 Elected to the Sudden Cardiac Arrest Foundation Board of Directors

2011 American Board of Internal Medicine Practice Improvement Module Expert panel for Preventive Cardiology

2012- Treasurer of the American Society of Preventive Cardiology

2012- Chair of the American College of Cardiology Foundation Cardiometabolic working group

2012- Chair of the National Cardiometabolic Quality Care Alliance (American College of Cardiology, American Association of Clinical Endocrinologists, National Minority Quality Forum)

2013-2014 member of American Heart Association’s Genomics & Translational Biology Epi & Observational Epi-Clinical (GTOE-CL) Peer Review Committee

2013 Invited founding member of The Familial Hypercholesterolemia Consortium working group

2013 Invited participant in the Global CVD Prevention Leadership meeting/group (Rome, Italy)

2013-2014 President-Elect, American Society for Preventive Cardiology

2013 Steering committee member, Familial Hypercholesterolemia Summit

2014- Representative on the International Council of Cardiovascular Prevention and Rehabilitation (ICCPR)

2014- Member of the Diabetes Collaborative Registry Research and Publications Subcommittee of The American College of Cardiology’s National Cardiovascular Data Registry (NCDR)

2014-2016 President, American Society for Preventive Cardiology

2014- ASPC Liaison to the Leadership Committee of the American Heart Association’s Epidemiology & Prevention Council

2013- Delegate of the World Heart Federation Global Alliance for CVD Prevention in Clinical Practice, Leadership committee

2014- Founding member of CROSS-Europe CV Collaboration

2014-2016 Member of the American College of Cardiology’s Population Health Policy and Health Promotion Committee

2015- Member of the AHA Predictors of CVD committee, Cardiovascular Genome-Phenome Study

2016- Appointed to 2nd term as member of ACC Population Health Policy and Health Promotions Committee

2015- Member scientific executive committee, Chairman, section of Preventive Cardiology, International Academy of Cardiology

2016- Member of the Alliance for Patient Access, Physicians Cardiovascular Disease working group

2016-2018 Immediate Past-President American Society for Preventive Cardiology

2016 Invited participant, American College of Cardiology LDL: Address the Risk Think Tank

2016 Invited participant, Familial Hypercholesterolemia Global Summit, Dallas, TX

2017- Invited member of the Writing Group for the 2018 ACC/ AHA Guidelines on the Management of Blood Cholesterol

2017 Co-Chair of ACC Diabetes and Cardiovascular Risk Roundtable, Heart House, Washington, D.C.

2017 Member of Steering Committee- Familial Hypercholesterolemia Global Summit

2016-2018 American Society for Preventive Cardiology

a. Chair of Nominating & Awards Committee

b. Chair Congress Abstract Review Committee

c. Chair Past Presidents Advisory Committee

2018 Chair of the World Heart Federation Writing Group- Roadmap for the Prevention of CVD in People with Diabetes

2018 Co-Chair of the ACC Diabetes and Cardiovascular Risk Roundtable 2, Heart House, Washington, D.C.

2019 Member of Steering Committee, 7th Familial Hypercholesterolemia Global Summit

2019- Chair of the Million Hearts Cardiac Rehabilitation Collaborative

2019- Member of United States Tobacco Control Steering Committee under the U.S. Surgeon General

2020- Special Advisor to the World Heart Federation Global COVID-19 Study

2020- Special Advisor to the World Heart Federation Use Heart for Cardiovascular Disease and Diabetes Project

2020 American Society for Preventive Cardiology, Chair Early Career Abstract Award Committee

2020 Invited Participant, ACC Virtual Roundtable in LDL-C Lowering Therapies: The Changing Lipid Landscape

2020 CDC Subject Matter Expert, Strategies to Update NHANES Cholesterol Measurements

2020 Invited Expert Working Group member, CMS Measure 22 / 317: Screening for High Blood Pressure and Follow-up Documented

2020 Invited Expert Working Group member, CMS Measure 347 / 438: Statin therapy for the Prevention and Treatment of Cardiovascular Disease

2020 National Association of Community Health Centers (NACHC) Preventing Heart Attacks and Strokes (PHAS) Steering Committee

2020 Member of Detection and Treatment Group, American Heart Association National PAD Action Plan, Activating Health Care Systems

2020 Chair, National Million Hearts Cardiac Rehabilitation Think Tank; Advancing New Care Models

2020 Member, American College of Cardiology Applied Health Innovation Consortium; Virtual Summit

2020 Reviewer / Counsel to the Surgeon General’s Call to Action to Control Hypertension

2020 Chair, Federal Hypertension Control Leadership Council (AHRQ, CDC, CMS, FDA, HRSA, IHS, NHLBI, NINDS, ODPHP, OMH, ONC, OWH, OSG)

2020 Member of the Familial Hypercholesterolemia Surveillance Collaborative Group

2021 Faculty for American College of Cardiology Cardiovascular Overview and Board Prep 2021

2021 Co-Chair, Million Hearts Cardiac Rehabilitation Innovation Model Test Work Group

2021 Invited participant, NHLBI Stakeholder Meeting, Prevention of CVD in Patients with Psoriasis and Psoriatic Arthritis (CP3 Study): Bridging the Evidence to Practice Gap

2021 Invited member American Society for Preventive Cardiology Writing Group: Core Components, Key Attributes, and Effective Models of Clinical Preventive Cardiology Programs

2021 American College of Cardiology Fellow in Training Mentor

2021 Clinical Advisor, National Association of Community Health Centers Million Hearts Preventing Heart Attacks and Strokes in Primary Care

2022 Key Opinion Leader, World Heart Vision 2030, World Heart Federation

2022 Steering Committee Member, INTERASPIRE, International Survey of Secondary Prevention of Coronary Heart Disease in Six WHO Regions

2022 Advisor, Centers for Medicare and Medicaid QIO 13th Scope of Work, Chronic Disease Management, Hypertension, Diabetes, CKD Work Group

2022 Planning committee member, CDC Office of Genomics and Precision Public Health Panel Discussion on Implementing Precision and Equitable Public Health Cascade Testing for Genetic Disorders

2022 Invited participant, Health Policy Partnership CVD Thought Leadership Forum

2022 Invited NIH RECOVER Post-Acute Sequelae COVID (PASC) Intervention Prioritization Panel (PIPP) sub-committee on Rehabilitation

2022 member AHA Writing Group, Lipoprotein Apheresis- Utility, Outcomes, and Implementation in Clinical Practice

b. Regional and State:

1999 Member of Georgia Association of Cardiopulmonary Rehabilitation, (Board of Directors and Vice President)

2001-present Member of Southeast Lipid Association

2003-2005 Member of the Georgia Department of Human Resources Tobacco Use Prevention Physician Advisory Board

2011-present Member of the Advisory Board for the Georgia Coalition to Combat Cardiometabolic Syndrome

c. Institutional:

1992-1993 Emory University Hospital Resuscitation Committee

1994-present Associate Member, Emory Medical School Admissions Committee

1999-2001 Member, Intern Applicant Committee, Department of Medicine

1999-2001 Member, Committee to Re-evaluate Teaching Programs, Department of Medicine

1999-2001 Chairman, Physician Retention Committee, Emory Cardiology

2000-2006 Member, Emory Heart Center Board

2000-2006 Co-Chairman, Education and Community Outreach Committee, Emory Heart Center

2000-2015 Member, Cardiology Physician Compensation Committee, Emory Clinic

2007-present Member, Emory Cardiology Clinical Operations Committee

2007-2013 Member, Dean’s Electives subcommittee

2007-present Member, Foundations of Medicine Steering Committee (Healthy Human Subcommittee)

2008-present Member, Heart and Vascular Center Program Team

2008-present Member, Internal Medicine Leadership Group on Quality and Patient Safety

2009-2011 Appointed to Dr. Sanfilipo’s WHSC Healthcare Benefactor Program

2009-2011 Appointed to Dr. Sanfilipo’s WHSC Culture Transformation Group

2009-present Appointed to Internal Medicine School of Medicine Mentoring Program: mentees-

Dr. Allen Dollar

Dr. Jefferson Baer

Dr. Bryan Wells

Dr. Ijeoma Isiadinso

2009-present Appointed to Department of Internal Medicine Ambassador program

2010-present member of MyEmoryHealthcare Development Support team

2010 member of the Search committee for the Director of Physical Therapy for Emory University

2012-2013 Emory Univ. School of Medicine Dean’s CME Advisory Committee

2013 member of the search committee to recruit expert in global health and physical activity to The Hubert Dept. of global Health in the Rollins School of Public Health

2013 co-chair of the search committee to recruit Director of the Physician’s Assistant Program

2013- Member of the Emory University School of Medicine Progress and Promotions committee

2014 invited member of the Emory Healthcare Mobile Cardiac Screening Oversight / Advisory committee

2014 member of the Curricular Content Committee of the Liaison Committee on Medical Education for Emory Univ. School of Medicine

2014 Member of the Emory Healthcare Telemedicine steering committee

2015- Invited member of the Executive Education committee for the Department of Medicine

2015 faculty advisor for Hispanic Health Fair Cardiovascular Risk Assessment

2016 member of Emory Healthcare Clinical Network Strategy Local subcommittee

2016 member of the Emory Healthcare Diabetes Collaborative Care/ Population Health Strategy committee

2017 member of GME Consortium of Champions, Well Being sub-committee

2018 member of Cardiology Clinical Leadership Committee

2018- Emory Pharmacy Health Plan- Strategy Expert Consultant

2019- Faculty volunteer, Emory College Phi Eta Sigma Honor Society Scholarship night

2019 member of Circle of Advisors for Emory Healthcare System Strategy Care Transformation Initiative

2019 faculty lead for Emory Innovation Hub, Sharecare partnership

2019 faculty member, Emory Innovation Hub, Somalogics relationship

2020 Search Committee member, Chief Wellness Officer, Emory Healthcare

2020- Advisory Board, Emory Food Studies and Ethics Program

2020- Member, Emory School of Medicine Alumni Board (Service on Nominating Committee)

2021- NIH (Emory Site) All of Us Trial Clinical Champion

2021- CHOA / EHC GENI (GI, Endocrinology, and Nutrition Innovation) Steering Committee

2022 Founder of Emory Healthcare Evinacumab Infusion Program for People Living with Homozygous Familial Hypercholesterolemia

12. Consultantships:

2003-2004 Appointment to the Research Participation Program at the Centers for Disease Control and Prevention, National Immunization Program administered by the Oak Ridge Institute for Science and Education related to investigation of cardiovascular complications of smallpox vaccine

2008-present Cardiovascular Consultant for the European Malaria Vaccine Initiative

2009-present Appointed consultant to National Vaccine Adverse Event Program

2011-present Consultant to U.S. News and World Report on diets and health; “Best Diets”

2021- Consultant to CDC CISA (Clinical Immunization Safety Assessment) Program reviewing possible COVID vaccination-related myocarditis and pericarditis

2021- Host, Medscape / WebMD InDiscussion Podcast Series on Dyslipidemia

13. Editorships and Editorial Boards:

2007-present Member of Editorial Board for Clinical Cardiology

2007-present Section Editor (Prevention), Current Treatment options in Cardiovascular Medicine

2009 Co-Editor of American College of Cardiology’s Diabetes Self-Assessment Program

2015- Member of the Editorial Board for Cardiovascular Endocrinology and Metabolism

2015-2016 Associate Editor Journal of Clinical Lipidology

2016- Member of the Editorial Board for Clinical Lipidology

2020- Member of the Editorial Board for American Journal of Preventive Cardiology

2020- Section Editor, Current Cardiology Reports, Global Cardiovascular Health

2020- Associate Editor, American Journal of Preventive Cardiology

2021- Guest Associate Editor, JACC Asia

14. Manuscript reviewer:

1999-present Reviewer for ABIM Cardiovascular Disease Exam

2001-present invited reviewer for *Annals of Epidemiology*

2001-present invited reviewer for *Journal of Clinical Outcomes Management*

2001-present invited reviewer for *The American Journal of Cardiology*

2001-present invited reviewer for *Hypertension*

2001-present invited reviewer for *The American Heart Journal*

2001-presentinvited reviewer for *The American Journal of Medicine*

2001-present invited reviewer for *The Journal of the American Medical Association*

2001-present invited reviewer for *Mayo Clinic Proceedings*

*2009-present invited reviewer for Atherosclerosis*

2010-present invited reviewer for Circulation

2004-present ACC abstract reviewer and session Co-Chair

2012-present invited reviewer for The European Journal of Preventive Cardiology

2012-present invited reviewer for The Journal of the American College of Cardiology

2012-present invited reviewer of Vox Sanguinis

2012 Expert scientific reviewer for The NHLBI Adult CV Risk Factor Reduction Guidelines (Risk Assessment report)

2013-present AHA Scientific Sessions abstract reviewer

2013-present invited reviewer for Journal of Clinical Lipidology

2013-present invited reviewer for Circulation Quality and Outcomes

2014 invited reviewer of the 2nd WHO Global Status Report on Non-Communicable Diseases (2014)

2016-present invited reviewer for JACC Imaging

2017-present invited reviewer for JAMA

2020-present invited reviewer for American Journal of Preventive Cardiology

2020-present invited reviewer for Lancet

2020-present invited reviewer for JAMA Cardiology

2020-present invited reviewer for European Heart Journal

15. Honors and Awards:

1982 Alpha Epsilon Upsilon

1983 Emory Medical School Early Acceptance (as college sophomore)

1984 Phi Beta Kappa

1984 Robert T. Jones Scholarship Finalist

1985 Dooley’s Honorary Bodyguard

1987 Lange Book Award for Academic Excellence (Emory Medical School)

1991 Alpha Omega Alpha

1994 NIH Training Grant in vascular/molecular biology

1995 Bristol-Meyers Squibb Fellow’s Abstract Award, American Heart Association

1999 Elected Fellow of the American College of Cardiology

1999 Elected Fellow of the American College of Physicians

2001 American College of Cardiology Harry B. Graf Career Development Award for Heart Disease Prevention

2001 Excellence in Teaching Award at Emory University Hospital presented by graduating Cardiovascular Fellowship Class of 2001

2001 American Heart Association Council on Clinical Cardiology Scholarship for Physical Activity and Public Health

2002 Emory University Attending Teaching Award

2003 Elected as member of Georgia Department of Human Resources Tobacco Use Prevention Physician Advisory Board

2003 Appointed to American College of Cardiology Education Strategic Directions Committee (Working Group on Live Programs)

2004 Mentorship Award for the J. Willis Hurst Internal Medicine Residency Program

2004 Golden Apple Award for Excellence in Teaching at Emory Hospital for the J. Willis Hurst Internal Medicine Residency Program

2006 Selected one of America’s “Top Cardiologists”, Consumers’ Research Council of America

2007 Golden Apple Award for Excellence in Teaching at Emory University Hospital for the J. Willis Hurst Internal Medicine Residency Program

2008 Fellow of Emory Woodruff Leadership Academy

2009 Named as one of Atlanta’s Top Doctors by Atlanta Magazine

2009 Golden Apple Award for Excellence in Teaching at EUH for J. Willis Hurst IM Residency Program

2010 Named as one of Atlanta’s Top Doctors by Atlanta Magazine

2010 Emory College Class of 1985 Luminary

2010 Emory University School of Medicine Dean’s Teaching Award

2011 Featured physician on the first interactive web chat in the history of Emory Healthcare

2011 Honorary Alumni Athlete at the Emory University Victory Bell Celebration for student athletes.

2011 Named as one of Atlanta’s Top Doctors by Atlanta Magazine

2012 Named as one of Atlanta’s Top Doctors by Atlanta Magazine

2012 elected to the Department of Medicine Academy of Medical Educators

2013 President-elect, American Society for Preventive Cardiology

2013 America’s Top doctors, U.S. News & World Reports

2013 Named as one of Atlanta’s Top Doctors by Atlanta Magazine

2014 Named as one of Atlanta’s Top Doctors by Atlanta Magazine

2014 President, American Society for Preventive Cardiology

2014 Recognized as 1 of 23 Emory Healthcare physicians to receive > 90th% patient satisfaction scores for all quarters of 2014 at the Inaugural Dean’s Emory Medicine Program

2015 Emory University, Division of Campus Life CLASS service award, Friends in Faculty Award

2015 Nominee for the Emory Department of Medicine Nanette K. Wenger distinguished Service Award

2015 Named as one of Atlanta’s Top doctors by Atlanta Magazine

2015 Golden Apple Award for Excellence in Teaching at Emory University Hospital

2016 National Doctor’s Day Recognized & Featured Physicians- Emory Medicine

2016 Nationwide Gold Provider (Top 10% Patient Satisfaction)

2016 Nominee for the Emory Department of Medicine Nanette K. Wenger Distinguished Service Award

2016 Named as one of Atlanta’s Top Doctors by Atlanta Magazine

2016 Invited participant, Making Healthcare Better Series: Cardiovascular Health (White House Sept. 9, 2016)

2016 Elected Fellow of the American Society for Preventive Cardiology, Inaugural Fellowship Class

2016 Hong Kong Heart Foundation Lecture, 6th Asian Preventive Cardiology Conference

2017 Emory Campus Life Executive Roundtable invited speaker- Ethical Leadership in a Global Society: Pressing Concerns, New Possibilities

2017 Named as one of Atlanta’s Top Doctors by Atlanta Magazine

2017 Emory University School of Medicine 2017 Alumni Award of Honor

2017 Recognized Educator, Emory Univ. School of Medicine Recognitions Committee

2017 Nominee for the Emory Department of Medicine Nanette K. Wenger Distinguished Service Award

2017 Emory Department of Medicine Distinction as Master Clinician

2017 Cardiovascular Disease Fellowship R. Wayne Alexander Research Mentoring Award

2018 endowed Katz Professor in Preventive Cardiology

2018 Nominee for the Emory Department of Medicine Nanette K. Wenger Distinguished Service Award

2018 Named as one of Atlanta’s Top Doctors by Atlanta Magazine

2018 Recognized with Inaugural Emory Department of Medicine Laurence Sperling Outstanding Faculty Research Mentor Award

2018 Emory University School of Medicine Mentoring Award

2019 Nominee for the American College of Cardiology Distinguished Mentor Award

2019 Named as one of Atlanta’s Top Doctors by Atlanta Magazine

2019 Nominee for the Emory Department of Medicine Nanette K. Wenger Distinguished Service Award

2020 Named as one of Atlanta’s Top Doctors by Atlanta Magazine

2020 Member, Emory University School of Medicine Alumni Board

2021 Nominee for European Society of Cardiology Geoffrey Rose Lecture on Population Science

2021 Named as one of Atlanta’s Top Doctors by Atlanta Magazine

2021 Emory University School of Medicine Distinction as Master Clinician

2021 Emory University School of Medicine Millipub Club, Co-author, 2018 ACC/ AHA/ Multispecialty Cholesterol Guidelines, 2021

2021 Wedding Officiant, 2021

16. Society Memberships:

1997-2003 Member of Georgia Association of Cardiopulmonary Rehabilitation, (Board of Directors and Vice President 1999)

* 1. Member of American Association of Cardiovascular and Pulmonary Rehabilitation

1999 Fellow of the American College of Cardiology

2000 Fellow of the American College of Physicians

2001-present Member of Southeast Lipid Association

2001-present Member of AHA Vascular Biology Working Group

2001-present Member of AHA Council on Clinical Cardiology

2004-present Member of National Lipid Association

2007 Fellow of the American Heart Association

2011-present Member of the American Society for Preventive Cardiology

2012-2013 Treasurer of the American Society of Preventive

Cardiology

2011-2014 Member of the New York Academy of Sciences

2014-2016 President, American Society for Preventive Cardiology

2020- Member of International Society for Cardiovascular Disease Prevention

17. Organization of National or International Conferences:

ACC abstract reviewer and session Co-Chair since 2004

AHA abstract reviewer since 2007

WHF abstract reviewer since 2014

ESC abstract reviewer since 2013

18. Research focus:

*Research efforts focused in preventive cardiology. Diets and cardiovascular disease, utilization of omega 3 fatty acids, and effects of therapeutic lifestyle change on vascular risk. Other investigative pursuits include premature coronary disease and novel lipid therapies.*

*Faculty member of Emory Clinical Cardiovascular Research Institute (ECCRI)*

19. Grant Support:

Current Support:

BARI 2D (Bypass Angioplasty Revascularization Investigation 2 Diabetes) core site at the University of Pittsburgh Medical Center (UPMC). Co principal investigator, BARI 2D study; 10/00-present $5000

Funded Katz Foundation grant for fellowship for preventive cardiology $500,000/yr support over 2 years. 1st fellow recruited, 2009; 2nd funded fellowship July 2015.

Funded Katz Foundation grant to support preventive cardiology education development, $70,000, 2009.

NIH/ NIDDK P30 Diabetes Center Grant (Emory-GA Tech-Morehouse), Georgia Center for Diabetes Translational Research, 2016-

Emory PI, National Familial Hypercholesterolemia Registry, 2017-2020

Emory and Kaiser Permanente Collaborative COVID-19 Study, Co-Investigator, 2020

Previous Support**:**

NY Department ofHealth Grant for Cancer Research, Roswell Park Memorial Institute, Buffalo, NY, “Determination of circulating plasminogen activators in the blood of cancer patients as a diagnostic tool.” Summer 1983

Molecular/Vascular Biology Research Fellowship in Cardiology, Emory University projects (under the supervision of Dr. Marschall Runge), 1993-1994

* + 1. Thrombin receptor regulation in human microvascular endothelial cells

Plasminogen activators as mediators of endothelial cell migration projects (under the supervision of Dr. Patrick Delafontaine), 1994-1995

1. Cloning and sequencing the porcine insulin-like growth factor-1 receptor

2. Role of IGF-1 in restenosis following overstretch balloon injury of porcine coronary arteries

3. Growth factor mediated IRS-1 signal transduction in rat aortic smooth muscle cells

NIH Training Grant in vascular / molecular biology, $40,000, 1994

The effects of physiologic doses of estrogen on conduit and resistance artery endothelial cell function and exercise test results in postmenopausal women with defined coronary artery disease (Emory Estrogen Vascular Study with Dr. Nanette Wenger), 1996 – 1997

Grant for evaluation of the role of MRI in the diagnosis of cardiac sarcoidosis, 1997

Sub-investigator, COURAGE (Clinical Outcomes Using Revascularization and Aggressive Drug Evaluation) trial, 1999-2006

Co-principal investigator, Exercise-induced immunomodulation of vaccine responses in elderly humans, University Research Committee Grant, $29,956, 2000

Premature coronary artery disease: 15 year follow-up in patients under the age of 40 (with Dr. William Weintraub), 2001

Effects of exercise training on endothelial function, nitric oxide, and ecSOD production in human subjects (with Dr. David Harrison), 2001

American College of Cardiology Harry B. Graf Career Development Award for Heart Disease Prevention, $40,000, 2001

STARR (Strategies to Achieve Risk Reduction)- Emory Hospital-based physician small grant award, $10,000, 2001

Prime of Our Lives- Multifaceted educational program for post-menopausal women ($10,000 grant-Pfizer), 2002

Principal investigator for CHESS trial - Comparative HDL Efficacy and Safety Study (Merck), 2003

Co-Investigator of NIH sponsored HF-ACTION Trial (Heart Failure and A Controlled Trial Investigating Outcomes of Exercise Training), 2005-2008. No funding for investigator – only for other personnel

Astra-Zeneca. Principal Investigator for JUPITER trial (study of Rosuvastatin in the Primary Prevention of Cardiovascular Events among subjects with low LDL and elevated C- Reactive Protein), 2005 – 2008. Funding was for personnel but ultimately no funds were received as no subjects were used in trial.

Internal Advisory Board for NHLBI P01 Program Project Grant- Precision Cardiovascular Phenotyping and Pathophysiological Pathways in the CARRS Cohort (Precision-CARRS)

Mentor for Dr. Danny Eapen, Emory FAME (Fostering the Academic Mission of Emory) Grant, Chasing Cholesterol: Investigating the Utility of a Machine Learning Algorithmic Approach to Flag, Identify, Network, and Deliver (FIND) Patients with Familial Hypercholesterolemia within the Emory Healthcare System, 2021-

20. Clinical Service Contributions:

Founder and Director of the Preventive Cardiology section and HeartWise Risk Reduction Program at Emory since 1997

Attending on the Hurst Clinical Cardiology Teaching Service at Emory University Hospital since 1997

Founder and co-Director of the first (only) LDL Apheresis Program in the state of Georgia since 2003

21. Formal Teaching:

1. Medical Student Teaching:

1992-2006 Clinical Methods Physical Exam and Diagnosis Course

* 1. Mentor, Problem-Based Learning Course

1998-2006 Faculty lecture in Clinical Correlations of Medical Biochemistry (M1’s)

2007-present Faculty lecture on Clinical Correlations in Lipids and Atherosclerosis, M1 Cardiology module

* 1. Junior Medicine Clerkship Handbook-wrote Cardiology syllabus

2000-2005 Mentor for M1’s in Patient-Doctor course

2001 Lecture to M1’s on exercise testing/physiology

2002 Faculty lecture in Pathophysiology course (M2’s)

2002-present Course Director for M4 elective in Preventive Cardiology

2002-present Co-Course Director for Emory Cardiology CME programs ESCAPE and Cardiology for the Primary Care Physician

2007-present Appointed by Dean to Osler Society Advisor for Medical student education

2007-present Co-Director of M1 module on Exercise and the Healthy Human

2012 M4 Discovery project mentor/ advisor to Max Weiss, M4

2015 M4 Discovery project mentor/ advisor to Elliot Mahlof, M4

b. Graduate Program

Residency program:

1997-present Faculty supervisor for housestaff in Medicine-outpatient preventive

Cardiology

1997-present Faculty supervisor for housestaff in Family and Preventive Medicine-outpatient clinic

1997-present Faculty supervisor for cardiology fellows - outpatient preventive

Cardiology

1997-present Faculty supervisor for housestaff in Rehab Medicine-cardiac rehab

1. Other categories:

1998-present Faculty supervisor for Physician’s Assistant Program

2000-present Faculty supervisor for Family Nurse Practitioner Program

2017 Spring Semester, University Course, Eating Ethics Guest Lecturer- “Heart Healthy Dietary Patterns: A Recipe for Life”

2019 Spring Semester University Course, Eating Ethics Guest Lecturer- “Heart Healthy Dietary Patterns: A Recipe for Life”

2017 Fall Semester, Emory College Course, HLTH 320, Nutrition and Chronic Disease Guest Lecturer, Heart Healthy Dietary Patterns: A Recipe for Life

22. Supervisory Teaching:

a. Post-doctoral fellows directly supervised:

Joseph I. Miller, III, 2000-2007, currently Director of Preventive Cardiology at Piedmont Hospital

Andrew DeFilippis, 2003-2007, Cardiology Fellow at the John Hopkins Hospital /faculty University of Louisville, KY

Danny Eapen, 2010-2012 (current faculty Emory Healthcare)

Nima Ghasemzadeh, 2012-2014

Jia Shen, 2012- 2014 (current faculty at UCSD)

Heval Mohamed Kelli, 2015-2018

Pratik Sandesara, 2016- 2018

Anurag Mehta, 2018-2019

Devinder Dhindsa, 2018-2019

Brian Cheung, 2021-

Merilyn Varghese, 2021-, AHA Post-doc fellowship; BI Deaconess MC, Harvard, Real-world Cost-effectiveness of cardiac rehabilitation

b. Residency Program

Jason Cole, 2001-2005, currently faculty at University of South Alabama, Mobile, Alabama

Kimberly Champney, 2003-2007, currently Preventive Cardiologist at Northside Hospital, Atlanta, Georgia

Thura Abd, 2008-2011, currently cardiology fellow at John Hopkins

Vimal Ramjee, 2008-2011, currently cardiology fellow at University of Pennsylvania

Ria Nieva, 2008-2011, starting cardiology fellowship at The University of Colorado

23. Lectureships, Seminar Invitations, and Visiting Professorships:

02/2001 Visiting Professor, Columbus Medical Center

06/2003 Visiting Professor, University of South Carolina Charleston

09/2006 Visiting Professor, University of South Florida Tampa

10/2006 Visiting Professor, University of North Carolina Chapel Hill School of Medicine

09/2013 Visiting Professor, University of Alberta, Canada

12/ 2013 Visiting Professor, University of California Irvine

09/ 2014 Visiting Professor, Johns Hopkins Medical Center

11/2014 Anandi L. Sharma Visiting Professorship & Simon Dack, M.D. Memorial Lecturer, Mt. Sinai Medical Center, N.Y.

4/ 2015 Visiting Professor, Weill Cornell Medical Center, N.Y.

6/2015 Visiting Professor, Stony Brook Medical Center, N.Y.

6/2015 Visiting Professorship, Lynchburg General Hospital, Centra Heart & Vascular Center, VA

9/2015 Visiting Professorship, Sulpizio Cardiovascular Center, UC San Diego, CA

12/16-1/17 Visiting Professorship, National Heart & Lung Institute of the Faculty of Medicine at Imperial College, London, UK

5/2017 Visiting Professorship, University of Minnesota Lillehei Heart Institute, Minneapolis, MN

6/2017 Visiting Professorship, University of Nebraska Medical Center, Omaha, NE

6/2018 Visiting Professor, 6th Emory-Tibet Medical Sciences Program,

Men-Tsee-Khang Medical School, Dharamsala, India

Regional invitations:

* + - 1. Cardiology in Primary Care, When to Return to Work and Sex after a Cardiac Event, Atlanta, GA, 1997

1. 20th Annual Georgia Cardiopulmonary Rehab Update, New Frontiers in the Primary Prevention of Coronary Artery Disease, Atlanta, GA, 1998
2. Cardiology in Primary Care, Preparing for Discharge after a Cardiovascular Event, Atlanta, GA 1998
3. Update on Transplantation, Reducing the Risk of Cardiovascular Disease in the Renal Transplant Patient, Savannah, GA, 1999
4. Cardiology in Primary Care, Hyperlipidemia: Current Thoughts and Future Directions, Sea Island, GA, 1999
5. 9th Annual Update in Preventive Medicine, Prevention and Regression of Coronary Artery Disease, Turnersville, GA, 1999
6. Management of Lipoprotein Disorders, Assessment of Coronary Artery Disease, Callaway Gardens, GA, 1999
7. Cardiology in Primary Care, Hyperlipidemia as a Cardiovascular Risk Factor, Atlanta, GA, 1999
8. ACC Visiting Fellowship Program, Cardiovascular Risk Reduction for the Interventional Cardiologist, Atlanta, GA, 1999
9. Emory Updates in Primary Care, Assessment of Coronary Artery Disease, Atlanta, GA, 2000
10. Emory Updates in Primary Care, Prevention of Coronary Artery Disease, Atlanta, GA, 2000
11. Cardiology in Primary Care, Lipid Lowering Agents: Pharmacology and Beyond, Sea Island, GA, 2000
12. Alabama Medical Directors Association Meeting, Hyperlipidemia and Cardiovascular Disease, Sandestin, FL, 2000
13. Georgia Association of Physician Assistant’s 25th Annual Conference, Lipids and Cardiovascular Disease, Jekyll Island, GA, 2000
14. Cardiology in Primary Care, Role of Risk Factors in Coronary Atherosclerosis, Atlanta, GA, 2000
15. Visiting Professor for a Day with Emory, Columbus Medical Center, Columbus, GA, 2001
16. Medical Grand Rounds, Northlake Hospital, New Insights into Lipid Therapy, Atlanta, GA, 2001
17. Merck Regional Consultant’s Meeting, Inflammation in Atherosclerosis, Charleston, SC, 2001
18. The Bays Medical Society Annual Meeting, New Insights into Lipid Therapy, Panama City Beach, FL, 2001
19. 23rd Annual Georgia Cardiopulmonary Rehabilitation Update, New Insights into Lipid Therapy, Callaway Gardens, GA, 2001
20. Cardiology in Primary Care, A Practical, Office-based Approach to Hypertension, Sea Island, GA, 2001
21. Wellstar Health System Cardiology Symposium, Insights from NCEP ATP III and Closing The Treatment Gap, Marietta, GA, 2001
22. Georgia Academy of Family Practice 53rd Annual Meeting, A Practical Office-Based Approach to Hypertension, Cobb, GA, 2001
23. Emory Updates in Primary Care, New Frontiers in Lipids and Atherosclerosis, Atlanta, GA, 2001
24. EPIC (Emory Practical Intervention course), Real World Approach to Coronary Risk Reduction, Atlanta, GA, 2002
25. Emory Symposium on Coronary Atherosclerosis Prevention (ESCAPE), Inflammatory Markers and Atherosclerosis, (Course Co-Director), Sea Island, GA, 2002
26. Medical Grand Rounds, Emerging Concepts in Lipids and Atherosclerosis, Athens Regional Medical Center, Athens, GA, 2002
27. Coronary Calcium Scoring as a Screening Tool: Subclinical Markers of Atherosclerosis, Spartanburg Regional Medical Center, Spartanburg, SC, 2002
28. Leaders of Emerging Science of Lipid Management Southeast Regional Working Group Meeting, Strategies for Educating Special Populations about Cardiovascular Risk, Naples, FL, 2002
29. Cardiology in Primary Care Meeting, Workshop on Management of Lipid Disorders, (Course Co-Director) Atlanta, GA, 2002
30. 37th American Society of Hospital Pharmacists Meeting, Cholesterol-Lowering Agents and the Implications for Diabetics, Atlanta, GA, 2002
31. DeKalb County School Board meeting, New Frontiers in Heart Disease Prevention, Atlanta, GA, 2002
32. Medical Grand Rounds, New Frontiers in Lipids and Atherosclerosis, St. Vincent’s Medical Center, Jacksonville, FL, 2003
33. 24th Annual Georgia Cardiopulmonary Rehabilitation Update, New Frontiers in Heart Disease Prevention, Savannah, GA, 2003
34. Setting the Pace 2003: Emerging Trends for Cardiovascular Nursing, New Frontiers in Heart Disease Prevention, Atlanta, GA, 2003
35. Emory Symposium on Coronary Atherosclerosis Prevention and Education (ESCAPE), Setting the Goals for Lipid Management and the Strategies for Achieving Them (Co-Course Director), Sea Island, GA, 2003
36. Cardiology Grand Rounds, Inflammatory Markers and Atherosclerosis, Medical University of South Carolina, Charleston, SC, 2003
37. Southeast Lipid Association Scientific Forum, How to Run a Successful Lipid Clinic/Preventive Cardiology Center in 2003, Boca Raton, FL, 2003
38. Cardiology in Primary Care, Beyond LDL: What Do We Need to Know about Lipid Lowering? Atlanta, GA, 2003
39. EPIC (Emory Practical Intervention Course) A Real World Approach to Coronary Risk reduction, Atlanta, GA, 2004
40. ESCAPE (Emory Symposium on Coronary Atherosclerosis Prevention and Education), Placing the Recent Lipid Trials in Perspective, Sea Island, GA, 2004
41. ESCAPE (Emory Symposium on Coronary Atherosclerosis Prevention and Education), Exercise/Weight/Diet-How much/How little? (Co-Course Director), Sea Island, GA, 2004
42. 25th Annual Georgia Cardiopulmonary Rehabilitation Meeting, Beyond LDL, Savannah, GA, 2004
43. Cardiology in Primary Care, Lipid Targets and Goals, (Co-Course Director) Atlanta, GA, 2004
44. EPIC 2005, New Approaches to Coronary Risk Reduction, Atlanta, GA, 2005
45. Boca Raton Cardiovascular Summit II. Beyond LDL…, Boca Raton, FL, 2005
46. ESCAPE 2005, Diets and CVD: Assessment of current Evidence, (Co-Course Director), Amelia Island, FL, 2005
47. Cardiology in Primary Care, Beyond LDL…, (Co-Course Director) Atlanta, GA, 2005
48. Georgia Chapter of the American College of Cardiology, Beyond LDL, Reynolds Plantation, GA, 2005
49. CME Symposium-Diagnosis and Treatment of Lipid Disorders. Non-invasive Imaging in the Atherosclerosis. Emory Conference Center, Atlanta, GA, 2006
50. Internal Medicine Update, Diets and CVD: An Evidence-Based Approach, Boca Raton, GL, 2006
51. 10th Annual Day of Cardiology. Diets and CVD. Columbus Medical Center, GA, 2006
52. ESCAPE 2006. LDL: Can We Go Too Low? (Course Director), Amelia Island, FL, 2006
53. Cardiology Grand Rounds/Visiting Professor. Approach to Chronic Angina, University of South Florida, Tampa, 2006
54. Cardiology in Primary Care. What should our goals be for LDL and does it matter how we get there? Atlanta, GA 2006
55. South Miami Heart Center Comprehensive Cardiovascular Conference, Heart Healthy Diet, Coral Gables, FL, 2006
56. Cardiology Grand Rounds/Visiting Professor. Diets and CVD: An Evidence-Based Assessment. UNC Chapel Hill School of Medicine, 2006
57. First Annual Internal Medicine Conference: Heart and Vascular Disease Update. Diets and CVD. Memorial University Medical Center, Savannah, GA, 2007
58. 11th Annual Symposium on The Prevention of Cardiovascular Disease, Heart Health Living: Focus on Diet and Exercise. Coral Gables, FL, 2007
59. 6th Annual Emory ESCAPE meeting. New Approaches to Tobacco Cessation. (Course Director) Amelia Island, FL, 2007
60. 6th Annual Emory ESCAPE meeting. Understanding Omega 3’s Amelia Island, FL, 2007
61. 6th Annual Emory ESCAPE meeting. Psychological Influences in Atherosclerosis. Amelia Island, FL, 2007
62. Emory Comprehensive Update in OBGyn. Diets and Obesity: What is the Evidence? Amelia Island, FL, 2007
63. Cardiology in Primary Care, The Role of Sophisticated Lipid Analysis, Atlanta, GA, 2007
64. NLA Comprehensive Cardiometabolic Risk Reduction Program, The Drivers of Cardiometabolic Risk, Atlanta, GA, 2008
65. 7th Annual ESCAPE meeting (Course Director), Does Size Matter? Role of Advanced Lipid Testing, Amelia Island, FL, 2008
66. 7th Annual ESCAPE meeting, Prehypertension: Detection, Evaluation, and Management, Amelia Island, FL, 2008
67. Invited speaker for The Georgia ACP meeting, Cardiovascular Disease Prevention, Savannah, GA, 2009
68. Invited presentation at 36th South Atlantic Cardiovascular Society Meeting, “New Strategies in Lipid Management: Medical and Surgical Implications,” Isle of Palms, S.C., 2009
69. Course Director of 8th Annual ESCAPE meeting, Amelia Island, FL [Emory Symposium on Coronary Atherosclerosis Prevention and Education],2009

Presentation: “Should We Use CRP on Earth or Just on Jupiter?”

Presentation: “Should We Put Statins in the Water?”

1. Cardiology in Primary Care (Course Director)

HDL, hS-CRP, LP(a): Pieces of the Puzzle?

The patient with Recurrent Chest Pain and Normal Angiograms

Atlanta, GA, 2009

1. Course Director of 9th Annual ESCAPE meeting, Amelia Island, FL, 2010
   1. “Focus on non-HDL Cholesterol: Do the Math”
   2. “Office-based Risk Assessment: Practical Approach”
2. Cardiology in Primary Care (Course Director), Atlanta, GA, 2010
   1. Office-based risk assessment: Practical approach
3. EPIC (Emory Practical Intervention Course), Keys to a better, longer life, Atlanta, GA,2011
4. Course Director of 10th Annual ESCAPE meeting, Amelia Island, FL, 2011
   1. “Diets and CVD: Is there a recipe for success?”
   2. “Omega 3 Fatty Acids and CVD: Is something fishy?”
5. Cardiology in Primary Care (Course Director), Atlanta, Ga 2011
   1. Optimal Lipid Targets (OLT) for the New Era of Cardiovascular Prevention
6. Atlanta Clinical Cardiology Update. Optimal Lipid Targets for the New Era of Cardiovascular Prevention. Atlanta, Ga., 2012
7. Course Director of The 11th Annual ESCAPE meeting, Amelia Island, FL, 2012
   1. Optimal Lipid Targets (OLT) for the New Era of CV Prevention
   2. Keys to a Better, Longer Life
8. St. Josephs Hospital Heart and Vascular Institute Grand Rounds, Optimal Lipid Targets for the new Era of Cardiovascular Prevention, Atlanta, GA, 2012
9. St. Joseph’s Hospital 6th Annual Women and Heart Disease Conference: Evolving Concepts and New Therapies. Moderator, Stone Mountain, GA, 2012
10. Atlanta Clinical Cardiology Update. Time to Focus on Cardiovascular Health (not Disease). Atlanta, Ga. 2013
11. Internal Medicine Update 2013. Time to Focus on Cardiovascular Health (Not Disease). Boca Raton, FL. 2013
12. Dekalb Hospital Grand Rounds, Optimal Lipid Targets for the New Era of Cardiovascular Prevention, Atlanta, GA. 2013
13. Course Director of The 12th Annual ESCAPE meeting, Amelia Island, FL, 2013
    1. Increasing Awareness of & Approach to Familial Hypercholesterolemia
    2. Time to Focus on Cardiovascular Health (Not Disease)
14. Invited speaker, Centers for Disease Control and Prevention, Division of Heart Disease and Stroke Prevention Science Seminar Series, Time to Focus on Cardiovascular Health (Not Disease). Atlanta, GA, 2013
15. Keynote speaker, St. Joseph’s Hospital Reward Your Heart Program. Best Diets. Atlanta, GA, 2013
16. 7th Annual St. Joseph’s Hospital Women and Heart Disease meeting. Diets and Cardiovascular Disease: An evidence-based assessment. Atlanta, GA, 2013
17. Cardiology in Primary Care. The Heart Healthy Diet. Atlanta, GA. 2013
18. Atlanta Clinical Cardiology Update. Treatment of Blood Cholesterol: New Approaches / New Agents. Atlanta. Ga. 2013
19. Georgia ACC APP Meeting. Treatment of Blood Cholesterol: New Approaches / New Agents. Atlanta. Ga. 2014
20. Georgia Leadership in Worksite Wellness and Cardiometabolic Health. National Cardiometabolic Health Initiatives. Ga. 2014
21. Course Director of the 13th Annual ESCAPE meeting, Amelia Island, FL, 2014
    1. HIV and Cardiovascular Risk
    2. Navigating the 2013 ACC/AHA Blood Cholesterol Guidelines
22. South East Lipid Research Conference. Omega 3’s and CVD: Is something fishy? Callaway Gardens, GA. 2014
23. Cardiology in Primary Care. Heart Healthy Diet. Atlanta, GA. 2014
24. Heart and Vascular Institute Grand Rounds. Treatment of Blood Cholesterol: New Approaches / New Agents. Emory St. Joseph’s Hospital. Atlanta, Ga. 2014
25. Primed Meeting Symposium. Meeting the Challenges of Managing Lipids Beyond LDL-C. Fort Lauderdale, Fl. 2015
26. 11th Annual Cardiovascular Symposium at Sarasota Memorial Hospital. Sarasota, FL 2015
    1. Time to Focus on Cardiovascular Health (not CV Disease)
    2. The Heart Healthy Diet
27. 34th EPIC SEC (Emory Practical Intervention Course). Guideline-based and Novel Anti-Atherosclerotic Therapies, Atlanta, GA, 2015
28. Course Director for the 14th Annual ESCAPE meeting, Amelia Island, FL, 2015
    1. Cholesterol goals & Targets: Opportunities for Improvement
    2. Heart Healthy Diet
29. Cardiology for the Primary Care Physician, Emory Conference Center, 2015
    1. Heart Healthy Diet
30. Baptist Health South Florida Obesity Symposium, Miami, FL, 2016
    1. Medical Consequences of Obesity- Metabolic Syndrome & Diabetes
    2. Obesity, Dyslipidemia, and CVD Risk
    3. Preventive Cardiology and the future of cardiovascular medicine: Opportunities for Improvement
31. Cardiovascular Center of Sarasota 12th Annual CV Symposium, Sarasota, FL, 2016
    1. Preventive Cardiology and the future of cardiovascular medicine: Opportunities for Improvement
    2. New approaches to Understanding Cardiometabolic risk
    3. Therapeutic Lifestyle Changes for CVD Prevention
32. 7th Annual AnMEd Health Cardiovascular Symposium. Anderson, S. Carolina, 2016
    1. Living Longer and Better
33. Emory Practical Intervention Course Southeastern Consortium (EPIC-SEC), Atlanta, GA, 2016

Interventional Preventive Cardiology: Perspectives, Pitfalls, and Possibilities

1. Medical Grand Rounds, University of Tennessee College of Medicine Treatment of Blood Cholesterol: New Approach / New Agents. Chattanooga, TN, 2016.
2. Course Director for the 15th Annual ESCAPE meeting, Amelia Island, FL, 2016
   1. Comprehensive Cardiovascular Risk Reduction in the Metabolic Syndrome and Diabetes
   2. Treatment of Blood Cholesterol: New Approaches/ New Agents- Promise of PCSK9 Inhibitors
3. Cardiology for the Primary Care Physician, Emory Conference Center, 2016
   1. The Art of Cardiovascular Risk Assessment
4. 13th Annual Congress on Early Cardiovascular Disease Prevention: Update 2017, Sarasota, FL
   1. Cardiobesity
   2. Comprehensive Cardiovascular Risk Reduction in the Metabolic Syndrome & Diabetes
   3. Living Longer & Better
5. 8th Annual AnMed Health Cardiovascular Symposium, Anderson, SC, 2017
   1. The Art of Cardiovascular Risk Assessment
6. 14th Annual Boca Raton Regional Hospital Internal Medicine Conference, 2017
   1. Preventive Cardiology & the Future of Cardiovascular Medicine: Opportunities for Improvement
7. Emory Practical Intervention Course Southeastern Consortium (EPIC-SEC), Atlanta, GA, 2017
   1. Co-Chair for Symposia on The Evolution of Lipid-Lowering Treatments for Reducing the Burden of Atherosclerosis
   2. Management of Blood Cholesterol 2017: New Approaches / New Agents
8. 16th Annual Emory ESCAPE Cardiovascular Prevention meeting, Amelia Island, FL, 2017
   1. Course Director
   2. PCSK9 Inhibition: Promise and Possibilities
   3. Cardiac Rehabilitation and Secondary Prevention: New Care Models for A New World
9. 9th Annual AnMed Health Cardiovascular Symposium, Anderson, SC. 2018
   1. Preventive Cardiology and the Future of Cardiovascular Medicine: Opportunities for Improvement
10. Emory Practical Intervention Course Southeastern Consortium (EPIC-SEC), Atlanta, GA, 2018
    1. Co-Chair Clinical Cardiology Prevention Symposium
    2. Presentation- “The Era of PCSK9 Inhibition: How Low is Too Low?”
11. Course Director, 17th Annual Emory ESCAPE meeting, Amelia Island, FL, 2018
    1. Non-pharmacologic interventions for Elevated BP
    2. Roundtable: Diets & CV Prevention
    3. Transforming the Heart Team approach to comprehensive CV Prevention in Diabetes

Transforming the Heart Team approach to comprehensive CV Prevention in Diabetes

1. 10th Annual AnMed Health Cardiovascular Symposium, Anderson, SC. 2019
   1. Cardiac Rehabilitation and Secondary Prevention: New Care Models for a New World
2. Georgia Chapter ACC Annual Scientific Meeting. Session Moderator- Diabetes and Cardiovascular Disease. Greensboro, Ga. 2018
3. Georgia Association of Cardiovascular and Pulmonary Rehabilitation Conference, Marietta, Ga, 2019
   1. Reconfiguring Cardiac Rehabilitation and Secondary Prevention: New Care Models for a New World
4. 16th Annual Boca Raton Regional Hospital Internal Medicine Conference, Boca Raton, FL, 2019
   1. Use of Risk Assessment Tools to Guide Decision-Making in the Primary Prevention of ASCVD
5. Emory Practical Intervention Course Southeastern Consortium (EPIC-SEC) Clinical CV Update, Atlanta, GA, 2019
   1. Moderator for 2 Sessions: CV Prevention; New Treatments for CAD
   2. Lessons from the 2018 Cholesterol Guidelines
6. Course Director, 18th Annual Emory ESCAPE meeting, Amelia Island, FL, 2019
   1. Statin Safety and Statin-Associated Side Effects
   2. Approach to CV Risk Assessment: Enhancing and Informing
7. Emory Women’s Heart Center 13th Annual Women & Heart Disease: Evolving Concepts & New Therapies
   1. Lessons from the 2018 Cholesterol Guidelines
8. Georgia Chapter ACC Annual Scientific Session Meeting. Biomarkers for CV Risk Prediction for the Practicing Cardiologist. Greensboro, GA, 2019
9. Emory Practical Intervention Course – Southeastern Consortium- Clinical Cardiovascular Update, 2020
   1. Moderator for Session- MI, Chest Pain, Ischemia, and Cardiovascular Disease in Women
   2. New Lipid Agents
10. A Minute with Mayor Muryn: Heart Health- Virtual Event with the Mayor of Findlay, Ohio, 2020
11. Advancing Million Hearts South Carolina. Virtual Meeting. Million Hearts 2022 Update, 2020
12. Advancing Million Hearts Montana. Virtual Meeting. Million Hearts 2022 Update, 2020

a. Managing Chronic Conditions in the Midst of COVID-19, Moderator

1. 19th Emory ESCAPE meeting (Virtual), Co-Course Director and Moderator, 2021

a. The (Post-COVID) Future of Cardiovascular Disease Prevention

129. President’s Invited Lecture, Southern Thoracic Surgical Association meeting, 2021

a. Impact of COVID-19 on Cardiovascular Care and Cardiovascular Disease Prevention

130. 20th Emory ESCAPE meeting, Co-Course Director and Moderator, Amelia Island, FL, 2022

a. Heart Healthy Dietary Patterns: A Recipe for Life

b. NAFLD: The Heart of the Matter

131. Inaugural Georgia Heart and Vascular Symposium, Braselton, GA, 2022

a. The (Post-COVID) Future of CVD Prevention

Institutional Invitations:

1. Diagnostic Electrocardiography Conference, EKG of Myocardial Infarction, Emory Conference Center, Atlanta, GA, 1996
2. Family Practice Grand Rounds, New Frontiers in the Primary Prevention of Coronary Artery Disease, Grady Hospital, Atlanta, GA, 1998
3. Grady Hospital, Cardiology Grand Rounds, C-Reactive Protein: A Marker for Cardiovascular Risk?, Atlanta, GA, 2000
4. Medical Grand Rounds, Emory University Hospital, Diabetes and Cardiovascular Disease: New and Unresolved Issues, Atlanta, GA, 2001
5. Medical Grand Rounds, Crawford Long Hospital, New Frontiers in Lipids and Atherosclerosis, Atlanta, GA, 2001
6. Cardiology Grand Rounds, Grady Memorial Hospital, Emerging Concepts in Lipids and Atherosclerosis, Atlanta, GA, 2002
7. Medical Grand Rounds, New Frontiers in Preventive Cardiology, The Atlanta Medical Center, Atlanta, GA, 2002
8. Medical Grand Rounds, Inflammatory Markers and Atherosclerosis, Emory University Hospital, Atlanta, GA, 2003
9. Family and Preventive Medicine Grand Rounds, Beyond LDL, Grady Memorial Hospital, Atlanta, GA, 2004
10. Cardiology Grand Rounds, Low Carbohydrate or Low Fat? (Or Somewhere in between): The Current Evidence. Grady Memorial Hospital, Atlanta, GA 2004
11. Medical Grand Rounds, Beyond LDL. St. Joseph’s Hospital, Atlanta, GA, 2004
12. Cardiology Grand Rounds, Cardiac Complications of the Smallpox Vaccine Grady Memorial Hospital, Atlanta, GA, 2005
13. Medical Grand Rounds, Diets and CVD: Assessment of Current Evidence, Hamilton Medical Center, Dalton, GA, 2005
14. Grand Rounds, Emory-Dunwoody Hospital. Diets, Hypertension and CVD: Assessment of Current Evidence, Dunwoody, GA, 2005
15. Emory’s Mini-Medical School, The Healthy Heart, Atlanta, GA, 2005
16. Cardiology Grand Rounds, Diets and Cardiovascular Disease: An Evidence-Based Assessment. Grady Memorial Hospital, Atlanta, GA, 2005
17. Medical Grand Rounds at Emory University Hospital, 55 yo F with Progressive Dyspnea on Exertion and Lower Extremity Edema; Discussant, Atlanta, GA, 2006
18. Cardiology Grand Rounds. LDL: Can We Go Too Low? Grady Memorial Hospital, Atlanta, GA, 2006
19. Cardiology Grand Rounds, Grady Memorial Hospital, Prehypertension: Detection, Evaluation, and Management, Atlanta, GA, 2008
20. Presentation at Emory Internal Medicine Board Review: Lipid Disorders, 2008.
21. Presentation at Grady Memorial Hospital Cardiology Grand Rounds, “Primary Prevention of Cardiovascular Disease, 2009
22. Presentation at Emory Center for Lifelong Learning, “Heart Disease Prevention”, 2009
23. Presentation, Pathology and Laboratory Medicine Grand Rounds, “Advanced Lipid Testing,”, EUH, 2009
24. Presentation at Emory Internal Medicine Board Review: Lipid Disorders, 2009
25. Clinical outcomes and Epi Conference, “Surrogate Markers are Necessary for Clinical Practice and Research”, 2009
26. Presentation at Emory Internal Medicine Board Review: Lipid Disorders, 2010
27. Cardiology Fellow’s Core Conference, Lipid Disorders, 2011
28. Cardiology Fellow’s Core Conference, Lipids, Risk Assessment, Cardiac Rehab, 2012
29. Heart and Vascular Grand Rounds, Time to focus on cardiovascular health (not disease), 2013
30. Grady Memorial Cardiology Grand Rounds, Time to focus on cardiovascular health (not disease), 2013
31. Cardiology Fellow’s Core Conference. Office-based cardiovascular risk assessment: A perspective on the 2013 AHA/ ACC Prevention Guidelines. 2014
32. The Emory Clinic Primary Care Conference. Office-based cardiovascular risk assessment: A perspective on the 2013 AHA/ ACC Prevention Guidelines. 2014
33. Internal Medicine Housestaff Core Curriculum Conference. Office-based CV Risk Assessment: A perspective on the 2013 AHA/ ACC Prevention Guidelines. 2014
34. Emory Clinical Cardiovascular Research Institute Research conference. Office-based CV Risk Assessment: A Perspective on the 2013 ACC/ AHA Prevention Guidelines. 2014
35. Emory-Pfizer Atrial Fibrillation Seminar: Atrial Fibrillation- Diagnosis & Consequences, 2014
36. Department of Medicine Education Community Orientation. Teaching in the Inpatient Environment. 2014
37. Cardiology Fellow’s Core Conference: Treatment of Blood Cholesterol: New Approaches / New Agents, 2015
38. Department of Medicine Education Community Orientation. Teaching in the Inpatient Environment. 2015
39. Emory Specialty Associates for Primary Care Quarterly Best Practice CME lecture/ webinar. Treatment of Blood Cholesterol: New Approaches/ New Agents. 2015
40. 6th Annual Mark Silverman invited lecture. Preventive Cardiology and the Future of Cardiovascular Medicine: Opportunities for Improvement. Grady Memorial Hospital. 2015
41. ACC Cardiosmart Program. Managing Cholesterol. Atlanta, GA. 2015
42. Medical Grand Rounds, Emory University Hospital, Update in Preventive Cardiology, 2016
43. Cardiology Grand Rounds, Emory St. Joseph’s Hospital, Preventive Cardiology & the Future of Cardiovascular Medicine: Opportunities for Improvement, 2016.
44. Cardiology Fellow’s Core Conference: Lipids and Atherosclerosis. 2016
45. Cardiology Fellow’s Core Conference: Cardiovascular Risk Assessment; Comprehensive Risk Reduction in Metabolic Syndrome & Diabetes; Diets and Cardiovascular Disease. 2016
46. Emory Cardiovascular Grand Rounds, Preventive Cardiology & the Future of CV Medicine: Opportunities for Improvement, 2016
47. Emory Department of Medicine, Fellows Educator Development Conference, Teaching in the Inpatient Environment, 2017
48. Emory School of Medicine Society Advisor Grand Rounds, Academic Pursuits as an Extension of Medical Education, 2017
49. Emory University Rollins School of Public Health, Hubert Department of Global Health Seminar, Reconfiguring Cardiac Rehabilitation & Secondary Prevention into a New Care Model for the New World, 2017
50. Cardiology Fellows’ Core Conference: Preventive Cardiology, 2017
51. Emory Alumni Association Lifelong Learning Faculty Webinar: Heart Healthy Diets: A Recipe for Life, 2017
52. Emory Univ. School of Medicine Learning to be Better Teachers Conference, “Academic Pursuits as an Extension of Medical Education”, 2017
53. Presentation to the Emory Employee Council, Health, Wellness, Mindfulness, and Movement. 2018
54. Presentation to the Office of Clinical Research- Research Matters meeting. Health, Wellness, Mindfulness, and Movement. 2018
55. Guest lecture in Cardiovascular Disease Epidemiology, Rollins School of Public Health, Preventive Cardiology & the Future of CV Medicine, 2018
56. Guest lecture in Chronic Disease Prevention and Control (NCDs), Rollins School of Public Health, Cardiac Rehabilitation and Secondary Prevention: New Care Models for a New World, 2018
57. Department of Medicine Mentoring Series: How to Determine your Academic Niche as a Clinician, 2018
58. Guest lecture, Emory College Center for the Study of Human Health, Nutrition and Chronic Disease CHSS-320, Diets and Cardiovascular disease: A Recipe for Life, 2017 and 2018
59. Emory University School of Medicine, Society Advisor Grand Rounds, Health, Well-being, Mindfulness, and Movement. 2018.
60. Emory Monthly Primary Care Forum. The 2018 Cholesterol Guidelines, 2019
61. Emory College Course-Introduction to Predictive Health, predicting Cardiovascular Health and Disease, 2019
62. Guest lecture, Emory Interdisciplinary Studies Course, Eating Ethics, Heart Healthy Dietary Patterns: A Recipe for Life, 2019
63. Invited faculty speaker, Emory Phi Eta Sigma Freshman Honor Society Scholarship night, 2019
64. Guest Lecture, Emory Rollins School of Public Health, Cardiovascular Epidemiology, Preventive Cardiology and the Future of Cardiovascular Medicine: Opportunities for Improvement, 2019
65. Guest lecture, Rollins School of Public Health, Chronic Disease in Global Health, Cardiac Rehabilitation and Secondary Prevention: New Care Models for a New World, 2019
66. Emory Rollins School of Public Health Seminar, The Future of Cardiovascular Disease Prevention, 2019
67. Guest lecture, Emory Interdisciplinary Studies Course, Eating Ethics, Heart Healthy Dietary Patterns: A Recipe for Life, 2020
68. Guest lecture, Rollins School of Public Health, Chronic Disease in Global Health, Cardiac Rehabilitation and Secondary Prevention: New Care Models for a New World, 2020
69. Guest lecture, Rollins School of Public Health, Cardiovascular Disease Epidemiology, The Future of Cardiovascular Prevention, 2020
70. Emory Cardiology Grand Rounds, The (Post-COVID) Future of Cardiovascular Medicine, 2020
71. Emory Goizueta Alzheimer’s Disease Research Center Webinar, The State of Men’s Health. Focus on Men’s Cardiovascular Health, 2020
72. Emory School of Medicine M1 Class lecture, Integrated Human Physiology Module, Exercise and the Healthy Human; Director SOM Virtual Fun Run Week, 2020
73. Emory-Clifton Rotary Club 3rd Annual Polio & Health Symposium: Overcoming the Challenges of COVID-19 to Achieve a Global Health Legacy.

The (Post-COVID) Future of Cardiovascular Disease Prevention, 2020.

1. Emory University Emeritus College Luncheon Colloquium, Heart Healthy Dietary Patterns: A Recipe for Life, 2020
2. CDC DHDSP / NCCDPHP Moderated Panel Discussion- Racial Discrimination, Resilience, and Cardiovascular Risk, 2020
3. Conversations with CDC Authors: Social Determinants of Health- Disparities in Influenza Vaccination- Opportunity to Extend Cardiovascular Prevention to Millions of Hearts, 2020
4. Guest lecture, Rollins School of Public Health, Genetic Epidemiology, Familial Hypercholesterolemia: From Gene discovery to Population Health Impact, 2021
5. Guest lecture, Rollins School of Public Health, Cardiovascular Epidemiology 543. The (Post-COVID)Future of CVD Prevention, 2021
6. Emory University Hospital Midtown, Medicine Faculty Peer Mentoring Group, How to Determine Your Academic Niche as a Clinician, 2021
7. CDC DHDSP Science Office: CVD 101- Enduring Video for Staff Orientation, 2021
8. Emory University Alumni Global 60+ Network Series, Cardiovascular Health: Living Longer and Better, 2022
9. Guest lecture, Emory Rollins School of Public Health, Cardiovascular Epidemiology 543. The (Post-COVID) Future of CVD Prevention, 2022

24. Invitations to National or International Conferences:

1. AACVPR 12th Annual National Meeting, New Frontiers in Preventive Cardiology Session, Pathogenesis of Atherosclerosis, Dallas, TX, 1997
2. 12th Annual Kentucky Coalition of Nurse Practitioner Conference, Managing Lipid Disorders, Louisville, KY, 2000
3. Merck Regional Consultant’s meeting, Inflammation in Atherosclerosis, Toronto, Canada, 2001
4. Merck Regional Consultant’s meeting, New insights into Lipid Therapy, Panama City Beach, FL, 2001
5. Leaders of Emerging Science of Lipid Management Mid-Atlantic Regional Working Group Meeting. Low-Carbohydrate and Mediterranean Diets: Assessment of the Current Evidence, Washington, DC, 2003
6. AACVPR 18th Annual Meeting, The Primary Prevention of Cardiovascular Disease: Focus on the Guidelines, Kansas City, MO, 2003
7. Current Trends in Cardiovascular Disease VIII, Beyond LDL (Keynote Speaker), Spokane, WA, 2004
8. 15th Annual Convention ACC Puerto Rico Chapter, New Frontiers in the Management of Hypertension and Dyslipidemia, San Juan, Puerto Rico, 2004
9. 145th Annual Session for The American Dental Association, Distinguished Speaker Series, Men’s Conference. Risk Reduction in Cardiovascular Disease, Orlando, FL, 2004
10. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, Cardiac events following smallpox vaccination, Washington, DC, 2004
11. Council of Science Editors Meeting, Readers Speak Out, Atlanta, GA, 2005
12. Johns’ Hopkins CME at Sea, workup of Suspected Coronary Disease: Assessment of Cardiovascular Risk; Cholesterol Management; Anticoagulant And Antiplatelet Therapy, Holland America (MASDAM), 2005
13. Nephrology and Transplantation Update 2005 for NKFG, Beyond LDL, Ponte Vedra Beach, FL, 2005
14. LDL Apheresis, Hoxworth Blood Center, University of Cincinnati, 2006
15. 55th Annual ACC meeting. Role of Inflammation and the Immune System in Atherosclerosis, Atlanta, GA, 2006
16. 24th Annual Central American Congress of Cardiology. Primary Prevention and CAD, Havana, Cuba, 2006
17. 39th Annual ACC Foundation New York Cardiovascular Symposium. Diets and Overweight: An Evidence-Based Assessment, New York, NY, 2006
18. 56th Annual American College of Cardiology meeting, Which Diet is Best for Obesity? New Orleans, LA, 2007
19. ACC Pri-med Initiative: Clinical Focus on Cardiovascular Risk, Atlanta, GA, 2008
20. World Congress of Cardiology, Which diet is best for obesity? Buenos Aires, Argentina, 2008
21. SCAI Strategies for Success XVI meeting, The Economics of a Preventive Cardiology Program for your Practice, Cayman Islands, BWI, 2008
22. National AHA meeting, The View from Framingham: The Basis of ATP3 and ATP3.5, New Orleans, LA, 2008
23. Invited speaker for the AHA Quality of Care and Outcomes Research Conference, Surrogate Outcomes in clinical research and Practice, Washington, D.C, 2009
24. Invited speaker for the American Heart Association’s spotlight series on Mixed Dyslipidemias, 2009
25. Invited participant 8th Annual Nitroglycerin Symposium, Hamburg, Germany, 2009
26. Meet the Expert Presentation at National American College of Cardiology meeting, “Educational Initiatives of the ACC”, Orlando, Fl., 2009
27. National Lipid Association meeting, Non-HDL: Do the Math……, Washington, D.C., 2009
28. HIV DART meeting, HIV, Inflammation, and Cardiovascular Disease, Cabo San Lucas, Mexico, 2010
29. 60th American College of Cardiology meeting, Lipid Management in the Elderly, New Orleans, LA, 2011
30. 6th Annual Europrevent meeting, Diets and Cardiovascular Disease: An Evidence-based Assessment, Geneva, Switzerland, 2011
31. 7th American College of Cardiology / Sociedad Espanola de Cardiologia Official Joint Meeting. Dyslipidemia challenges: optimal LDL, HDL, and triglycerides. Washington, D.C., 2011
32. Evolving Challenges in Promoting Cardiovascular Health (sponsored by the New York Academy of Sciences). Optimal Lipid Targets (OLT) for the New Era of Cardiovascular Prevention. Barcelona, Spain, 2011
33. 11th Annual Cardiology Conference at Mohonk. The New York Cardiological Society. Diets and CV Disease: An Evidence-Based Assessment ,New Paltz, N.Y., 2012
34. 38th Annual Tutorials in the Tetons Conference. Office-based cardiovascular risk assessment; Optimal Lipid targets in the new era of cardiovascular prevention. Jackson, WY, 2012
35. American Society of Preventive Cardiology Update 2012. Office-based cardiovascular risk assessment; Increasing awareness and approach to the patient with familial hypercholesterolemia. Chicago, Illinois, 2012
36. 51st Romania National Congress of Cardiology. Global Challenges in cardiovascular prevention: The polypill or public health? Sinaia, Romania, 2012
37. 51st Romania National Congress of Cardiology. From the American “dream” to Romanian reality: Focus on cardiovascular prevention. Sinaia, Romania, 2012.
38. 51st Romania National Congress of Cardiology. From prevention to intervention- to be or not to be? Prevention in the U.S. measure for measure. Sinaia, Romania, 2012.
39. 11th Annual Cardiovascular Disease Prevention International Symposium. The optimal diet for cardiovascular health. Miami, Fl. 2013
40. 11th Annual Cardiovascular Disease Prevention International Symposium. The role of exercise in cardiovascular disease risk reduction: Does it make a difference? Miami, Fl. 2013
41. Invited presenter. Familial Hypercholesterolemia Roundtable. New Orleans, LA. 2013
42. Panelist in session: Managing statin side effects and complications, American College of Cardiology meeting. San Francisco, CA. 2013
43. GE Medical Council Conference. Time to focus on Cardiovascular Health (Not Disease). Atlanta, GA. 2013
44. Europrevent 2013. Optimal Lipid Targets for the New Era of Cardiovascular Prevention. (Poster Judge) Rome, Italy. 2013
45. Inaugural U.S. Familial Hypercholesterolemia Summit. Steering committee member and moderator of opening session. Annapolis, MD. 2013
46. Cardiology Divisional Rounds. Time to focus on cardiovascular health (not Disease). Mazankowski Alberta Heart Institute, Alberta, Canada. 2013
47. 8th Cardiometabolic Health Congress. Moderator of session- Cardiometabolic risk in racial/ethnic minorities: unique aspects and practical solutions. Presentation- Lifestyle Management. Boston, MA. 2013
48. Kansas City Southwest Clinical Society’s 91st Annual Clinical Care Conference. Time to focus on cardiovascular health (not disease). Kansas City, KS. 2013
49. Cardiology Grand Rounds, University of California Irvine. Office-based cardiovascular risk assessment: A perspective on the 2013 AHA/ ACC Prevention Guidelines. 2013
50. Preventive Cardiology Seminar. UC Irvine. Time to focus on cardiovascular health (not disease). 2013
51. Preventive Cardiology of Orange County meeting, California chapter of the ACC. Office-based cardiovascular risk assessment: A perspective on the 2013 AHA/ ACC Prevention Guidelines. 2013
52. 50th Research Day-The Heart of Medicine, invited speaker. Ross University School of Medicine. Time to focus on CV Health (not CV Disease). Dominica, WI. 2014
53. 63rd American College of Cardiology meeting, Washington, D.C. 2014
    1. Prevention Intensive: Sorting out Risk Prevention in 2014- Prevention Risk Assessment Tools: Practice Changers
    2. Co-Chair and moderator of International session- Conquering Healthcare Challenges in the Emerging World

54. World Congress of Cardiology. Melbourne, Australia. 2014

a. Overview of non-traditional biomarkers in CVD risk assessment

b. Co-Chair: Global patterns and health consequences of

cardiometabolic risk factors

* 1. Co- Chair: Use of risk factor surveys in health policy development

1. 3rd Annual American Society for Preventive Cardiology Cardiovascular Disease Prevention Conference. Boca Raton, FL. 2014
   1. Familial Hypercholesterolemia: Hidden in Plain Sight-Current and Novel Approaches
   2. Participant in ACC/ AHA Guideline Dialectic
2. International Academy of Cardiology19th World Congress on Heart Disease, Boston MA, 2014
   1. Invited member of scientific executive committee
   2. Co-chair of Plenary session on CVD Prevention and Risk factors
   3. Time to Focus on CV Health (not CV Disease)
3. European Society of Cardiology Congress, Barcelona Spain, 2014
   1. Familial Hypercholesterolemia: Hidden in Plain Sight; Current Treatment Approaches
   2. Moderated poster judge: Addressing the challenges of cardiac rehabilitation
   3. Rapid fire oral abstract session chair: Diabetes under siege
4. Visiting Professor, Johns Hopkins Ciccarone Prevention Center. Baltimore, MD. 2014
   1. Familial Hypercholesterolemia: Hidden in Plain Sight- Diagnosis, Management, and Focus on LDL Apheresis
5. Cardiovascular Disease Prevention Joint meeting with the Moroccan Society of Cardiology: New Guidelines and Global Strategies for Reducing Cardiovascular Risk, El Jadida, Morocco. 2014
   1. Time to Focus on Cardiovascular Health (not Disease)
   2. Session Chair: Guidelines for Europe and America: Understanding the Differences
   3. Are Current Guidelines Relevant or Helpful?
6. 25th Great Wall of China- International Cardiovascular Conference. Beijing, China. 2014
   1. 2013 ACC/ AHA Guideline on the Assessment of Cardiovascular Risk
   2. Session Chair: ASPC @ GW-ICC: New Prevention of Cardiovascular Disease Guidelines
   3. Overview of the ACC/ AHA Cholesterol Management and JNC-8 Blood Pressure Guidelines
7. 9th Annual Cardiometabolic Health Congress. Boston, MA. 2014
   1. Session Chair: Confronting Racial and Ethnic Disparities in Cardiometabolic Disease
   2. Epidemiological Profiles of Racial and Ethnic Disparities in Cardiometabolic Disease
8. Anandi L. Sharma Visiting Professorship & Simon Dack, M.D. Memorial Lecturer, Mt. Sinai Medical Center, New York, N.Y. 2014
   1. Time to Focus on Cardiovascular Health (Not CV Disease)
   2. Controversies in Cardiology Session- Cholesterol Goals and Targets: Should we IMPROVE-IT?
9. HIV DART (Frontiers in Drug Development for Aniretroviral Therapies) 2014. Protecting the Heart during HAART. Key Biscayne, FL. 2014
10. American College of Cardiology Cardiovascular Summit: Solutions for Thriving in a Time of Change. Orlando, FL. 2015
    1. Academic Realities in a New Economic World: Strategies to Preserve all the Missions
    2. Case Studies in Disease Management: Doing Well by Doing Good: The Successful ”Business” of a Preventive Cardiology Program
11. American Heart Association Epi/ Lifestyle meeting. Baltimore, MD. 2015
    1. Moderator of ASPC Annual Debate- New Blood Pressure Guidelines (JNC 8): Right or Wrong?
    2. Presented The William B. Kannel Memorial Lecture to Dr. Daniel Levy
    3. Presented the 20th ASPC Joseph Stokes III Award to Dr. Virgil Brown
12. 64th American College of Cardiology meeting, San Diego, CA. 2015
    1. A Seaside Chat with the Experts: Fighting Fats and Kicking “butts”: How do we prescribe diet and help our patients quit smoking?
13. 7th Annual Advance in Heart Disease Prevention and Rehabilitation. Beaumont Health System. Time to focus on cardiovascular health (not CV disease). Troy, MI. 2015
14. Visiting Professor, Cardiology Grand Rounds, Weill Cornell Medical Center. Time to Focus on Cardiovascular Health (Not CV Disease). New York, N.Y., 2015
15. Visiting Professorship, Cardiology Grand Rounds, Stony Brook Medical Center. Time to Focus on Cardiovascular Health (Not CV Disease). Stony Brook, N.Y. 2015
16. Visiting Professorship, Cardiology Grand Rounds, Lynchburg General Hospital, Centra Heart & Vascular Center. Preventive Cardiology & the Future of Cardiovascular Medicine: Opportunities for Improvement. Lynchburg, VA. 2015
17. 28th Annual International Cardiovascular Disease Prevention Symposium
    1. Co-Chair of joint session with the Ecuadorian Society of Cardiology, Quito, Ecuador
    2. Time to Focus on CV Health (Not CV Disease), Quito, Ecuador. 2015
    3. Familial Hypercholesterolemia: Hidden in Plain Sight- Current & Novel Approaches; Joint Session with the Peruvian Society of Cardiology, Lima, Peru. 2015.
18. International Academy of Cardiology 20th Annual World Congress on Heart Disease, Vancouver, Canada. 2015.
    1. Member of Scientific Executive Committee
    2. Co-Chair of Session- Assessment & Management of CV Risk/ Modification of Lipoproteins
    3. CAC Testing in 2015: Role in Shared Decision Making?
    4. Cholesterol Goals & Targets: Opportunities for Improvement
19. American Society for Preventive Cardiology CV Disease Prevention Conference, Boca Raton, FL. 2015
    1. Conference Co-Chair
    2. Expert’s Course- Time to Focus on Cardiovascular Health (Not Disease)
    3. Risk Assessment-Have we Over-simplified the Task of Risk Stratification?
20. European Society of Cardiology Congress, London England, 2015
    1. Debate- Are there metabolically healthy obese patients? Contra
    2. Statin- Still the best preventive drug?
    3. Chair of session- Diabetes Management: The way to control atherosclerosis
21. Moderator of session at American Society of Nuclear Cardiology meeting, Washington, D.C., 2015
    1. Nuclear Cardiology in a Value system: Choosing the best test wisely
22. Sulpizio Cardiovascular Center Grand Rounds, UC San Diego , 2015
    1. Preventive Cardiology & the future of Cardiovascular Medicine: Opportunities for Improvement
23. American Society for Preventive Cardiology’s 7th Annual Orange County Symposium on Prevention of Cardiovascular Disease, Costa Mesa, CA. 2015
    1. Roundtable Case Discussion- How do I best assess CVD Risk?
    2. Focus on Cardiovascular Health(Not Disease)
24. The First China-US Cardiac Rehabilitation Forum: The 7th Jilin Provincial Atherosclerosis Conference. Changchun, China. 2015
    1. Preventive Cardiology & the Future of Cardiovascular Medicine: Opportunities for Improvement
25. ACC Summit: Solutions for Thriving in a time of Change. Las Vegas, NV, 2016
    1. National Drivers: Population Health- How to build a successful preventive cardiology program
    2. Primary prevention program- A model that works
26. American Heart Association Epi/ Lifestyle meeting. Phoenix, AZ. 2016
    1. Moderator of ASPC Annual Debate- WHO Sugar Guidelines
    2. Presented The William B. Kannel Memorial Lecture to Dr. Peter Wilson
    3. Presented the 21st ASPC Joseph Stokes III Award to Dr. Aaron Folsom
27. Jim Pattison Cardiac Rehabilitation Symposium sponsored by Mazankowski Alberta Heart Institute. Banff, BC, Canada, 2016
    1. Comprehensive Cardiovascular Risk Reduction in Diabetes & the Metabolic Syndrome
28. The Future of Medicine Centura Health Conference. Preventive Cardiology and the Future of Cardiovascular Medicine: Opportunities for Improvement. Colorado Spring, CO. 2016
29. World Congress of Cardiology and Cardiovascular Health. Mexico City, Mexico. 2016
    1. Cardiac Rehabilitation & Preventive Cardiology: Time to Reinvent and Reinvigorate
    2. Reconfiguring Cardiac Rehabilitation & Secondary Prevention into a New Service Model for a New World
30. Slovenian Society of Cardiology meeting. Ljubljana, Slovenia. 2016
    1. Co-Chair session on Cardiovascular Prevention
    2. Comprehensive cardiovascular risk reduction in the metabolic syndrome and diabetes
    3. Preventive Cardiology & the Future of Cardiovascular Medicine: Opportunities for Improvement
31. 21st World Congress on Heart Disease. Boston, MA. 2016
    1. Comprehensive cardiovascular risk reduction in the metabolic syndrome and diabetes
    2. Co-Chair session on risk stratification and secondary prevention of CVD
32. European Society of Cardiology Congress, invited presentations, Rome, Italy, 2016
    1. Evolution of the metabolic syndrome: Therapy by Stages
    2. State of the art: Cardiobesity
33. American Society for Preventive Cardiology Expert’s Course, Boca Raton, FL, 2016
    1. Time to change our focus on optimal cardiovascular population health
34. American Society for Preventive Cardiology National Congress, Boca Raton , FL, 2016
    1. Chair & Moderator of Young Investigator Presentations
    2. Moderator of Keynote address session: Rethinking Dietary Fat
35. Sharp Grossmont Hospital Heart and Vascular Conference, San Diego, CA, 2016
    1. Preventive Cardiology and the Future of Cardiovascular Medicine: Opportunities for Improvement
36. 6th Asian Preventive Cardiology and Cardiac Rehabilitation Conference, Hong Kong, 2016
    1. Hong Kong Heart Foundation Lecture- Preventive Cardiology and the Future of Cardiovascular Medicine: Opportunities for Improvement
    2. Diets and Cardiovascular Disease: An Evidence-based Assessment
    3. Treatment of Blood Cholesterol: New Approaches / New Agents
    4. The Art of Cardiovascular Risk Assessment
37. Invited presentation, Bart’s Heart Centre, Preventive Cardiology and the Future of CV Medicine : Opportunities for Improvement, London, UK, 2016
38. Invited presentations, Imperial College, London, UK, 2016
    1. Preventive Cardiology and the Future of CV Medicine: Opportunities for Improvement
    2. The Art of CV Risk Assessment
39. 66th American College of Cardiology Meeting, Washington, D.C., 2017
    1. Moderated Poster Judge- Obesity Management 2017: Weighing the Issues
    2. Intensive Co-Chair- Are we there yet? The Long Journey to Health Equity
40. Cardiology Grand Rounds at the University of California San Francisco, 2017
    1. Preventive Cardiology & the Future of CV Medicine: Opportunities for Improvement
41. Cardiology Grand Rounds, University of Minnesota Lillehei Heart Institute, Minneapolis, MN, 2017
    1. Preventive Cardiology and the Future of CV Medicine: Opportunities for Improvement
42. Long Island State of the Art Cardiovascular Care for the Clinician. Melville, N.Y., 2017
    1. Management of Blood Cholesterol: New Approaches / New Agents
43. National Lipid Association Annual Scientific Sessions, Philadelphia, PA, 2017
    1. The Perplexing Exception of Lipoprotein-X Disease
44. Visiting Professorship, University of Nebraska Medical Center, Omaha, NE, 2017
    1. Cardiology Grand Rounds- Preventive Cardiology and the Future of Cardiovascular Medicine: Opportunities for Improvement
45. American College of Cardiology Managing CV Disease Risk in Diabetes Heart House Roundtable
    1. Co-Chair
    2. Adapting the “Heart Team” Approach for the Care of High-Risk Patients with T2DM
46. European Society of Cardiology meeting, Barcelona, Spain, 2017
    1. Moderator for Poster Session Hypertension and Bedtime Stories
47. 1st International Symposium of the Kangbuk Samsung Diabetes and Vascular Center, Seoul, Korea, 2017
    1. Preventive Cardiology and the Future of Cardiovascular Medicine: Focus on Comprehensive Risk Reduction in the Metabolic Syndrome and Diabetes
48. Familial Hypercholesterolemia (FH) Global Summit: Diagnosis, Treatment, and Access Across Diverse Populations, Miami, FL, 2017
    1. Women and FH: Physician and Patient’s Perspective
    2. U.S. Representative for The Meeting of the Americas
49. Northwell Healthcare Invited presentations, New York, 2017
    1. Fellow’s Journal Club, Lenox Hill Hospital
    2. Cardiology Grand Rounds, Northshore University Hospital, Preventive Cardiology and the Future of CV Medicine: Opportunities for Improvement
50. 9th Annual Sharp Grossmont Heart & Vascular Conference, San Diego, CA, 2017
    1. Heart Healthy Dietary Patterns: A Recipe for Life
    2. Management of Blood Cholesterol: New Approaches/ New Agents
51. ACC Global ASCVD Primary Prevention, Buenos Aires, Argentina, 2017
    1. Risk factor burden and risk assessment of Cardiovascular Disease
52. 15th World Congress on Insulin Resistance, Diabetes, and CV Disease.

Los Angeles, CA, 2017

* 1. Is “Extreme Risk” a Valid and Viable Cardiovascular Risk Category?

1. 67th American College of Cardiology Scientific Sessions, Orlando, FL. 2018
   1. Session Co-Chair: Ensuring a bright future for patients with T2DM: Comprehensive Risk Management
   2. Presentation- “Evolving role of the CV Clinician in Management of CVD Risk in T2DM
   3. Presentation in Clinical Focus Session- “Who is involved: Your role in championing comprehensive diabetes care”
   4. ACC Prevention Section Highlights “Top # presentations in diabetes most likely to impact or change clinical practice or research agendas”
   5. ACCEL interview: “ There’s no sugar coating the new reality: Changing Paradigm for CVD risk reduction in T2DM
2. Association of Physician Assistants in Cardiology National Meeting, Atlanta, GA. 2018
   1. Management of Blood Cholesterol: New Approaches / New Agent
3. Mazankowski Alberta Heart Institute Jim Pattison Cardiac Rehabilitation Symposium, Banff, Canada. 2018
   1. Cardiac Rehabilitation and Secondary Prevention: New Care Models for a New World
4. Preventive Cardiology Grand Rounds, The Mayo Clinic, Rochester, MN, 2018
   1. Preventive Cardiology and the Future of CV Medicine: Opportunities for Improvement
5. Visiting Professor for the 6th Emory-Tibet Medical Sciences Program, Men-Tsee-Khang School of Medicine, Dharamsala, India, 2018
   1. Nutrition and Cardiovascular Risk Factors
6. 1st Annual SCCT / ASPC Cardiovascular Disease Prevention Symposium, Dallas, TX, 2018
   1. Challenging Lipid/ Prevention Cases: Panel Discussion
   2. Which patients should be treated with PCSK9 Inhibitors in 2018?
7. U.S. Center for Disease Control and Prevention’s Science Seminar, Division for Heart Disease and Stroke Prevention, Atlanta, Ga, 2018
   1. Management of Blood Cholesterol: New Approaches / New Agents
8. European Society of Cardiology Congress, Munich, Germany, 2018
   1. The Year in Hypertension: Hot Papers in Epidemiology and Risk
9. Pre-meeting Session for AHA. Sex and Gender Influence on Cardiovascular Disease. Differences in Atherosclerotic Risk Factors in Men. Chicago, 2018.
10. American Heart Association Scientific Sessions, Chicago, 2018.
    1. Presented 2018 Cholesterol Guidelines in Main Session, Statin Safety and Statin Associated Side Effects
    2. Poster Professor, Cardiovascular Epidemiology
11. NIH/ NHLBI Reducing the Population Burden of Familial Hypercholesterolemia (FH): A Prototype for Translational Research and Implementation Science in Genomics and Precision Medicine Workshop. Assessing Current Treatment Options for FH: Improving Outcomes for Patients Transitioning from Pediatrics to Adult Health Care. Bethesda, MD. 2018.
12. 15th Global Cardiovascular Clinical Trialists Forum. CVCT-NHLBI Joint workshop- Maximizing the Impact of Clinical Trial Findings: NIH Funding Opportunities for Dissemination & Implementation Research. Grand Challenges: Clinical Trial Findings and Quality Cardiovascular Health Care Delivery. French Embassy, Washington, D.C. 2018
13. American College of Cardiology Second Heart House Roundtable on Managing CV Disease Risk in Diabetes. Washington, D.C. 2018

a. Co-Chair

b. Protecting the Heart of the Patient with Type 2 Diabetes: Insights from the Cardiology Community

1. Cardiovascular Grand Rounds, University of Chicago, 2018
   1. Preventive Cardiology and the Future of Cardiovascular Medicine: Opportunities for Improvement
2. Vu-Medi Webinar- ASPC Update on the 2018 Cholesterol Guidelines, 2019
   1. Approach to Risk Assessment and Shared Decision Making
3. Cardiology Grand Rounds, Cleveland Clinic of Florida, Preventive Cardiology and the Future of CV Medicine: Opportunities for Improvement, 2019
4. 68th American College of Cardiology Scientific Sessions, New Orleans, LA, 2019
   1. Tell me the Facts about the 2018 Cholesterol Guidelines: Diabetes and Lipid Lowering Therapy
   2. Overview of the WHF / IDF Diabetes Roadmap
   3. Use of Non-Statin Therapies in Secondary Prevention: Evidence and Guidelines
   4. Co-Chair of Session: Changing Paradigm in CV Risk Reduction in Diabetes
   5. ACCEL Interview: Diabetes and Lipid Lowering Therapy
   6. Secondary Prevention of CAD in Diabetic Patients
   7. Prevention Section Meeting Highlights: Top 3 Presentations in Diabetes Most Likely to Impact or Change Clinical Practice or Future Research Agenda
5. Europrevent , European Congress on Preventive Cardiology, Lisbon, Portugal, 2019
   1. Primary Cardiovascular Disease Prevention: Understanding International Guidelines
6. 26th Annual NMHI Current Concepts in Cardiovascular Disease. Albuquerque, NM, 2019
   1. Lessons from the 2018 Cholesterol Guidelines
   2. Cases in Preventive Cardiology workshops
7. 72nd World Health Assembly Event sponsored by World Heart Federation- Joining Forces to Fight CVD in People with Diabetes: Pathways to Solutions (Moderator), Geneva, Switzerland, 2019
   1. Setting the Scene- Focus on CV Prevention in Diabetes / The WHF/ IDF Roadmap
8. American College of Cardiology Cardiovascular Health Promotion Course, Heart House, Washington, D.C., 2019
   1. New Diabetes Therapies: When should the Cardiovascular Clinician Prescribe and Who should follow up?
   2. Hitting the Easy Button: Conversations with Your Patient- The Latest Approaches for the Comprehensive management of DM2
9. Association of Black Cardiologists Access Roundtable Regroup, Heart House, Washington, D.C., 2019
   1. Overcoming Access to Newer Diabetes Therapies: Importance of the Cardiologist
10. University of California Irvine, Irvine, CA, 2019
    1. University Grand Rounds- Time to Focus on Cardiovascular Health (Not CV Disease)
    2. Preventive Cardiology of Orange County meeting- Strategies to Manage Residual Risk in Patients with or at High Risk of CV Events
    3. Cardiology Grand Rounds- Preventive Cardiology and the Future of CV Medicine: Opportunities for Improvement
11. 3rd Annual Heart in Diabetes meeting, Philadelphia, PA, 2019
    1. Scientific Committee member
    2. Co-Chair Session on Management & Prevention of ASCVD
    3. Lessons from the 2018 Cholesterol Guidelines: Focus on Diabetes
12. American Society for Preventive Cardiology Congress on CVD Prevention, San Antonio, Texas, 2019
    1. Moderator of Young Investigator Awardees Session
    2. Panelist- Session on Prevention Guidelines and Cases
    3. Co-Chair Session on Exercise and Preventive Practice
    4. Presentation- “ Doing well by doing good: The Business of CV Prevention
13. European Society of Cardiology Congress / World Congress of Cardiology, Paris, France, 2019
    1. Tackling the Growing Burden of Diabetes and Cardiovascular Disease: Introducing the Roadmap on CVD Prevention among People Living with Diabetes
14. Inaugural NASH Leadership Forum, Washington, D.C., 2019
    1. NAFLD and the Heart (Cardiovascular Linkage)
15. Preventive Cardiology Summit for Fellows, Chicago, IL, 2019
    1. Approach to Cardiovascular Risk Assessment
    2. The Interplay between Diabetes and Cardiovascular Disease
16. Case Western Reserve Harington Heart & Vascular Institute 13th Annual Cardiovascular Disease Update, Cleveland, OH, 2019
    1. PCSK9 Inhibitors: New Data and Guideline Recommendations
17. 7th FH Global Summit, Familial Hypercholesterolemia: A Prototype for Precision Public Health, Atlanta, GA, 2019
    1. Disparities in Care in FH
18. National Forum for Heat Disease & Stroke Prevention 17th Annual Meeting. Washington, D.C., 2019
    1. Million Hearts 2022
19. HEP DART 2019. NAFLD and the Heart. Kauai, Hawaii. 2019
20. University of California San Diego Grand Rounds, The Future of Cardiovascular Prevention. San Diego, CA, 2020
21. National Press Foundation Event, Covering the Heart Beat, Million Hearts 2022. Palm Beach, FL, 2020
22. Million Hearts Collaborative Meeting, Million Hearts: Initiatives, Goals, and Priorities for 2020. Washington, D.C., 2020
23. Keynote Presentation, Mid-America Million Hearts Conference. Million Hearts 2022: How do we achieve the Million Heart’s Vision in Mid-America? Blue Springs, MO, 2020
24. 20th Annual National Sarasota Congress on Cardiovascular Disease Prevention: Update 2020. Sarasota, FL, 2020
    1. Risk Assessment Tools for Primary Cardiovascular Disease Prevention
    2. Diabetes and Cardiovascular Disease (American College of Cardiology’s Expert Consensus Decision Pathway)
25. CMS Quality Conference. Million Hearts 2022: Outcomes, Initiatives, and Focus on Quality Improvement. Baltimore, MD, 2020.
26. National Forum for Heart Disease and Stroke Prevention, Mid-Year meeting, Improving BP Control at the Community Level- Million Hearts Hypertension Control Champions, Webinar, 2020
27. American Heart Association / CDC COVID-19 Update for Healthcare Professionals, Webinar, 2020
28. Whole Health Cure Podcast, 100th Episode, The Heart of Cardiovascular Prevention, 2020
29. Health Resources & Services Administration (HRSA) National Men’s Health Week Webinar, Heart to Heart. Million Hearts and Men’s Cardiovascular Health, 2020.
30. Missouri Department of Health and American Heart Association Webinar, Provider’s Perspective: Hypertension and COVID-19, Million Hearts 2022: Focus on Hypertension Control, 2020.
31. American Society for Preventive Cardiology 2020 Virtual Summit, Million Hearts: Moving the Prevention Needle for the Population, 2020
32. American Heart Association Million Hearts Collaboration Virtual Quarterly Meeting, Executive Director Update, 2020
33. Right Care Virtual University of Best Practice Symposium, Keynote Address, The (Post-COVID) Future of Cardiovascular Disease Prevention, 2020
34. Partnership to Advance Cardiovascular Health National Webinar, Pandemic Lessons- What COVID-19 Revealed About America’s Healthcare System, Continuity of Care and the Promise of Telemedicine, 2020
35. Health Resources and Service Administration / Federal Office of Rural Health Care Services and Policy-Virtual Seminar. Cardiovascular Health and Prevention Remain a Priority in the Midst of a Pandemic. 2020
36. 4th Annual Heart in Diabetes Virtual Scientific Meeting, 2020
    1. Member of Scientific Committee, Session Chair, and Oral Abstract Judge
    2. The Impact of COVID-19 on Cardiovascular Care and the Post-Pandemic Future of Cardiovascular Prevention
    3. NAFLD and the Heart as a Part of the Spectrum of Cardiometabolic Risk
37. American Heart Association House Calls: Real Docs, Real Talk: Focus on COVID and the Heart, 2020
38. CDC Business Health Executive Quarterly Meeting, Virtual, Million Hearts 2022- Breaking News, 2020
39. Association of Black Cardiologist Webinar: Avoiding Heartbreak- COVID-19 Complications and Risk Mitigation in Diverse Populations ;

Structural Racism, COVID-19, and Healthcare, panelist, 2020

1. 35th Annual American Association of Cardiopulmonary Rehabilitation Meeting, Virtual, Improving Cardiovascular Outcomes through Million Hearts Quality Improvement Tools and Agency for Healthcare Research and Quality’s TAKEheart Initiative, 2020.
2. Houston Methodist DeBakey Heart and Vascular Center CVD Prevention Virtual Symposium. Cardiovascular Risk Stratification: Lipid and Inflammatory Biomarkers. 2020
3. American Heart Association Pre-PAD Summit Virtual Workshop. Building PAD into Current Initiatives- Million Hearts. 2020
4. NHLBI / CDC Implementation Science Virtual Workshop on Hypertension Control. Hypertension Control Rates in the U.S./ Hypertension Control as a National Priority. Discussant- Hypertension Control in the United States over Two Decades. 2020
5. Mexican Society of Cardiology 3rd Scientific Sessions (Virtual), Joint MSC-WHF Session, Tackling the Growing Global Burden: World Heart Federation Roadmap on the Prevention of CVD in People Living with Diabetes, 2020
6. Million Hearts Cardiac Rehabilitation Think Tank Pre-meeting workshop, Cardiac Rehabilitation 101: Needs and Opportunities to Address Disparities, moderator, 2020
7. Keynote Guest Speaker, Closing Ceremony of the Timisoara, Romania (Virtual) Cardio Culture Meeting, Timisoara CV Institute Annual Conference, 2020
8. Chair, National Million Hearts Cardiac Rehabilitation Think Tank; Advancing New Care Models, 2020
9. 12th Annual Orange County Symposium on CVD Prevention, The (Post-COVID) Future of Cardiovascular Disease Prevention, 2020
10. Stanford Cardiology Grand Rounds, The (Post-COVID) Future of Cardiovascular Disease Prevention, 2020
11. Invited Panelist, World Heart Federation Heart-To-Heart Diabetes Virtual Debate, Silos in Healthcare, Geneva, Switzerland, 2020
12. World Heart Federation / Lund University Virtual Roundtable on Diabetes and Cardiovascular Disease, speaker and panelist, Malmo, Sweden, 2020

a. Roadmap on Prevention of Cardiovascular Disease in People Living with Diabetes.

1. National Business Group on Health Webinar: Top Drivers of Healthcare Costs for Large Employers. Cardiovascular Disease: Driver of Healthcare Costs for Employers- Millions of Opportunities, 2021
2. American College of Cardiology Webinar- Transform Cardiovascular Risk in Diabetes: Setting the Stage, 2021
3. Northwell Heart Center Virtual Cardiology Grand Rounds, The (Post-COVID) Future of Cardiovascular Disease Prevention, 2021
4. Million Hearts Value-Based Insurance Design Webinar: Opportunities for Cardiovascular Disease Prevention. Burden of CVD and Million Hearts 2022, 2021
5. Familial Hypercholesterolemia Foundation Webinar, The (Post-COVID) Future of Cardiovascular Disease Prevention, 2021
6. World Congress of Cardiology, Joint World Heart Federation- Chinese Society of Cardiology Session on Diabetes and Heart Failure. Tackling the Global Burden of Diabetes and Heart Failure: The WHF Roadmap on the Prevention of CVD in People Living with Diabetes, Japan, 2021
7. Million Hearts SMBP Forum 1st Quarter Meeting. Making an Economic Case for Self-Measured Blood Pressure Monitoring. 2021
8. National Hypertension Control Roundtable Steering Committee meeting. Introduction to the Federal Hypertension Control Leadership Council. 2021
9. CDC, Division for Heart Disease and Stroke Prevention Science Seminar. The Impact of COVID-19 on Cardiovascular Care and CVD Prevention, 2021
10. CMMI Million Hearts Innovation Model Learning Group Webinar, The Impact of COVID-19 on Cardiovascular Care and CVD Prevention, 2021
11. 70th Annual American College of Cardiology Virtual Meeting, 2021

a. Yes, Home May be an Option: Hybrid CR, Featured Session- the Telehealth Cardiac Team: Challenges and Opportunities

b. Lipid Management to Reduce ASCVD Risk: To Infinity and Beyond

c. Faculty Mentor Session for Fellows in Training

182. National Forum on Heart Disease and Stroke Prevention Mid-Year Virtual Convening. Answering the Surgeon’s General’s Call to Action to Control Hypertension: Success Stories, Million Hearts Hypertension Control Champions. 2021

183. National Adult and Influenza Immunization Summit Virtual meeting. Plenary Session, Expanding influenza vaccination among specialty medical providers and raising awareness of influenza’s role in chronic disease. Influenza Vaccination- Opportunity to Extend Cardiovascular Disease Prevention to Millions of Hearts, 2021

184. American College of Cardiology Board Review Course, 2021

a. Epidemiology and Prevention of Metabolic Syndrome and Diabetes

b. Comprehensive Cardiovascular Risk Reduction in Diabetes

c. Diabetes Medications

185. Million Hearts Partners Call, Impact of COVID-19 on Cardiovascular Care and Cardiovascular Disease Prevention, 2021

186. 21st Annual National Sarasota Congress on Cardiovascular Disease Prevention, 2021

a. The (Post-COVID) Future of Cardiovascular Disease Prevention

b. Influenza Vaccination: Opportunity for Cardiovascular Disease Prevention

187. Invited Participant, Preventive Cardiology Nurses Association ASCVD Population Health Summit, 2021

188. American College of Cardiology Global Virtual Cardiometabolic Webinar, Cardiometabolic Medicine and Diabetes Care: Extending the Paradigm of Cardiovascular Disease Prevention, Guangzhou, China, 2021

189. American Society for Preventive Cardiology Virtual Summit on CVD Prevention, Chair of Early Career Abstract Presentations. Louisville, KY, 2021.

190. Million Hearts National Partner Call, COVID Vaccine-Associated Myocarditis and Pericarditis, 2021

191. CVD Prevention 101. Overview and Q & A. CDC Foundation Million Hearts Campaign Communications Team, 2021

192. 5th Annual Heart in Diabetes Conference, New York, NY, 2021

a. The Contemporary Role of Medications (And the Heart in Diabetes)

b. Co-Chair: Sessions on Contemporary Approach to ASCVD in Diabetes, and Heart Disease in Women

c. Member of Scientific and Abstract Committees

193. Cardiology Grand Rounds, Indiana University, The (Post-COVID) Future of CVD Prevention, Virtual Presentation, 2021

194. Invited speaker, American College of Cardiology Federal Section Webinar, Alternate Careers in Cardiology, 2021

195. 12th Annual Emirates Cardiac Society Conference, The Impact of the Pandemic on Non-Communicable Diseases / Cardiovascular Disease: When Communicable meets Non-Communicable, Dubai, UAE, 2021

196. 36th Annual American Association of Cardiovascular and Pulmonary Rehabilitation meeting, Preparing for the Post-COVID Future of Cardiac Rehabilitation: Synergy with the Million Hearts 2022 Participation Goals, virtual presentation, San Antonio, Texas, 2021.

197. World Heart Federation Educational Session, Diabetes and Cardiovascular Disease, Geneva, Switzerland, virtual, 2021

198. CMS Innovation Center / CDC Million Hearts Value-based Insurance Design and Opportunities to Improve Medication Adherence for CVD Prevention, 2021

a. Inequities in Heart Disease and Stroke Burden

199. Faculty for the 5 day World Heart Federation Emerging Leaders Seminar (Diabetes and CVD Prevention), Lisbon, Portugal, 2021

a. WHF Roadmap for the Prevention of CVD among People Living with Diabetes

b. Co-faculty mentor for the America’s Group

200. Great Wall of China-International Congress of Cardiology, JACC Asia at the GW-ICC Joint Session: From Vision to Executing on Quality, Virtual Beijing, China, 2021

a. Invited commentary on the 2021 Consensus Pathway of the Taiwan Society of Cardiology on Novel Therapy for Type 2 Diabetes

b. member of panel discussion

201. Belarusian Society of Endocrinology and Metabolism: Diabetes and Metabolic Risk, Virtual, 2021

a. World Heart Federation Roadmap for the Prevention of Cardiovascular Disease among People Living with Diabetes

202. 19th World Congress on Insulin Resistance Diabetes and Cardiovascular Disease, Los Angeles, CA, 2021

a. NAFLD: The Heart of the Matter

203. 38th Annual University of San Francisco Annual Advances in Heart Disease, 2021

a. Heart Healthy Dietary Patterns: A Recipe for Life

204. Cardiology Grand Rounds, University of Utah, 2021

a. The (Post-COVID) Future of Cardiovascular Disease Prevention

205. CDC /CMS Million Hearts Partner Call, 2021

a. Million Hearts 2027: Aiming for Impact

206. Telemed Now: National Twitter Chat. Benefits and Challenges to Supporting Heart Health via Telemedicine, 2021

207. 22nd International Society for CVD Prevention Congress on CVD Prevention, Sarasota, FL, 2022

a. Lipid Management to Reduce CV Risk: To Infinity and Beyond

b. Non-Alcoholic Fatty Liver Disease: The Heart of the Matter

208. National Association of Community Health Centers Million Hearts Learning Lab: Optimizing Care for High Risk Patients with LDL-C > 190 mg/dL- Messaging and

Management, 2022

209. Q1 Million Hearts Cardiac Rehabilitation Collaborative meeting, Million Hearts Cardiac Rehab Think Tank Innovation Model Development, 2022

210. 86th Annual Japanese Circulation Society / Asian Pacific Society of Cardiology Congress. Kobe, Japan, 2022

a. Non-Alcoholic Fatty Liver Disease: The Heart of the Matter

211. Q1 Million Hearts Collaboration Meeting (hosted by American Kidney Fund). Million Hearts 2027: Aiming for Impact, 2022

212. 71st American College of Cardiology Meeting, Washington, DC, 2022

a. presentation to ACC Board of Governors, Million Hearts 2027: Aiming for Impact

b. Session Chair, Cardiometabolic Clinics: The Time has Come

213. Center for Medicare and Medicaid (CMS) Quality Conference: New Hope, New Health- Charting a Path Forward, Baltimore, MD, 2022

a. Session Moderator: Million Hearts 2027: Pandemic, Partnership, Progress, and Possibilities

b. Million Hearts 2027: Aiming for Impact

214. Kaiser Permanente Northern California Division of Research Seminar, 2022

a. Million Hearts 2027: Aiming for Impact

215. ACC Asia-Korean Society of Cardiology Conference- Hybrid, Gyeungju, Korea, 2022

a. Co-Chair for session: Cardiovascular Risk Assessment for Koreans: Opportunities for Improvement

216. 19th Annual Oregon ACC Cardiovascular Symposium, Portland, OR, 2022

a. The Battle of the Bulge: SGLT2i and GLP1-RA in the Prevention and Treatment of Cardiometabolic Disease

b. Faculty for Cardiology Fellows Case Presentations

217. NACHC / HRSA Healthchoice Network Cardiovascular Health Work Group, Chicago, IL, 2022

a. Statins Save Lives: Optimizing Cholesterol Management in High Risk Patients

218. Slovenian Society of Cardiology Contemporary Cardiology, Ljubljana, Slovenia, 2022

a. Aiming for Impact: Million Hearts 2027

219. 6th Annual Heart in Diabetes Conference, Philadelphia, PA, 2022

a. Aspirin for Primary Prevention: Trials, Tribulations, and Trust

b. Co-Chair: State of the Art Cardio-Renal-Metabolic Diseases

c. Scientific Committee; Program Committee; Abstract Committee

220. National Minority Quality Forum Champions for Total Health webinar, 2022

a. Hypertension and Vaccines

221. State of California Master Plan meeting for Preventing Heart Attacks and Strokes, 2022

a. Aiming for Impact: Million Hearts 2027

25. Other Activities:

Local and national TV, newspaper, radio and magazine appearances (CNN, NBC national, Channels 2, 5, 11, PBS, *Atlanta Journal and Constitution*, *Newsweek,* Time, *Atlanta Magazine)*

26. Bibliography:

a. Published and accepted research articles (clinical, basic science, other) in refereed journals:

1. **Sperling LS** and Horowitz JL. Methamphetamine-induced choreoathetosis and rhabdomyolysis. *Ann Int Med* 1994;121(12):986.
2. **Sperling LS** and Tumlin JA. Delayed hypercalcemia following rhabdomyolysis-induced acute renal failure. *Am J Med Sc* 1996;311(4): 186-188.
3. **Sperling LS**, Du J, Marrero M, Delafontaine P. G protein and tyrosine kinase receptor cross talk in rat aortic smooth muscle cells: thrombin and angiotensin II-induced tyrosine phosphorylation of insulin receptor substrate-1 and insulin-like growth factor-1 receptor. *BBRC* 1996;218(3):934-939.
4. Morrison DJ, **Sperling LS**, Schwartz DA, Felner JM. Escherichia coli endocarditis of a native aortic valve. *Arch Pathol Lab Med* 1997;121:1292-1295.
5. Rice CR, Berkuysen M, Nauright L, **Sperling LS**. Phase II cardiac rehabilitation education: meeting the time challenge. *J Cardiopulm Rehab* 1999;19:347-351.
6. Frank E, **Sperling L,** Wu K. Aspirin use among women physicians in the United States. *Am J* *Cardiol* 2000;86:465-466.
7. Cole J, Miller JI, **Sperling LS**, Weintraub WS. Longterm follow-up of coronary artery disease presenting in young adults. *J Am Coll Cardiol* 2003;41:521-528.
8. Cole JH, **Sperling LS**. Premature coronary artery disease: Clinical risk factors and prognosis. *Current Atherosclerosis Reports* 2004;6:121-125.
9. Baman TS, Cole JH, Devireddy CM, **Sperling LS**. Risk factors and outcomes in patients with coronary artery aneurysms. *Am J Cardiol* 2004;93:1549-1551.
10. Gordon N, Salmon R, Franklin B, **Sperling L,** Hall L, Leighton R, Haskell W . Effectiveness of therapeutic lifestyle changes in patients with hypertension, hyperlipidemia, and/or hyperglycemia. *Am J Cardiol* 2004;94:1558-1561.
11. Parikh P, Mcdaniel MC, Ashen MD, Miller JI, Sorrentino M, Chan V, Blumenthal RS, **Sperling LS.** Diets and cardiovascular disease: An Evidence-based assessment. *J Am Coll Cardiol* 2005;45:1379-1387.
12. Sims DB, **Sperling LS**. ST segment elevation resulting from Hyperkalemia. *Circulation* 2005;111:e295-296.
13. DeFilippis AP, **Sperling LS**. Understanding Omega 3’s. *Am Heart J* 2006;151:564-70.
14. DeFilippis AP, Larned JM, Cole JH, Nell C, Miller JI, **Sperling LS.** Clues to cardiovascular risk: An office based approach. *Preventive Cardiology* 2007;10(1):36-41.
15. Mackie BD, Satija S, Nell C, Miller J, **Sperling LS**. Monday, Wednesday, Friday dosing of Rosuvastatin in patients previously intolerant to statin therapy. *Am J Cardiol* 2007;99:291.
16. Liff DA, Kraft C, Pohlel FK, Wade J, **Sperling LS**, Chen EP, Paredes CF. Nocardia nova aortitis following coronary bypass surgery. *J Am Soc* *Echocardiogr* 2007;20(5):537.
17. Swerdlow DL, Roper MH, Morgan J, Schieber RA, **Sperling LS**, et al. and the Smallpox Vaccine Cardiac Adverse Events Working Group. Ischemic cardiac events during the Department of Health and Human Services smallpox vaccination program. *Clinical Infectious Diseases* 2008;46:S234-41.
18. Morgan J, Roper MH, **Sperling L**, et al. for the Smallpox Vaccine Adverse Monitoring and Response Activity. Myo/pericarditis and dilated cardiomyopathy following smallpox vaccination among civilians, United States, January-October, 2003. *Clin Infect Dis.* 2008;10:273-282.
19. Bavikati VV, **Sperling LS**, Salmon RD, Faircloth GC, Gordon TL, Franklin BA, Gordon NF. Effect of comprehensive therapeutic lifestyle changes on prehypertension. *Am J Cardiol* 2008;102:1677-1680.
20. Baseline characteristics of patients with diabetes and coronary artery disease enrolled in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. Am Heart J. 2008;156(3)528-536.
21. Mora LF, Khan AH, **Sperling LS**. Cardiac complications after smallpox vaccination. *Southern Medical Journal* 2009;102(6):615-619.
22. Yehya A, Baer JT, Smiley W, Dollar A, **Sperling L.** Hypervitaminosis A altering the lipid profile in a hypercholesterolemic patient. Journal of Clinical Lipidology 2009, 3(3): 205-207.
23. Rowe D, DeFilippis A, Dantzler D, Doyle J, Kripalani S, **Sperling L.** Assesing housestaff gender specific preventive cardiovascular knowledge: Potential impact on cardiovascular management. Gender Medicine 2009, 6(3) 471 – 478.
24. The BARI 2D Study Group. A Randomized Trial of Therapies for Type 2 Diabetes and Coronary Artery Disease. N Engl J Med 2009 (360): 2503-2515.
25. Prevalence of diabetic peripheral neuropathy and relation to glycemic control therapies at baseline in the BARI 2D cohort. J Peripher Nerv Syst. 2009;14(1):1-13.
26. Georgiopoulou VV, Denker A, Bishop KL, Brown JM. Hirsh B, Wolfenden L, **Sperling L.** Metabolic abnormalities in adults with cystic fibrosis. Respirology 2010 Jul15(5):823-9.
27. Salman T, Satja S, Martin SF, **Sperling L.** Saddle pulmonary embolism in the setting of a 3-chamber thrombus: Successful resolution after thrombolytic therapy. Texas Heart Insititute J. 2010;37(2)234-236.
28. Shehab N, **Sperling LS**, Budnitz DS. National estimates of emergency department visits for hemorrhage-related adverse events from clopidogrel plus aspirin and from warfarin. Arch Intern Med. 2010; 170(21):1926-33.
29. Chaudhry S, Arean R, Hansen JE, Lewis GD, Myers J, **Sperling LS**, LaBudde B, Wasserman K. The Utility of Cardiopulmonary Exercise Testing to Detect and Track Early Stage Ischemic Heart Disease. Mayo Clin Proc. 2010;85(10):928-32.
30. Eapen DJ, Clements S, Block P, **Sperling LS**. Metastatic carcinoid disease inducing coronary vasospasm. Tex Heart Inst J 2012;39(1):76-78.
31. Yehya A, Jacobs S. Mashman W, **Sperling L**. Takotsubo cardiomyopathy in a patient with presumptive autoimmune polyendocrine syndrome II. Cardiac Cath Lab Director 2011, 1(3/4):117-119.
32. The BARI-2D Study Group. The prevalence and predictors of an abnormal ankle-brachial index in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. Diabetes Care 2011;34(2):464-7.
33. Gordon NF, Habib A, Salmon RD, Bishop KL, Drimmer A, Reid KS, Wright BS, Faircloth GC, Gordon TL, Franklin BA, Rubenfire M, Gracik T, **Sperling LS**. Effect of exercise-based cardiac rehabilitation on multiple atherosclerotic risk factors in patients taking antidepressant medication. Am J Cardiol. 2013;111(3):346-51.
34. Eapen DJ, Valiani K, Reddy S, **Sperling L**. Management of familial hypercholesterolemia during pregnancy: case series and discussion. Journal of Clinical Lipidology 2012; 6(1): 88-91.
35. Abd T, Kobyliver A, Perry A, Miller J, **Sperling LS.** Work-related physical activity among cardiovascular specialists. Clin Cardiol. 2012;35(2):78-82
36. Kella DK, Shoukat S, **Sperling L**. Plasma exchange for severe hypertriglyceridemia-induced pancreatitis in an orthotopic heart transplant recipient. J Clin Lipidol.2012;6(5):474-6.
37. Nieva R, Safavynia S, Bishop KL, **Sperling L**. Herbal, vitamin, and mineral supplement use in patients enrolled in a cardiac rehabilitation program. The Journal of Cardiopulmonary Rehabilitation 2012;32:1-8
38. Parashar S, Spertus JA, Tang F, Bishop KL, Vaccarino V, Jackson CF, Boyden TF, **Sperling L**. Predictors of early and late enrollment in cardiac rehabilitation, among those referred, after acute myocardial infarction. Circulation. 2012;126(13):1587-95.
39. Ramjee V, Guo Y, Bhatia N, Vaugh L, Nell-Dybdahl C, Baer J, Wilson PWF, Le NA, **Sperling LS**. Rebound kinetics of inflammatory and lipid markers after LDL apheresis: The INFLAME study (under review, Am J Cardiol)
40. Bhatia N, Eapen DJ, Stewart J, Babaliaros V, **Sperling L**. Right coronary artery aneurysm communication with the right atrium following NSTEMI treated with coil embolization. Circulation. 2013;127(14):e537-8.
41. Eapen D, Manocha P, Patel R, Hammadah M, Veledar E, Wassel C, Nanjundappa R, Sikora S, Malayter D, Wilson P, **Sperling LS**, Quyyumi A, Epstein S. Aggregate Risk Score Based on Markers of Inflammation, Cell Stress, and Coagulation is an Independent Predictor of Adverse Cardiovascular Outcomes. J Am Coll Cardiol. 2013;62(4):329-37.
42. Bittner V, Bertolet M, Feliz RB, Farkouh ME, Goldberg S, Ramanathan KB, Redmon JB**, Sperling L**, Rutter MK. Comprehensive Cardiovascular Risk Factor Control Improves Survival: The Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial. J Am Coll Cardiol 2015;66:765-73.
43. Ghasemzadeh N, Hritani AW, De Staercke C, Eapen DJ, Veledar E, Al Kassem H, Khayata M, Zafari AM, **Sperling L**, Hooper C, Waller EK, Vaccarino V, Mavromatis K, Quyyumi A. Plasma stromal cell-derived factor-1 alpha/ CXCL12 level predicts long-term adverse cardiovascular outcomes in patients with coronary artery disease. Atherosclerosis. 2015;238(1):113-8.
44. Ghasemzadeh N, Patel RS, Eapen DJ, Veledar E, Al Kassem H, Manocha P, Khayata M, Zafari AM, **Sperling L**, Jones DP, Quyyumi, AA. Increased systemic oxidative stress is associated with pulmonary hypertension in humans. Hypertension 2014; 63:1270-1275.
45. Eapen DL, Manocha P, Ghasemzedah N, Patel RS, Al Kassem H, Hammadah M, Veledar E, Le NA, Pielak T, Thorball CW, Velegraki A, Kremastinos DT, Lerakis**, Sperling L,** Quyyumi AA. Soluble urokinase plasminogen activator receptor level is an independent predictor of the presence and severity of coronary artery disease and of future events. J Am Heart Assoc. 2014;3(5):e001118.
46. Mekonnen G, Corban MT, Hung OY, Eshtehardi P, Eapen DJ, AL-Kassem H, Rasoul-Arzrumly E, Gogas BD, McDaniel MC, Pielak T, Thorball CW, **Sperling L**. Quyyumi AA, Samady H. Plasma soluble urokinas-type plasminogen activator receptor level is independently associated with coronary microvascular function in patients with non-obstructive coronary artery disease. Atherosclerosis. 2014;239(1):55-60.
47. Patel RS, Li Q, Ghasemzadeh N, Eapen DJ, Owens LM, Janjua AU, Manocha P, Al Kassem H, Veledar E, Samady H, Taylor WR, Zafari AM, **Sperling L**, Vaccarino V, Waller, EK, Quyyumi AA. Circulating CD34+ Progenitor Cells and Risk of Mortality in a Population with Coronary Artery Disease. Circ Res. 2015;116(2):289-97.
48. Ghasemzadeh N, Zhang L, Al Mheid I, Li Q, **Sperling L,** Waller EK, Taylor WR, Guest J, Quyyumi AA, Mavromatis K. Circulating progenitor cells are reduced in HIV positive , antiretroviral naïve patients. Int J Cardiol. 2014;176(3):1150-2.
49. Kim JH, Sher S, Wang F, Berkstresser B, Shoop JL, Galante A, Al Mheid I, Ghasemzadeh N, Hutter AM, Williams BR, **Sperling L**, Weiner RB, Quyyumi AA, Baggish AL. Impact of American-style Football on Vascular Function. Am J Cardiol. 2015;115(2):262-7.
50. Sahebkar A, Seban C, Ursoniu S, Wong ND, Muntner P, Graham IM, Mikhailidis DP, Rizzo M, Rysz J, **Sperling LS**, Lip GYH, Banach M. Lipid and Blood Pressure Meta-Analysis Collaboration (LBPMC) Group. Lack of effect of resveratrol on C-reactive protein and selected cardiovascular risk factors. Results from a systematic review and meta-analysis of randomized controlled trials. (accepted for publication, International Journal of Cardiology)
51. Ghasemzadeh N, Brooks MM, Vlachos H, Hardison MS, Sikora S, **Sperling L**, Quyyumi AA, Epstein SE. An Aggregate Biomarker Risk Score Predicts High Risk of Near-term Myocardial Infarction and Death: Findings from the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D). (accepted for publication, Journal of the American Heart Association ).
52. Hayek S, Sever S, Ko YA, Trachtman H, Awad M, Wadhwani S, Altintas M, Wei C, Hotton A, French A, **Sperling L**, Lerakis S, Quyyumi A, Reiser J. Elevated Soluble Urokinase-type Plasminogen Activator is a Predictor of Incident Chronic Kidney Disease. (accepted for publication, N Eng J Med)
53. Patel RS, Ghasemzadeh N, Eapen DJ, Sher S, Arshad S, Ko Y, Veledar E, Samady H, Zafari M, **Sperling L**, Vaccarino V, Jones DP, Quyyumi AA. A novel biomarker of oxidative stress is associated with risk of death in patients with coronary artery disease. (accepted to Circulation)
54. Patel RS, Ghasemzadeh N, Eapen DJ, Sher S, Arshad S, Ko Y, Veledar E, Samady H, Zafari M, **Sperling L**, Vaccarino V, Jones DP, Quyyumi AA. Response to letter regarding article A novel biomarker of oxidative stress is associated with risk of death in patients with coronary artery disease. (accepted to Circulation)
55. Gordon NF, Salmon RD, **Sperling LS**, Wright BS, Faircloth GC, Gordon TL, Berk MR, Rubenfire M, Franklin BA. Multi-center Study of Temporal Trends in the achievement of ASCVD Risk factor goals during cardiac rehabilitation. (accepted for publication- Journal of Cardiopulmonary Rehabilitation and Prevention).
56. Arnold SV, Inzucchi SE, McGuire DK, Mehta SN, Goyal A, **Sperling LS**, Maddox TM,Einhorn D, Wong ND, Ratner RE, Hammar N, Fenici P, Sheehan JJ, Wong JL, Kosiborod M. Evaluating the Quality of comprehensive cardiometabolic care for patients with Type 2 diabetes in the U.S.: The Diabetes Collaborative Registry, published in Diabetes Care.
57. Corban MT, Hung OY, Mekonnen G, Eshtehardi P, Eapen DJ, Rasoul-Aezrumly E, Al Kassem H, Manocha P, Sikora S, Ko YA, **Sperling LS**, Quyyumi AA, Samady H. elevated levels of serum fibrinogen and fibrinogen degradation products are independent predictors of larger coronary plaques and greater plaque necrotic core. (accepted for publication, Circulation)
58. Kim JH, Ko YA, MacNamara J, Awad M, taylor W, Healy S, Aida H, Le NA, Wilson Pw, White M, **Sperling LS**, Wilson JS, Baggish Al. The impact of moderate distance recreational running and aging on cardiac physiology. (accepted to Heart)
59. Hayek SS, Ko YA, awad M, Del Mar Soto A, Ahmed H, Patel K, Yuan M, Maddox S, Gray B**, Sperling L**, Shah A, Vaccarino V, Quyyumi AA. Depression and Chest Pain in Patients with Coronary Artery Disease (under review European Heart Journal)
60. Chaudhry S, Kumar N, Behbahani H, Bagai A, Singh B, Menasco N, Lewis GD, **Sperling L**, Myers. Abnormal heart-rate response during cardiopulmonary exercise testing identifies cardiac dysfunction in symptomatic patients with non-obstructive coronary artery disease. (accepted for publication, International Journal of Cardiology)
61. Shin E, Ochuko P, Bhatt K, Howard B, McGorisk G, Delaney L, Langdon K, Khosravanipour M, Nambi AA, Grahovec A, Morris DC, **Sperling LS**, Shaw LJ, Castellano PZ, Goyal A. Electronic health record-based overestimation of failure to prescribe statins in patients with coronary artery disease in a large academic multispecialty clinic. J Am Heart Assoc 2018;7: e007762
62. Arnold SV, Inzucchi SE, Tang F, McGuire DK, Mehta SN, Maddox TM, Goyal A, **Sperling LS**, Einhorn D, Wong ND, Kosiborod M. Real world use and modeled impact of glucose lowering therapies used in recent cardiovascular outcomes trials: Observations form the Diabetes Collaborative Registry (DCR). (submitted to JACC for consideration).
63. Arnold SV, Inzucchi SE, McGuire DK, Tang F, Mehta SN, Goyal A, **Sperling LS**, Maddox TM, Einhorn D, Wong ND, Hammer N, Fenici P, Sheehan JJ, Kosiborod M. Quality of care in the initial patient cohort of the Diabetes Collaborative Registry. (submitted for consideration to Diabetes Care).
64. Ghasemzadeh N, Hayek SS, Ko YA, Eapen DJ, Patel RS, Manocha P, Al Kassem H, Khayata M, Veledar E, Kremastinos D, Thorball C, Pielak T, Sikora S, Zafari M, Lerakis S**, Sperling L**, Vaccarino V, Epstein SE, Quyyumi AA. Pathway-specific Aggregate Biomarker Risk Score is Associated with Burden of CAD and Predicts near-term Myocardial Infarction and Death. Circ Cardiovasc Qual Outcomes 2017;10
65. Hammadah M, Tamman AS, Al Mheid I, Wilmot K, Ramadan R, Kindya BR, Kelli HM, O’Neal WT, Sandesara P, Sullivan S, Almuwaqqat Z, Obideen M, Abdelhadi N, Alkhoder A, Pimple PM, Levantsevych O, Mohammed KH, Weng L, **Sperling LS**, Shah A, Sun YV, Pearce B, Kutner M, Ward L, Bremner D, Kim J, Waller EK, Raggi P, Sheps D, Vaccarino V, Quyyumi AA. Myocardial Ischemia and Mobilization of Circulating progenitor Cells. (under review, Circulation Research)
66. Sandesara PB, Ramjee V, Ghasemzadeh N, Guo Y, Bhatia N, Li Q, Vaughn L, Nell-Dybdahl C, Waller EK, Mahar EA, Brigham K, Wilson PWF, Quyyumi A, Le NA and **Sperling LS**. Circulating progenitor cells in patients with familial hypercholesterolemia. *J Clin Apher*. 2017.
67. Sandesara PB, O'Neal WT, Kelli HM, Samman-Tahhan A, Hammadah M, Quyyumi AA and **Sperling LS**. The Prognostic Significance of Diabetes and Microvascular Complications in Patients With Heart Failure With Preserved Ejection Fraction. *Diabetes Care*. 2017.
68. Samman Tahhan A, Sandesara PB, Hayek SS, Alkhoder A, Chivukula K, Hammadah M, Mohamed-Kelli H, O'Neal WT, Topel M, Ghasemzadeh N, Ko YA, Aida H, Gafeer M, **Sperling L**, Vaccarino V, Liang Y, Jones DP and Quyyumi AA. Association between oxidative stress and atrial fibrillation. *Heart Rhythm*. 2017.
69. Samman Tahhan A, Hayek SS, Sandesara P, Hajjari J, Hammadah M, O'Neal WT, Kelli HM, Alkhoder A, Ghasemzadeh N, Ko YA, Aida H, Gafeer MM, Abdelhadi N, Mohammed KH, Patel K, Arya S, Reiser J, Vaccarino V, **Sperling L** and Quyyumi A. Circulating soluble urokinase plasminogen activator receptor levels and peripheral arterial disease outcomes. *Atherosclerosis*. 2017;264:108-114.
70. Kim JH, Ko YA, Hedley J, MacNamara J, Awad M, Taylor W, Healy S, Aida H, Le NA, Wilson PW, White M, **Sperling LS**, Wilson JS, Jr. and Baggish AL. The impact of moderate distance recreational running and ageing on cardiac physiology. *Heart*. 2017;103:219-226.
71. Kelli HM, Hammadah M, Ahmed H, Ko YA, Topel M, Samman-Tahhan A, Awad M, Patel K, Mohammed K, **Sperling LS**, Pemu P, Vaccarino V, Lewis T, Taylor H, Martin G, Gibbons GH and Quyyumi AA. Association Between Living in Food Deserts and Cardiovascular Risk. *Circ Cardiovasc Qual Outcomes*. 2017;10.
72. Kelli HM, Corrigan FE, 3rd, Heinl RE, Dhindsa DS, Hammadah M, Samman-Tahhan A, Sandesara P, O'Neal WT, Al Mheid I, Ko YA, Vaccarino V, Ziegler TR, **Sperling LS,** Brigham K, Jones D, Martin GS and Quyyumi AA. Relation of Changes in Body Fat Distribution to Oxidative Stress. *Am J Cardiol*. 2017.
73. Hayek SS, Ko YA, Awad M, Del Mar Soto A, Ahmed H, Patel K, Yuan M, Maddox S, Gray B, Hajjari J, **Sperling L,** Shah A, Vaccarino V and Quyyumi AA. Depression and chest pain in patients with coronary artery disease. *Int J Cardiol*. 2017;230:420-426.
74. Gordon NF, Salmon RD, **Sperling LS**, Wright BS, Faircloth GC, Gordon TL, Berk MR, Rubenfire M and Franklin BA. Multicenter Study of Temporal Trends in the Achievement of Atherosclerotic Cardiovascular Disease Risk Factor Goals During Cardiac Rehabilitation. *J Cardiopulm Rehabil Prev*. 2017;37:11-21.
75. Ghasemzedah N, Hayek SS, Ko YA, Eapen DJ, Patel RS, Manocha P, Al Kassem H, Khayata M, Veledar E, Kremastinos D, Thorball CW, Pielak T, Sikora S, Zafari AM, Lerakis S, **Sperling L**, Vaccarino V, Epstein SE and Quyyumi AA. Pathway-Specific Aggregate Biomarker Risk Score Is Associated With Burden of Coronary Artery Disease and Predicts Near-Term Risk of Myocardial Infarction and Death. *Circ Cardiovasc Qual Outcomes*. 2017;10.
76. Ikeno F, Brooks MM, Nakagawa K, Kim MK, Kaneda H, Mitsutake Y, Vlachos HA, Schwartz L, Frye RL, Kelsey SF, Waseda K, Hlatky MA and Group B-DS. SYNTAX Score and Long-Term Outcomes: The BARI-2D Trial. *J Am Coll Cardiol*. 2017;69:395-403.
77. Ghasemzadeh N, Brooks MM, Vlachos H, Hardison R, Sikora S, **Sperling L,** Quyyumi AA and Epstein SE. An Aggregate Biomarker Risk Score Predicts High Risk of Near-Term Myocardial Infarction and Death: Findings From BARI 2D (Bypass Angioplasty Revascularization Investigation 2 Diabetes). *J Am Heart Assoc*. 2017;6.
78. Chaudhry S, Kumar N, Behbahani H, Bagai A, Singh BK, Menasco N, Lewis GD, **Sperling L** and Myers J. Abnormal heart-rate response during cardiopulmonary exercise testing identifies cardiac dysfunction in symptomatic patients with non-obstructive coronary artery disease. *Int J Cardiol*. 2017;228:114-121
79. Arnold SV, Inzucchi SE, Tang F, McGuire DK, Mehta SN, Maddox TM, Goyal A, **Sperling LS**, Einhorn D, Wong ND, Khunti K, Lam CS and Kosiborod M. Real-world use and modeled impact of glucose-lowering therapies evaluated in recent cardiovascular outcomes trials: An NCDR(R) Research to Practice project. *Eur J Prev Cardiol*. 2017;24:1637-1645.
80. Arnold SV, Goyal A, Inzucchi SE, McGuire DK, Tang F, Mehta SN, **Sperling LS,** Maddox TM, Einhorn D, Wong ND, Hammar N, Fenici P, Khunti K, Lam CSP and Kosiborod M. Quality of Care of the Initial Patient Cohort of the Diabetes Collaborative Registry(R). *J Am Heart Assoc*. 2017;6.
81. Patel RS, Ghasemzadeh N, Eapen DJ, Sher S, Arshad S, Ko YA, Veledar E, Samady H, Zafari AM, **Sperling L**, Vaccarino V, Jones DP and Quyyumi AA. Novel Biomarker of Oxidative Stress Is Associated With Risk of Death in Patients With Coronary Artery Disease. *Circulation*. 2016;133:361-9.
82. Patel RS, Ghasemzadeh N, Eapen DJ, Sher S, Arshad S, Ko YA, Veledar E, Samady H, Zafari AM, **Sperling L**, Vaccarino V, Jones DP and Quyyumi AA. Response to Letter Regarding Article "Novel Biomarker of Oxidative Stress Is Associated With Risk of Death in Patients With Coronary Artery Disease". *Circulation*. 2016;133:e667.
83. Corban MT, Hung OY, Mekonnen G, Eshtehardi P, Eapen DJ, Rasoul-Arzrumly E, Al Kassem H, Manocha P, Ko YA, **Sperling LS**, Quyyumi AA and Samady H. Elevated Levels of Serum Fibrin and Fibrinogen Degradation Products Are Independent Predictors of Larger Coronary Plaques and Greater Plaque Necrotic Core. *Circ J*. 2016;80:931-7.
84. Arnold SV, Inzucchi SE, McGuire DK, Mehta SN, Goyal A, **Sperling LS,** Maddox TM, Einhorn D, Wong ND, Ratner RE, Hammar N, Fenici P, Sheehan JJ, Wong JL and Kosiborod M. Evaluating the Quality of Comprehensive Cardiometabolic Care for Patients With Type 2 Diabetes in the U.S.: The Diabetes Collaborative Registry. *Diabetes Care*. 2016;39:e99-e101.
85. Arnold SV, McGuire DK, Inzucchi SE, Tang F, Mehta SN, Lam CSP, Goyal A, **Sperling LS**, Wong N, Hammar N, Fenici P, Kosiborod M. Assessing use of patient-focused pharmacotherapy in glycemic management through the Diabetes Collaborative Registry (DCR). J Diabetes Complications. In press
86. Sandesara PB, O’Neal WT, Kelli HM, Topel M, Samman-Tahhan A, **Sperling LS**. Diastolic blood pressure and adverse outcomes in the Treatment of Preserve Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) Trial. J Am Heart Assoc, 2017
87. Samman Tahhan A, Sandesara P, Hayek SS, Hammadah M, Alkhoder A, Kelli HM, Topel M, O’Neal WT, Ghasemzadeh N, KoYA, Gafer MM, Abdehadi N, Choudhary F, Patel K, Beshiri A, Murtagh G, Kim J, Wilson P, Shaw L, Vaccarino V, Epstein SE, **Sperling L**, Quyyumi AA. High-sensitivity Troponin-I levels and coronary artery disease severity, progression, and long-term outcomes. J Am Heart Assoc 2018; In press
88. Sandesara PB, O’Neal WT, Samman AT, Hayek S, Lee SK, Khambhati J, Topel M,L, Hammadah M, Akhodar A, KoY, Gafeer MM, Beshiri A, Murtagh G, Kim mJ, Wilson P, Shaw L, Epstein SE, **Sperling LS**, Quyyumi AA. Comparison of the association between hs-troponin I and adverse outcomes in patients with versus without chronic kidney disease. Am J Cardiol 2018; In Press.
89. Sandesara P, O’Neal W, Kelli HM, Mekhoukh J, Sathiyakumar V, Martin S, Blaha M, Blumenthal R, **Sperling LS**. Clinical significance of zero coronary artery calcium in individuals with LDL-C (greater than or equal to) 190 mg / Dl: The Multi-Ethnic Study of Atherosclerosis. JACC CV Imaging (under consideration) 2018
90. Arnold SV, Echouffo-Tcheuqui J, Lam CSP, Inzucchi SE, Tang F, McGuire DK, Goyal A, Maddox TM, **Sperling LS**, Fonarow GC, Masoudi F, Kosiborod M. Patterns of glucose-lowering medication use in patients with type 2 diabetes and heart failure. Insights from the Diabetes Collaborative Registry (DCR). Am Heart J. 2018 (in press)
91. Kelli H, Tahhan AS,Kim JH, Hammadah M, Sullivan S, Sandesara P, Alkhode A, Choudhary F, Gafeer M, Patel K, Qadir S, Ko YA, Lewis T, Vaccarino V, **Sperling L**, Quyyumi A, Living in Food Deserts and Outcomes in Patients with Cardiovascular Disease. (accepted for publication in JAHA, 2018)
92. Hammadah M, Kim JH, Tahhan AS, Kindya B, Liu C, Ko YA, Al Mheid I, Wilmot K, Ramadan R, Alkhder A, Choudhary F, Gafeer MM, Abdehadi N, Pimple P, Sandesara P, Lima BB, Shah AJ, Ward L, Kutner M, Bremner D, Sheps D, Raggi P, **Sperling LS**, Vaccarino V, Quyyumi AA. Use of High-Sensitivity Cardiac Troponin for the Exclusion of Inducible Myocardial Ischemia. (published Ann Intern Med, 2018)
93. Wong N, Fan W, Song Y, Inzucchi S**, Sperling L**, Cannon C, Arnold S, Kosiborod M. Composite Cardiovascular Risk Factor Target Achievement in U.S. Adults with Diabetes: The Diabetes Collaborative Registry. (accepted for publication in Obesity, and Metabolism, 2019)
94. Sandesara PB, Dhindsa D, Hirsh B, Jokhadar M, Cole RT, **Sperling LS**. PCSK9 Inhibition in Patients with Heart Transplantation: A Case Series (accepted for publication, J Clin Lipid, 2019)
95. Arnold SV, Inzucchi SE, Echouffo-Tcheugui JB, Tang F, Lam C, **Sperling LS**, Kosiborod M. Understanding the Contemporary Use of Thiazolinediones: An Analysis of the Diabetes Collaborative Registry( Circulation Heart Failure, 2019, in press)
96. Mehta A, Nayak A, Tahhan AS, Liu C, Ko YA, Dhindsa DS, Kim JH, Hayek SS, **Sperling LS**, Mehta PK, Sun Y, Uppal K, Jones DP, Quyyumi AA. High-resolution Plasma Metabolomics Profiling to Predict Outcomes in Patients with Coronary Artery Disease. (accepted for publication, PLOS One)
97. Kelli HM, Mehta A, Tahhan AS, Kim JH, Dong TA, Dhindsa DS, Ghazzal B, Choudhary MK, Sandesara PB, Hayek SS, Topel ML, Alkhoder AA, Gafeer MM, Choudhary FK, Patel K, Liu C, Ko YA, Lewis TT, Vaccarino V, **Sperling LS**, Quyyumi AA. Low Educational Attainment is a Predictor of Adverse Outcomes in Patients with Coronary Artery Disease. (accepted, JAHA, 2019)
98. Sandesara PB, Mehta A, O’Neal WT, Kelli HM, Sathiyakumar V, Martin SS, Blaha MJ, Blumenthal RS, **Sperling LS**. Clinical Significance of Zero Coronary Artery Calcium in Individuals with LDL Cholesterol > 190 mg/ dL. The Multi-Ethnic Study of Atherosclerosis. (accepted for publication, Atherosclerosis, 2019)
99. Gawey BJ, Tannu M, **Sperling LS**, Henry TL. Statin-induced Necrotizing Autoimmune Myopathy. (accepted for publication, JACC Case Reports, 2020)
100. Mehta A, Desai SR, Ko YA, Liu C, Dhindsa DS, Nayak A, Hooda A, Martini MA, Ejaz K, **Sperling LS**, Reiser J, Hayek SS, Quyyumi AA. Sex Differences in Circulating Soluble Urokinase-type Plasminogen Activator Receptor (suPAR) levels and Adverse Outcomes in Coronary Artery Disease. (accepted for publication, Journal of The American Heart Association, 2020; 9(5)).
101. Mehta A, Pandey A, Ayers CR, Khera A, **Sperling LS**, Szklo MS, Gottesman RF, Budoff MJ, Blaha MJ, Blumenthal RS, Nasir K, Joshi PH. Predictive Value of Coronary Artery Calcium Score Categories for Coronary Events versus Strokes: Impact of Gender and Race: Multiethnic Study of Atherosclerosis and Dallas Heart Study. Circulation Imaging 2020; 13(8).
102. Dhindsa DS, Jin Q, Sandesara PB, Mehta A, Liu C, Tahhan AS, Nayak A, Hooda A, Moazzami K, Islam SJ, Rogers SC, Almuwaqqt Z, Mokhtari A, Hesaroieh I, Ko YA, **Sperling LS**, Waller EK, Quyyumi. Circulating Progenitor Cells and Outcomes in Patients with Coronary Artery Disease. (submitted for review, JAMA Cardiology, 2020)
103. Mehta A, Meng Q, Desai SR, D’Souza MS, Ho AH, Islam SJ, Dhindsa DS, Nayak A, Alkhoder AA, Hooda A, Varughese A, Ahmad SF, Mokhtari A, Hesaroieh I, **Sperling LS**, Ko YA, Waller EK, Quyyumi AA. Vascular Regenerative Capacity and the Obesity Paradox in Coronary Artery Disease. (accepted, Arteriosclerosis, Thrombosis, and Vascular Biology, 2021)
104. Patel J, Mehta A, Al Rafai M, Blaha MJ, Nasir K, McEvoy JW, Pandey A, Kanaya AM, Kandula NR, Virani SS, Abbate A, **Sperling L**, Joshi PH. Hypertension Guidelines and Coronary Artery Calcification Among South Asians: Mediators of Atherosclerosis in South Asians Living in America (MASALA) And Multi-Ethnic Study of Atherosclerosis (MESA). (Accepted for publication, American Journal of Preventive Cardiology, 2021).
105. Mehta A, Rigdon J, Tattersall MC, German CA, Barringer TA, Joshi PH, **Sperling LS**, Budoff MJ, Bertoni A, Michos ED, Blaha MJ, Stein JH, Shapiro MD. Association of Carotid Artery Plaque with Cardiovascular Events and Incident Coronary Artery Calcium in Individuals with Absent Coronary Calcification: The Multi-Ethnic Study of Atherosclerosis (MESA)- (accepted for publication, Circulation Cardiovascular Imaging, 2021)
106. Attipoe-Dorcoo S, Ritchey MD, Loustalot F, Thompson-Paul A, Bull L, **Sperling LS**, Yang P. Characteristics and Trends of PCSK9 Inhibitor Prescription Fills in the United States. J Clin Lipidol 2021;S1933-2874(21)0027-1.
107. Almuwaqqat Z, Kim JH, Islam SJ, Tahhan AS, Mehta A, Ahmad S, Vatsa N, Beydoun N, Ejaz K, Dhindsa D, Alkhoder A, Ko YA, **Sperling LS**, Rye D, Quyyumi AA. Usefulness ofRestless Legs Symptoms to Predict Cardiovascular Outcomes in Men with Coronary Artery Disease. Accepted for publication, American Journal of Cardiology, 2021.
108. Okunrintemi V, Tibuakuu M, Virani S, **Sperling L**, Volgman A, Gulati M, Cho L, Leucker T, Blumenthal R, Michos E. Sex Differences in Diagnosis of Cardiovascular Disease: Trends from 2008-2017- The Medical Expenditure Panel Survey. (accepted for publication, JAHA, 2020)
109. Fanous MM, Gianos EG, **Sperling LS**, Mintz GL, Majure DT, Hirsh BJ. Early use of PCSK9 inhibitor therapy after heart transplantation from Hepatitis C Virus Positive Donors: Practice Management Pearls learned through a Clinical Case Series (accepted to Journal of Clinical Lipidology, 2021)
110. Dhindsa, DS, Ko YA, Sandesara PB, Mehta A, Liu C, Tahhan AS, Hayek SS, Ejaz K, Hooda A, Alkhoder A, Islam SJ, Rogers SC, Beshiri A, Murtagh G, Kim J, Wilson P, Almuwaqqat Z, **Sperling LS**, Quyyumi AA. Aggregate Clinical and Biomarker-Based Risk Model Predicts Adverse Outcomes in Patients with Coronary Artery Disease. (submitted to JAMA for consideration, 2020)
111. Thompson-Paul AM, Gillespie C, Wall HK, Loustalot F, **Sperling L**, Hong Y. Recommended and Observed Statin Use Among U.S. Adults- National Health and Nutrition Examination Survey, 2011-2018. (submitted to JACC for consideration, 2021)
112. Knijnik L, Fernandes M, Rivera M, Cardoso R, Goyal A, Liberman H, **Sperling LS**. McDaniel MC. Meta-analysis of Shorter Dual Anti-platelet Duration in Acute Coronary Syndromes treated with Percutaneous Coronary Intervention. (accepted for publication, Am J Cardiol,, 2021)
113. Mehta A, Vasquez N, Ayers C, Patel J, Hooda A, Khera A, Blumenthal R, Shapiro M, Rodriguez C, Tsai M, **Sperling L**, Virani S, Blaha M, Joshi P. Independent Association of Lipoprotein (a) and Coronary Artery Calcium with Atherosclerotic Cardiovascular Disease Risk. Accepted for publication, Journal of the American College of Cardiology, 2022
114. Liu C, Dhindsa D, Almuwaqqat Z, Ko YA, Mehta A, Alkhoder AA, Patel KJ, Hooda A, Wehbe M, **Sperling LS**, Sun YV, Quyyumi AA. U-Shaped Association between HDL-C Levels and Adverse Cardiovascular Outcomes in High-risk Populations. Published, JAMA Cardiology, 2022
115. Jain P, Hejjaji V, Thomas MB, Garcia RA, Tang Y, Tang F, Goyal A, **Sperling L**, Das SR, Hafida S, Enriquez JR, Arnold SV. Use of Bariatric Surgery among Patients with Obesity and Diabetes. Insights from the Diabetes Collaborative Registry. Accepted for publication, International Journal of Obesity, 2022.
116. Oster ME, Shay DK, Su JR, Gee JM, Marquez PL, Strid P, Woo J, Creech CB, Broder KR, Edwards K, Soslow JH, Dendy JM, Schlaudecker E, Lang SM, Barnett ED, Ruberg F, Smith MJ, Campbell MJ, Lopes R, **Sperling LS**, Baumblatt JA, Thompson DL, Pugsley R, Reagan-Steiner S, DeStefano F, Shimabukuro TT. Myocarditis after COVID-19 Vaccination. Accepted for publication, JAMA, 2022.
117. Nair PR, Jackson SL, Chang A, Schieb L, Loustalot F, Wall H, **Sperling LS**, Ritchey MD. Antihypertensive and Statin Medication adherence among Medicare Beneficiaries. Accepted for publication, American Journal of Preventive Medicine, 2022
118. Razavi AC, Iftekhar Uddin SM, Dardari ZA, Berman DS, Budoff MJ, Miedema MD, Osei AD, Obisesan OH, Nasir K, Rozanski A, Rumberger JA, Shaw LJ, **Sperling LS**, Whelton SP, Mortensen MB, Blaha MJ, Dzaye O. Coronary Artery Calcium for Risk Stratification of Sudden Cardiac Death: The Coronary Artery Calcium Consortium. Accepted for publication, JACC Imaging), 2022.
119. Yang PK, Attipoe-Dorcoo S, Park SY, Jackson SL, Ritchey MD, **Sperling LS**. Trends and Characteristics of Blood Pressure fills during the COVID-19 Pandemic in the United States. (submitted for consideration, Hypertension), 2021.
120. Mehta A, Ahmad SF, Meng Q, Ho AH, Zuniga JV, Desai SR, Dhindsa DS, Islam SJ, Almuwaqqat Z, Nayak A, Hooda A, Mokhtari A, **Sperling LS**, Ko YA, Waller EK, Quyyumi AA. Circulaitng Progenitor Cells, Cardiovascular Biomarkers, and Adverse Outcomes in Coronary Artery Disease. (submitted to JAHA for consideration), 2021.
121. Mosteoru S, Luca SA, Maximov D, Bucur A, Crisan S, **Sperling L**, Gaita D. Striving to improve the good clinical practice in the time of pandemic: Experience of a Romanian Centre: Preliminary data on COVID-19 Infection. Accepted for publication, Journal of Clinical and Diagnostic Research, 2021.
122. Jain V, Al Rafai M, Khan S, Kalra A, Rodriguez F, Samad Z, Pokharel Y, Misra A, **Sperling LS**, Rana J, Ullah W, Medhekar A, Virani SS. Association between Social Vulnerability Index and Cardiovascular Disease; A Behavioral Risk Factor Surveillance System (BRFSS) Study. Accepted, Journal of American Heart Association, 2022
123. Keteyian S, Jackson SL, Chang A, Brawner CA, Wall Hk, Forman DE, Sukul D, Ritchey MD, **Sperling LS**. Tracking Cardiac Rehabilitation Utilization in Medicare Beneficiaries-2017 Update. Accepted for publication. Journal of Cardiopulmonary Rehabilitation and Prevention, 2022
124. Abbas A, Hannan J, Stolp H, Coronado F, **Sperling LS**. Commitment to Hypertension Control during the COVID-19 Pandemic- Million Hearts Exemplars. Accepted for publication, Preventing Chronic Disease, 2022
125. Garney WR, Patterson MS, Panjwani S, Garcia K, Spadine MN, Muraleetharan D, Hahn LK, Clymer J, **Sperling L**. A Mixed Methods Network Evaluation of a National Cardiovascular Disease Prevention Effort: The Million Hearts Collaboration (under consideration, Journal of Prevention and Health Promotion, 2021)
126. Khan Minhas AM, Wyand RA, Ariss RW, Nazir S, Jain V, Al-Kindi SG, Shapiro MD, Clark D, **Sperling L**, Virani SS. Rural-Urban Trends in Congenital Heart Disease-related Mortality in the United States, 1999-2019. Accepted to JACC Advances, 2022.
127. Martin BI, Walter M, Javier G, Carolina R, Fernando G, Mariano G, Gerardo P, Mariano T, Federico A, Silvia , Luis G, Rodolfo, **Sperling L**. Survey of Latin American cardiologists’ attitude on Type 2 Diabetes Treatment. (submitted to Global Heart for consideration), 2022.
128. Issa R, Nazir S, Khan Minhas AM, Lang J, Ariss RW, Kayani WT, Khalid MU, **Sperling L**, Shapiro MD, Jneid H, Gupta R. Demographic and Regional Trends in Peripheral Arterial Disease Mortality in the United States, 2000-2019. (submitted to Circulation: Quality and Outcomes for consideration), 2022.
129. Khan Minhas AM, Ijaz SH, Javed N, Sheikh AB, Jain V, Michos ED, Greene SJ, Fudim M, Warraich HJ, Shapiro MD, Al-Kindi SG, **Sperling L**, Virani SS. National Trends and Disparities in Statin Use for Ischemic Heart Disease from 2006-2018: Insights from the National Ambulatory Medical Care Survey. Accepted for publication, Am Heart Journal for consideration). 2022
130. Faaborg-Andersen CC, Liu C, Subramaniyam V, Desai SR, Sun YV, Wilson PWF, **Sperling LS**, Quyyumi AA. Very High Apolipoproten A1 Levels are Associated with Increased Mortality. (submitted to JAHA for consideration). 2022
131. Woodruff RC, Garg S, George MG, Jackson SL, Loustalot F, Patel K, Taylor CA, Wortham JM, Whitaker M, Reingold A, Alden NB, Meek J, Anderson E, Weigel A, Henderson J, Bye E, Davis SS, Bennett NM, Barney G, Shiltz E, Sutton M, Talbot HK, Price A, **Sperling LS**, Havers FP for the COVID-19 –Associated Hospital Surveillance Network. Acute Cardiac Events among Adults during COVID-19-Associated Hospitalizations- 250 Hospitals in 14 states (January-November0: The COVID-19-Associated Hospitalization Surveillance Network. (submitted to Circulation for consideration, 2022)
132. Ford ND, DeSisto CL, Galang R, Kuklina E, **Sperling L**, Ko Y. Cardiac Arrest during Delivery Hospitalizations, United States, 207-2019. (submitted for consideration to JAMA, 2022)
133. Razavi AC, Dzaye O, Michos ED, Budoff MJ, Allen NB, Lima JAC, Polak JF, Post WS, Nasir K, Blumenthal RS, **Sperling LS**, Blaha MJ, Whelton SP. Non-traditional Risk Markers for Incident Coronary Calcium among Persons > 65 Years Old: The Multi-Ethnic Study of Atherosclerosis. (submitted to JACC Advances for consideration, 2022).
134. Sekkarie A, Park S, Therrien NL, Jackson SL, Woodruff RC, Attipoe-Dorcoo S, Yang PK, **Sperling L**, Loustalot F, Thompson-Paul AM. Trends in Lipid Lowering Prescriptions: Increasing Use of Guideline Concordant Pharmacotherapies, U.S., 2017-2022. (submitted to JAMA Cardiology Brief Reports for consideration, 2022)
135. Razavi AC, van Assen M, De Cecco CN, Dardari ZA, Berman DS, Budoff MJ, Miedema MD, Nasir K, Rozanski A, Rumberger JA, Shaw LJ, **Sperling LS**, Whelton SP, Mortensen MB, Blaha MJ, Dzaye O. Discordance between Coronary Artery Calcium Area and Density Predicts Long-term Atherosclerotic Cardiovascular Disease Risk. (accepted for publication, JACC CV Imaging,2022)
136. Arnold SV, Gosch k, Kosiborod M, Wong ND, **Sperling LS**, Newman JD, Vaduganathan M. Contemporary Use of Cardiovascular Risk Reduction Strategies in Type 2 Diabetes: Insights form the Diabetes Collaborative Registry. Submitted for consideration, Special focus issue- Journal of Cardiac Failure, 2022
137. Tso JV, Turner CG, Liu C, Miller AB, Eapen DJ, **Sperling LS**, Kim JH. Exercise Blood Pressure Changes and Aortic Dilatation in Male Masters Endurance Athletes. Submitted for consideration, JAMA Cardiology, 2022
138. Review articles:
139. **Sperling LS** and Delafontaine P. The current use of calcium antagonists. *Resident and Staff Physician* 1998; 44(6):68-72.
140. **Sperling, LS**, Nell C, Adams L, Barakat I. Case studies in preventive cardiology. *Cardiology Board Review Manual* *Hospital Physician* 1999; 5(3):1-12.
141. Kirby JF and **Sperling LS**. Electron beam computed tomography: a noninvasive method to evaluate coronary artery disease. *Physician Assistant Journal* 2000; 24(1):32-50.
142. Sorrentino M, **Sperling L**. The diet dilemma: Finding a rational resolution. *Lipid Letter* 2003; 3(2):1-9.
143. **Sperling, LS**. Follow-up of PROVE-IT. *ACC Current Journal* Review. 2004; 13(10):13-15.
144. **Sperling, LS**. TLC: Strategies for promoting a heart-healthy lifestyle. *Lipid* *Letter*. 2004; 4(2): 1-7.
145. Blumenthal RS and **Sperling LS**. Identifying and managing the vulnerable family. *Lipid Letter* 2005; 5(1):2-11.
146. Pacini R, Patel DR, Bavikati V, **Sperling LS**. Prehypertension: Detection, evaluation, and management. *Current Treatment Options in Cardiovascular* *Medicine* 2008;10:273-282.
147. Pandian A, **Sperling LS**, Khan BV. Targeting multiple dyslipidemias with fixed combinations-A focus on extended release niacian and simvastain. *Vascular Health/Risk Management,* 2008 October; 4(5): 1001–1009.
148. Smiley WH, Khan BV, **Sperling LS**. Management of the statin-intolerant patient. Current Treatment Options in Cardiovascular Medicine 2009, 11:263-271.
149. Mehta PK, Baer J, Nell C, **Sperling LS**. Low-density lipoprotein apheresis as a treatment option for hyperlipidemia. Current Treatment Options in Cardiovascular Medicine 2009, 11:279-288.
150. Ramsden CE, Favrot KR, Carera-Bastos P, Cordain L, DeLorgeril M, **Sperling LS.** Dietary fat quality and coronary heart disease prevention: A unified theory based on evolutionary, historical, global and modern perspectives. Current Treatment Options in Cardiovascular Medicine 2009, 11:289-301.
151. Brown WV, Brown AS, Raggi P, **Sperling LS.** Appropriate use of non-invasive vascular measures in prevention of arterial disease. Journal of Clinical Lipidology, 2009 3(5).
152. Bajpai A, Goyal A, **Sperling L.** Should we measure C-Reactive Protein on Earth or just on Jupiter? Clinical Cardiology 2010 33(4):190-198.
153. Bhatt KN, Wells BJ, **Sperling LS**, Baer J. High Density Lipoprotein Therapy: Is There Hope? Current Treatment Options in Cardiovascular Medicine. 2010;12(4):315-28.
154. Abraham, NS, Hlatky MA, Antman AM, Bhatt DL, Bjorkman DJ, Clark CB, Furberg CD, Johnson DA, Kahi CJ, Laine L, Mahaffey KW, Quigley EM, Scheiman J, **Sperling LS**, Tomaselli GF. ACCF/ACG/AHA 2010 Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines: a Focused Update of the ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use. J Am Coll Cardiol. 2010;56(24)2051-66.
155. Abraham, NS, Hlatky MA, Antman AM, Bhatt DL, Bjorkman DJ, Clark CB, Furberg CD, Johnson DA, Kahi CJ, Laine L, Mahaffey KW, Quigley EM, Scheiman J, **Sperling LS**, Tomaselli GF. ACCF/ACG/AHA 2010 Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines: a Focused Update of the ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use. Am J Gastroenterol. 2010;105(12):2533-49..
156. Abraham, NS, Hlatky MA, Antman AM, Bhatt DL, Bjorkman DJ, Clark CB, Furberg CD, Johnson DA, Kahi CJ, Laine L, Mahaffey KW, Quigley EM, Scheiman J, **Sperling LS**, Tomaselli GF. ACCF/ACG/AHA 2010 Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines: a Focused Update of the ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use. Circulation. 2010;122(24):2619-33.
157. Abd, TT, Eapen DJ, Bajpai A, Goyal A, Dollar A, **Sperling L**. The role of C-reactive protein as a risk predictor of coronary atherosclerosis: Implications from the JUPITER trial. Curr Atheroscler Rep 2011;13:154-161..
158. Ramjee V, **Sperling LS**, Jacobson TA. Non-HDL versus ApoB in Cardiovascular Risk Stratification: Do the Math. J Am Coll Cardiol 2011;58 (5):457-63.
159. Eapen DJ, Manocha P, Valiani K, Mantini N, **Sperling L**, McGorisk GM. Alcohol and the Heart: An ounce of Prevention. Current Treatment Options in Cardiovascular Medicine, 2011 Volume 13, Issue 2: 313-25
160. Burroughs Pena M, Patel DR, Rodriguez Leyva D, Khan BK, **Sperling L.** Lifestyle Risk Factors and Coronary Heart Disease in Cubans and Cuban Americans. Cardiol Res Pract. 2012:470705.
161. Shen J, Goyal A, **Sperling L**. The Emerging Epidemic of Obesity, Diabetes, and the Metabolic Syndrome in China. Cardiol Res Pract. 2012;178675.
162. Ramjee V, **Sperling LS**, Jacobson TA. The good, the bad, and the atherogenic.(Author reply) J Am Coll Cardiol 2012:59(14):1334.
163. Ramjee V, Eapen DJ, **Sperling LS**. Optimal lipid targets (OLT) in the new era of cardiovascular prevention. Ann NY Acad Sci.2012; 1254:106-14.
164. **Sperling, LS**. Lessons about the heart, of the heart, and from the heart: Remembering J. Willis Hurst. Clin. Cardiol. 2012. 35,4,199
165. Martin SS, Metkus TS, Horne A, Blaha M, Hasan R, Campbell CY, Yousuf O, Joshi P, Kaul S, Miller M, Michos E, Jones SR, Gluckman TJ, Cannon CP, **Sperling LS**, Blumenthal RS. Waiting for the National Cholesterol Education Program Adult Treatment Panel IV Guidelines and, in the meantime, some challenges and recommendations. Am J Cardiol. 2012;110(2):307-13.
166. Ramjee V, Jacobson T, **Sperling LS**. What should we measure to calculate CV risk- LDL, non-HDL, or apo B? (published as expert opinion in ACC Cardiosource);2012.
167. Daruwalla J, Nell C, **Sperling L**, Book W. All in the family? Review of pregnancy associated cardiomyopathy. J Med Assoc Ga. 2013;102(3):24-5.
168. Knowles JW, O’Brien EC, Greendale K, Wilemon K, Genest J, **Sperling LS,** Neal WA, Rader DJ, Khoury MJ. Reducing the burden of disease and death from familial hypercholesterolemia: A call to Action. Am Heart J 2014;168:807-11.
169. Knapper J, Schultz JC, Das G**, Sperling L**. Cardiac platypnea-orthodeoxia syndrome: an often unrecognized malady. Clin Cardiol. 2014;37(10):645-9.
170. Gaita D, Mosteoru S, **Sperling L**. Diabetes management: Lowering cardiovascular risk. European Cardiology Review 2014;9(1):7-9.
171. Feldman DI, Blaha MJ, Santos RD, Jones SR, Blumenthal RS, Toth PP, **Sperling LS**, Martin SS. Recommendations for the management of patients with Familial Hypercholesterolemia. Curr Atheroscler Rep. 2015;17(1):473.
172. Wilmot KA, Khan A, Krishnan S, Eapen DJ**, Sperling L**. Statins in the Elderly: A Patient-focused Approach. Clin Cardiol. 2015;38(1):56-61.
173. Lambert CT, Sandesara PB, Isiadinso I, Gongora CN, Eapen D, Bhatia NK, Baer JT, **Sperling**. Current Treatment of Familial Hypercholesterolemia. European Cardiology Review 2014;9(2):76-81.
174. Sandesara PB, Lambert CT, Gordon NF, Franklin BA, Wenger NK, **Sperling L**. Cardiac Rehabilitation and Risk Reduction: Time to “Rebrand and Reinvigorate” J Am Coll Cardiol 2015;65:389-95.
175. Martin SS, **Sperling LS**, Blaha MJ, Wilson PWF, Gluckman TJ, Blumenthal RS, Stone NJ. Spotlight on the Clinician-patient risk discussion for ASCVD Prevention: Importance to implementation of tthe 2013 ACC / AHA Guidelines. J Am Coll Cardiol 2015;65(13):1361-1368.
176. Shen J, Wilmot KA, Ghasemzadeh N, Molloy DL, Burkman G, Mekonnen G, Gongora CM, Quyyumi AA, **Sperling LS**. Mediterranean Dietary Pattern and Cardiovascular Health. (accepted for publication in the Annual Review of Nutrition, volume 35).
177. **Sperling LS**. Safety and Trust, Above All Else. J Am Coll Cardiol 2015;65:1593-1594.
178. Hirsh BJ, Smilowitz NR, Rosenson RS, Fuster V, **Sperling LS**. Utilization of and Adherence to Guideline-Recommended Lipid-Lowering Therapy after Acute Coronary Syndrome: Opportunities for Improvement. J Am Coll Cardiol 2015;66:184-92.
179. MacNamara JP, Eapen DJ, Quyyumi AA, **Sperling L**. Novel biomarkers for Cardiovascular risk assessment: Current status and future directions. Future Cardiology, accepted for publication in September of 2015.
180. **Sperling LS,** Mechanick JI, Neeland IJ, Herrick CJ, Despres JP, et al. The Cardiometabolic Health Alliance: Working Toward a New Care Model for the Metabolic Syndrome. J Am Coll Cardiol 2015;66:1050-67.
181. **Sperling LS**, Nelson JR. History and Future of Omega-3 Fatty Acids in Cardiovascular Disease (under review, Mayo Clinic Proceedings)
182. Kopecky S, Baum S, Foody JM, Koren M, McKenney J, **Sperling L**, Wong N. Insights into Statin Intolerance. Clin Cardiol 2015;38(9):520-526.
183. Lambert CT, Sandesara PB, Hirsh B, Shaw LT, Lewis W, Quyyumi AA, Schinazi RF, Post WS**, Sperling L**. HIV, HAART, and the Heart: A Cellular to Epidemiologic Review. (accepted to HIV Medicine)
184. Knapper JT, Ghasemzadeh N, Khayata M, Patel SP, Quyyumi AA, Mendis S, Mensah GA, Taubert K, **Sperling LS**. Time to Change our Focus: Defining, Promoting, and Impacting Cardiovascular Population Health. J Am Coll Cardiol 2015;66:960-71.
185. Forman DE, Alexander K, Brindis RG, Curtis AB, Maurer M, Rich MW, **Sperling L**, Wenger NK. Improved Cardiovascular Disease Outcomes in Older Adults. (accepted for publication, F1000Faculty Reviews, Jan 2016:112)
186. **Sperling LS**, Nelson JR. History and Future of Omega-3 Fatty Acids in Cardiovascular Disease. (accepted to Current Medical Research and Opinion)
187. Varghese T, Schultz WM, McCue AA, Lambert CT, Sandesara PB, Eapen DJ, Gordon NF, Franklin BA, **Sperling LS**. Physical Activity in the Prevention of CHD: Implications for the Clinician. (accepted for publication, BMJ-Heart, 2016)
188. Schultz WM, Varghese T, Heinl RE, Dhindsa DS, Mahlof EN, Cai HC, Southmayd G, Sandesara PB, Eapen DJ, **Sperling LS**. Natural Approaches in Diabetes management: A review of diet, exercise,, and natural products. (accepted for publication, Current Pharmaceutical Design).
189. Heinl RE, Dhindsa DS, Mahlof EN, Schultz WM, Ricketts J, Varghese T, Esmaeeli A, Allard-Ratick M, Kelli HM, Sandesara PB, Eapen DJ, **Sperling L**. Comprehensive Cardiovascular Risk Reduction and Cardiac Rehabilitation in the Metabolic Syndrome and Diabetes. (accepted for publication Canadian Journal of Cardiology)
190. Eapen DJ, Schultz WM, Heinl RE, Ghasemzadeh N, Varghese T, Kurian DE, Mathai CE, Sandesara P, Kindya BR, Allard-Ratick MP, Bhatia NK, Isiadinso I, **Sperling LS**. Primary Prevention of Cardiovascular Disease. (accepted to Cardiovascular Innovations and Applications)
191. Wong ND, **Sperling LS**, Baum SJ. The American Society for Preventive Cardiology: Our 30 Year Legacy. (accepted to Clinical Cardiology)
192. Heinl RE, Ricketts JC, Tennant HM, Sandesara PB, Moriarity PM, **Sperling L**. Lipoprotein X Disease in the Setting of Sever Cholestatic Hepatobiliary Autoimmune Disease. (accepted for publication, Journal of Clinical Lipidology)
193. **Sperling LS**, Sandesara PPB, Kim JH. Exercise is Medicine: Proof …and Posssibilities? (invited editorial, accepted for publication in JACC Imaging)
194. Hammadah M, Kindya BR, Allard-Rattick MP, Jazbeh S, Eapen D, Wilson Tang WH, **Sperling L**. Navigating Air Travel and Cardiovascular Concerns: Is the Sky the Limit? (under review, Clinical Cardiology)
195. Isakadze N, Sandesara PB, Patel R, Baer J, Isiadinso I, Alonso A, Lloyd M, **Sperling L**. Atrial Fibrillation: Focus on Prevention (under review, JAMA IM)
196. Lee SK, Khambhati J, Varghese T, Stahl E, Kumar S, Sandesara PB, Wenger NK, **Sperling L**. Comprehensive Primary Prevention of Cardiovascular Disease in Women. (under review, Clinical Cardiology)
197. Khambhati J, Allard-Rattick M, Dhindsa D, Lee S, Chen J, Sandesara PB, Quyyumi AA, Wong ND, Blumenthal RB, **Sperling L**. The Art of Cardiovascular Risk Assessment. (under review, JAMA Cardiology)
198. Franklin BA, Brinks J, Berra K, Lavie CJ, Gordon NF, **Sperling LS**. Using Metabolic Equivalents in Clinical Practice. *Am J Cardiol.* 2017.
199. **Sperling LS,** Sandesara PB and Kim JH. Exercise Is Medicine: Proof . . . and Possibilities? *JACC Cardiovasc Imaging*. 2017.
200. Lee SK, Khambhati J, Varghese T, Stahl EP, Kumar S, Sandesara PB, Wenger NK and **Sperling LS**. Comprehensive primary prevention of cardiovascular disease in women. *Clin Cardiol*. 2017;40:832-838.
201. Heinl RE, Tennant HM, Ricketts JC, Rice CR, Robinson CB, Sandesara PB, Moriarty PM and **Sperling L**. Lipoprotein-X disease in the setting of

severe cholestatic hepatobiliary autoimmune disease. *J Clin Lipidol*. 2017;11:282-286.

1. Hammadah M, Kindya BR, Allard-Ratick MP, Jazbeh S, Eapen D, Wilson Tang WH and **Sperling L**. Navigating air travel and cardiovascular concerns: Is the sky the limit? *Clin Cardiol*. 2017;40:660-666.
2. Cicero AFG, Colletti A, Bajraktari G, Descamps O, Djuric DM, Ezhov M, Fras Z, Katsiki N, Langlois M, Latkovskis G, Panagiotakos DB, Paragh G, Mikhailidis DP, Mitchenko O, Paulweber B, Pella D, Pitsavos C, Reiner Z, Ray KK, Rizzo M, Sahebkar A, Serban MC, **Sperling LS,** Toth PP, Vinereanu D, Vrablik M, Wong ND and Banach M. Lipid lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel. *Arch Med Sci*. 2017;13:965-1005.
3. Cicero AFG, Colletti A, Bajraktari G, Descamps O, Djuric DM, Ezhov M, Fras Z, Katsiki N, Langlois M, Latkovskis G, Panagiotakos DB, Paragh G, Mikhailidis DP, Mitchenko O, Paulweber B, Pella D, Pitsavos C, Reiner Z, Ray KK, Rizzo M, Sahebkar A, Serban MC, **Sperling LS,** Toth PP, Vinereanu D, Vrablik M, Wong ND and Banach M. Lipid-lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel. *Nutr Rev*. 2017;75:731-767.
4. Wong ND, **Sperling LS** and Baum SJ. The American Society for Preventive Cardiology: Our 30-year legacy. *Clin Cardiol*. 2016;39:627-630.
5. Varghese T, Schultz WM, McCue AA, Lambert CT, Sandesara PB, Eapen DJ, Gordon NF, Franklin BA and **Sperling LS**. Physical activity in the prevention of coronary heart disease: implications for the clinician. *Heart*. 2016;102:904-9.
6. **Sperling LS** and Nelson JR. History and future of omega-3 fatty acids in cardiovascular disease. *Curr Med Res Opin*. 2016;32:301-11.
7. Schultz WM, Varghese T, Hein RE, Dhindsa DS, Mahlof EN, Cai HC, Southmayd G, Sandesaraa PB, Eapen DJ and **Sperling LS**. Natural Approaches in Diabetes Management: A Review of Diet, Exercise, and Natural Products. *Curr Pharm Des*. 2016.
8. Lambert CT, Sandesara PB, Hirsh B, Shaw LJ, Lewis W, Quyyumi AA, Schinazi RF, Post WS and **Sperling L**. HIV, highly active antiretroviral therapy and the heart: a cellular to epidemiological review. *HIV Med*. 2016;17:411-24.
9. Heinl RE, Dhindsa DS, Mahlof EN, Schultz WM, Ricketts JC, Varghese T, Esmaeeli A, Allard-Ratick MP, Millard AJ, Kelli HM, Sandesara PB, Eapen DJ and **Sperling L.** Comprehensive Cardiovascular Risk Reduction and Cardiac Rehabilitation in Diabetes and the Metabolic Syndrome. *Can J Cardiol*. 2016;32:S349-S357.
10. Forman DE, Alexander K, Brindis RG, Curtis AB, Maurer M, Rich MW, **Sperling L** and Wenger NK. Improved Cardiovascular Disease Outcomes in Older Adults. *F1000Res*. 2016;5.
11. Wilmot KA, Khan A, Krishnan S, Eapen DJ and **Sperling L**. Statins in the elderly: a patient-focused approach. *Clin Cardiol*. 2015;38:56-61.
12. Franklin BA, Brinks J, Berra K, Lavie CJ, Gordon NJ, **Sperling LS**. Using Metabolic Equivalents in Clinical Practice. (accepted for publication Am J Cardiol)
13. Khambhati J, Allard-Ratick M, Dhidsa D, LeeS, Chen J, Sandesara PB, O’Neal W, Quyyumi AA, Wong ND, Blumenthal RB, **Sperling L**. The Art of Cardiovascular Risk Assessment. (accepted for publication, Clinical Cardiology)
14. Sandesara PB, **Sperling LS**. Caloric Restriction as a therapeutic approach to Heart Failure: Can less be more in (mice) and men? Circ Heart Fail 2018;11 e004930.
15. Schultz WM, Kelli HM, Lisko JC, Varghese T, Shen J, Sandesara P, Quyyumi AA, Taylor HA, Gulati M, Harold JG, Mieres JH, Ferdinand KC, Mensah GA, **Sperling LS**. Socioeconomic Status and Cardiovascular Outcomes: Challenges and Interventions. Circulation. 2018. 137;2166-2178.
16. Khambhati J, Engels M, Allard-Ratick M, Sandesara PB, Quyyumi AA, **Sperling LS**. Immunotherapy for the Prevention of Atherosclerotic Cardiovascular Disease: Promise and Possibilities. (accepted for publication, Atherosclerosis, 2018)
17. Sandesara PB, Dhindsa D, Khambhati J, Lee SK, Varghese T, O’Neal WT, Harzand A, Gaita D, Kotseva K, Connolly S, Jennings C, Grace SL, Wood DA, **Sperling LS.** Reconfiguring Cardiac Rehabilitation to Achieve Panvascular Prevention: New Care models for a New World. (accepted for publication, Canadian Journal of Cardiology, 2018)
18. Das SR, Everett BM, Birtcher KK, Brown JM, Cefalu WT, Januzzi JL Jr, Kalyani RR, Kosiborod M, Magwire ML, Morris PB, **Sperling LS.**

2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. J Am Coll Cardiol. 2018 Dec 18

1. Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, de Ferranti S, Faiella-Tommasino J, Forman DE, Goldberg R, Heidenreich PA, Hlatky MA, Jones DW, Lloyd-Jones D, Lopez-Pajares N, Ndumele CE, Orringer CE, Peralta CA, Saseen JJ, Smith SC Jr, **Sperling** **L**, Virani SS, Yeboah J. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol. Circulation. 2019; 139:e1082
2. Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, de Ferranti S, Faiella-Tommasino J, Forman DE, Goldberg R, Heidenreich PA, Hlatky MA, Jones DW, Lloyd-Jones D, Lopez-Pajares N, Ndumele CE, Orringer CE, Peralta CA, Saseen JJ, Smith SC Jr, **Sperling L**, Virani SS, Yeboah J. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol. J Am Coll Cardiol 2019 73(24); e285-350

1. Lloyd-Jones DM, Braun LT, Ndumele CE, Smith SC Jr, **Sperling LS**, Virani SS, Blumenthal RS. Use of Risk Assessment Tools to Guide Decision-Making in the Primary Prevention of Atherosclerotic Cardiovascular Disease. Circulation. 2018 Nov 10
2. Stahl EP, Dhindsa DS, Lee SK, Sandesara PB, Chalasani NP, **Sperling LS** . Nonalcoholic Fatty Liver disease and the Heart. J Am Coll Cardiol 2019 73(8): 948-63
3. Dhindsa DS, Mehta A, Sandesara PB, **Sperling LS**, Baer JT. Is there still a role for Aspirin in Primary Prevention? (accepted for publication in The NLA Lipid Spin, 2018)
4. Isakadze N, Sandesara PB, Patel R, Baer J, Isiadinso I, Alonso A, Lloyd M, **Sperling LS**, Life’s Simple 7 Approach to Atrial Fibrillation Prevention. JAFIB 2018; 11(3)
5. Mehta A, Dhindsa DS, Reidel VJ, Quyyumi AA, **Sperling LS**. The Need for Academic Preventive Cardiology Training: The Katz Fellowship Program at Emory University. (accepted for publication, EHJ Cardiopulse, 2019)
6. Allard-Ratick M, Sandesara PB, Quyyumi AA**, Sperling LS.** Everything in Moderation: Investigating the U-Shaped link between HDL-Cholesterol and Adverse Outcomes. (accepted for publication in U.S. Cardiology Review, 2019).
7. Thobani A, Dhindsa DS, DeMoss BD, Sandesara PB, Raad M, **Sperling LS,** Baer JT. Aspirin in Cardiovascular Disease: Rethinking Aspirin’s Role in Primary Prevention. (accepted for publication, Am J Cardiol, 2019)
8. Allard-Ratick MP, Kindya BR, Khambhati J, Engels MC, Sandesara PB, Rosenson RS, **Sperling LS**. HDL: Fact, Fiction, or Function? HDL Cholesterol and Cardiovascular Risk. (accepted for publication in European Journal of Preventive Cardiology, 2019)
9. Dhindsa DS, Mehta A, **Sperling L**. Comprehensive Cardiovascular Risk Reduction in Patients with Diabetes: Emphasis of the 2018 Cholesterol Guidelines. (Guest Editorial accepted for publication in NLA Lipid Spin)
10. Dhindsa DS, Mehta A, Sandesara PB, Thobani A, Brandt S, **Sperling LS**. Strategies for Appropriate Selection of SGLT2-I vs. GLP1-RA in Persons with Diabetes and Cardiovascular Disease. (requested review, Current Cardiology Reports, 2019)
11. Dixon DL, Sharma G, Sandesara P, Yang E, Braun L, Mensah G, **Sperling L**, Deedwania P, Virani SS. The Epidemic of Therapeutic Inertia in Cardiovascular Disease Prevention: Time to Move the Bar. J Am Coll Cardiol (accepted for publication, 2019)
12. Grundy SM, Stone NJ; Writing Committee for 2018 Cholesterol Guidelines. 2018 Cholesterol Clinical Practice Guidelines: Synopsis of the 2018 AHA/ ACC/ Multispecialty Cholesterol Guideline. Ann Intern Med 2019 doi: 10.73261M19-0365
13. Mitchell S, Malanda B, Damasceno A, Eckel R, Gaita D, Kotsova K, Januzzi JL, Mensah G, Plutzky J, Prystupivk M, Ryen L, Thierer J, Virani S, **Sperling L**. A Roadmap on the Prevention of Cardiovascular Disease Among People Living with Diabetes. (accepted for publication, Global Heart, 2019)
14. Shapiro M, Maron D, Virani S, Bhatt D, Khera A, Kosiborod M, Morris P, Sandesara P, **Sperling L**, Fazio S. Preventive Cardiology as a Subspecialty of Cardiovascular Medicine: Coming to Consensus. (accepted to JACC for publication)
15. Mehta A, Dhindsa DS, Hooda A, Nayak A, Massad CS, Rao B, Makue LF, Rajani RR, Alabi O, Quyyumi AA, Escobar GA, Wells BJ, **Sperling LS**. Premature Atherosclerotic Peripheral Arterial Disease: An Under-recognized and Undertreated Disorder with a Rising Global Prevalence(accepted, Trends in Cardiovascular Medicine, 2020)
16. Mehta A, Mahtta D, Gulati M, **Sperling LS**, Blumenthal RB, Virani SS. Major Cardiovascular Disease Prevention Studies Presented at the 2019 American Heart Association Scientific Sessions. (accepted for publication, Current Atherosclerosis Reports, 2019)
17. Ritchey M, Hannan J, Wall H, George M, **Sperling L**. Million Hearts Hypertension Control Champions, 2012-2019. (submitted to MMWR Notes from the Field for consideration, 2019)
18. Das SR, Everett BM, Birtcher KK, Brown JM, Cefalu WT, Januzzi JL, Kalyani RR, Kosiborod M, Magwire ML, Morris PB, **Sperling LS**. 2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular risk Reduction in Patients with Type 2 Diabetes (published, JACC, 2020)
19. Dong TA, Sandesara PB, Dhindsa DS, Mehta A, Arneson LC, Dollar AL, Taub PR, **Sperling LS**. Intermittent Fasting: A Heart Healthy Dietary Pattern? (accepted, American Journal of Medicine, 2020)
20. Joseph J, Deedwania P, Acharya T, Aguilar D, Bhatt DL, Chyun DA, DiPalo KE, Golden SH, **Sperling LS**. Comprehensive Management of Cardiovascular Risk Factors for Adults with Diabetes Mellitus: A Scientific Statement from the American Heart Asosciation. pubished in Circulation, 2022
21. Mehta A, **Sperling LS**, Wells BJ. Diagnostic test Interpretation: Ankle Brachial Index Testing. (published, JAMA, 2020)
22. Dong T, D’Souza M, **Sperling L**. The Cardiovascular Benefits of Intermittent Fasting. (accepted as Letter, New England Journal of Medicine). 2020
23. Mehta A, Singh S, Saeed A, Mahtta D, Bittner VA, **Sperling LS**, Virani SS. Pathophysiological Mechanisms Underlying Excess Risk for Diabetes and Cardiovascular Disease in South Asians: The Perfect Storm. (invited and submitted to Current Diabetes Review, 2020)
24. Grundy SM, Stone NJ, Blumenthal RS, Braun LT, Heidenreich PA, Jones DL, Orringer CE, Saseen JJ, Smith SC, **Sperling LS,** Virani SS. High Intensity Statins Benefit High Risk Patients: Why and How to Do Better. (accepted for publication, Mayo Clinic Proceedings, 2021)
25. **Sperling LS**. The Future of Cardiovascular Prevention: Unprecedented Times. (accepted to Circulation, 2020)
26. Ritchey MD, Wall HK, Hannan J, **Sperling LS**. Million Hearts 2012-2016 Final Report Addendum: Significant Impact, Significant Opportunity. (CDC NCCDPHP DHDSP Million Hearts Website, 2020).
27. Wall HK, Stolp H, Wright JS, Ritchey MD, Thomas RJ, Ades PA, **Sperling LS**. The Million Hearts Initiative: Catalyzing Utilization of Cardiac Rehabilitation and Accelerating Implementation of New Care Models. Journal of Cardiopulmonary Rehabilitation and Prevention 2020; 40: 290-293.
28. Dhindsa D, Wong ND, **Sperling L**. Cardiovascular and Cardiometabolic Prevention: High Level Priority in the Era of COVID-19. (published, Cardiovascular Endocrinology and Metabolism, 2020)
29. D’Souza MS, Dong TA, Ragazzo G, Dhindsa DS, Mehta A, Sandesara PB, Freeman AM, Taub P, **Sperling LS**. From Fad to Fact: Evaluating the Impact of Emerging Diets on the Prevention of Cardiovascular Disease. (accepted for publication, American Journal of Medicine, 2020)
30. **Sperling LS**, Albert MA, Koppaka R. Disparities in Influenza Vaccination: Opportunity to Extend Cardiovascular Prevention to Millions of Hearts. JAMA Cardiology, 2021 Jan 1:6(1):11-12.
31. Varughese A, Patel P, Dhindsa D, Eapen DJ, **Sperling LS**. Telehealth Visits in the Real World- How best to Use Them, For Whom, and in What Payment Models? Editorial, Lipid Spin, 2020).
32. King SC, Parker-Fiebelkorn A, **Sperling LS**. Influenza Vaccination: Proven and Effective Cardiovascular Disease Prevention. ACC Expert Analysis for Prevention Clinical Topic Collection, 2020.
33. Mehta A, **Sperling LS**, Wells BJ. JAMA Letter in Reply. Further Considerations for Post-Exercise ABI Testing. 2020.
34. **Sperling, L**. Overcoming Silos: The Case for Connected Healthcare. (World Economic Forum Agenda, 2020)
35. Karagiannis AD, Mehta A, Dhindsa Ds, Virani SS, Orringer CE, Blumenthal RS, Stone NJ, **Sperling LS**. How Low is Safe? The Frontier of Very Low (< 30 md/dL) LDL Cholesterol. ( published, European Heart Journal, 2021)
36. Patel P, Dhindsa D, Eapen DJ, Khera A, Gulati M, Stone NJ, Yancy CW, Rumsfeld JS, **Sperling LS**. Optimizing the Potential for Telehealth in Cardiovascular Care (In the Era of COVID-19): Time Will Tell. Am J Med. 2021 Apr 9: S0002-9343(21)00218-7.
37. Beatty AL, Brown TM, Corbett M, Diersing D, Keteyian SJ, Mola A, Stolp H, Wall HK, **Sperling LS**. Million Hearts Cardiac Rehabilitation Think Tank: Accelerating New Care Model. (submitted for consideration, Circulation Cardiovascular Quality and Outcomes, 2021)
38. Keteyian SJ, Ades P, Beatty A, Gavic A, Hines S, Lui K, Schopfer D, Thomas RJ, **Sperling LS**. A Review of the Design and Implementation of a Hybrid Cardiac Rehabilitation Program: An Expanding Opportunity for Optimizing Cardiovascular Care. (accepted to the Journal of Cardiopulmonary Rehabilitation and Prevention, 2021)
39. Thobani A, McLaughlin TJ, **Sperling LS**. Global Prevention of Cardiovascular Disease among People Living with Diabetes: Leading with Heart. ACC Expert Analysis. 2021.
40. Burke MA, **Sperling LS**, Dotson WD, Khoury MJ. An Expanding List of Tier 1 Genomic Applications: Evidence-based Guidelines for Hypertrophic Cardiomyopathy and Public Health. CDC Blog, 2021
41. **Sperling LS**. Taking Up Arms Against the Flu. World Heart News, 2021
42. Khoury MJ**,** Bowen S, Dotson WD, Drzymalla E, Green RF, Goldstein R, Kolor K, Liburd LC, **Sperling LS**, Bunnell R. Health Equity in the Implementation of Genomics and Precision Medicine: A Public Health Imperative. accepted for publication, Genetics in Medicine, 2022
43. Commodore-Mensah Y, Loustalot F, Himmelfarb CD, Desvigne-Nickens P, Sachdev V, Bibbens-Domingo K, Cohen D, Egan BM, Fendrick MA, Ferdinand KC, Graham GN, Jaffe MG, Krumholz H, Levy PD, Mays GP, McNellis R, Muntner P, Ogedegbe OG, Milani RV, Polgreen L, Sanchez E, **Sperling LS**, Wall HK, Whittens L, Wright JT, Wright JS, Fine L. Proceedings from a National Heart, Lung, and Blood Institute and the Centers for Disease Control and Prevention Workshop to Control Hypertension. Published. American Journal of Hypertension, 2022
44. Razavi AC, Agatston AS, Shaw LJ, De Cecco C, Van Assen M, **Sperling LS**, Bittencourt MS, Daubert MA, Nasir K, Blumenthal RS, Mortensen MB, Whelton SP, Blaha MJ, Dzaye O. Evolving Role of Calcium Density in Coronary Artery Calcium Scoring and Atherosclerotic Cardiovascular Risk. (accepted for publication, JACC CV Imaging), 2022.
45. Razavi A, Prabakaran S, Sawan M, Tummula L, Onuorah I, Whelton S, **Sperling L**, Rollin F. Transient Left Bundle Branch Block Associated with Very High Coronary Calcium. (submitted for consideration, BMC CVD Disorders, 2022)
46. Razavi AC, Mehta A, **Sperling LS**. Statin Therapy for the Primary Prevention of Cardiovascular Disease: Pros. Accepted. Atherosclerosis, 2022)
47. Armstrong KA, Halbert CH, Bedard AC, Bowen S, Bunnell R, Coronado F, Friedman S, Green RF, Grosse SD, Henrikson NB, Knowles JW, Kolor K, Liburd LC, Lubin IM, Lyon M, Pemu PE, Rahm AK, Roberts MC, Rodriguez JL, Senier L, Schrader KA, Schully SD, Shelburne N, **Sperling LS**, Trepanier AM, Wilemon KA, Clyne M, Dotson WD, Khoury MJ. Effective and Equitable Implementation of Cascade Genetic Testing: Determinants, Strategies, Actions, and Research Agenda. (submitted for consideration, Genetics in Medicine, 2022)

e. Book chapters:

1. **Sperling LS**, Cutler DA, and Runge MS. Thrombolytic therapy: risks, complications, and limitations, in complications of interventional procedures. Topics in Clinical Cardiology, Igaku-Shoin Publishers, N.Y., 1995.
2. **Sperling LS** (contributing author). Hurst’s The Heart. Pretest self-assessment and review, 9th edition, Mcgraw-Hill, 1998.
3. **Sperling LS**. Effective coordination of care, in A Successful Transition (a cardiology fellow’s guide to applying clinical skills to office-base care), Dowden Publishing Company, Montvale, N.J., 1999.
4. Guest TM, **Sperling LS**, Ballard DJ, and Weintraub WS. Cardiovascular complications of diabetes, in Clinical Diabetes Mellitus: a Problem-Oriented Approach, 3rd edition, Thieme medical publishers, N.Y., 2000.
5. Sayar S, Nell CL, **Sperling LS**. Atherosclerosis: pathophysiology and preventive strategies, in The AHA Clinical Cardiology Consult, Lippincott, Williams and Wilkens, Philadelphia. 2001
6. **Sperling LS,** Miller JI. Mangement of Ischemic Heart Disease, in Office Practice of Medicine, 4th Edition, Saunders, 2003.
7. **Sperling LS.** Diets and Cardiovacular disease, in Living Well by Montel Williams. Viking-Penguin New American Library. Pages 163-164. 2008.
8. Georgiopoulou VV, Kalogeropoulos A, **Sperling LS**, Butler J. Heart Failure Prevention, in Prevention of Cardiovascular Disease (A Companion to Braunwald’s Heart Disease). Elsevier, accepted for publication, 2010.
9. Nieva R, Achtchi A, Eapen D, Dollar AL, Baer J, Mavromatis K, **Sperling** **LS**. Impact of Medical Therapy on Cardiovascular Secondary Prevention, in Lifestyle Medicine, 2nd Ed. 2012
10. Eapen D, Achtchi A, Nieva R, Valiani K, Zarreen F, Patel A, Dollar A, Isiadinso I, Parashar S, Baer J, Mavromatis K, **Sperling L**. Impact of Preventive Therapies on Clinical Management and Outcomes, in Atherosclerosis: Risk, Mechanism, and Therapy. Wiley and sons.
11. Ashen MD, Nell-Dybdahl CL, **Sperling L,** Blumenthal RS. Development of a Center for Cardiovascular Disease Prevention, in The American Society for Preventive Cardiology Manual of Preventive Cardiology, Demos Medical, 2014.
12. Eapen DJ, Ghasemzadeh N, Bhatia N, Patel A, Clermont E, Cassimatis D, Isiadinso I, **Sperling L**. Primary Prevention of Cardiovascular Disease Guidelines, in The American Society for Preventive Cardiology Manual of Preventive Cardiology, Demos Medical, 2014

1. Eapen DJ, Ghasemzadeh N, Bellam N, Bhatia N, Viliani K, Shen J, VanDam RJ, Flueckiger P, Molloy DL, Kay J, Achtchi A, Wells BJ, Baer JT, Wenger NK, **Sperling L**. Principles of Primary and Secondary Prevention of Cardiovascular Disease, in Panvascular Medicine, 2015
2. Sandesara PB, Eapen D, **Sperling L**. Exercise Rehabilitation and Exercise for Prevention. American College of Cardiology Self-Assessment Program 9 (ACCSAP 9, 6.8). 2017
3. Gaita D, **Sperling L**. Prevention and Control of Cardiovascular Disease: What Works, in Prevention of Cardiovascular Diseases- From Current Evidence to Clinical Practice. Springer. 2015
4. Dhindsa DS, Shen J, Sandesara PB, **Sperling LS**. Integrative Approach in Cardiovascular Disease (Chapter 20), in Nutrition, Fitness, and Mindfulness: An Evidence-based Guide for Clinicians

1. Lee SK, Khambhati J, Sandesara PB, Eapen D, Lundberg G, Margolis B, Gordon N, Franklin B, **Sperling LS**. Comprehensive Secondary Prevention and Cardiac Rehabilitation after CABG Surgery. In DP Taggart, JD Puskas (ed.), Coronary Artery Bypass Grafting. London. Oxford Press.
2. Shen J, Eapen DJ, Wong ND, Deedwania P, **Sperling L**. Diabetes and Metabolic Syndrome. American College of Cardiology Self-Assessment Program 10 (ACCSAP 10, 5.5) 2019
3. Khetan AK, **Sperling L**, Josephson RA. Exercise Rehabilitation and Exercise for Prevention. American College of Cardiology Self-Assessment Program 10 (ACCSAP 10) 2019
4. Dhindsa D, Mehta A, **Sperling L**. Focus on Cardiovascular Health Promotion and Disease Prevention: Opportunities for Improvement. In The American Society for Preventive Cardiology Manual of Preventive Cardiology, 2020
5. D’Souza MS, Dong TA, Dhindsa DS, Mehta A, **Sperling LS.** Optimal Dietary Approaches for those Living with Metabolic Syndrome to prevent Progression to Diabetes and Reduce the Risk of Cardiovascular Disease. 1st Edition of Nutritional and Dietary Approaches to the Prevention and Treatment of Cardiovascular Disease. Contemporary Cardiology Book Series, 2021 Springer-Nature
6. Shen J, Eapen DJ, Wong ND, Deedwania P, **Sperling L**. Diabetes and Metabolic Syndrome. American College of Cardiology Self-Assessment Program 10 Update (ACC 10), 2020.
7. Mehta A, Dhindsa DS, **Sperling LS**. Global Approaches to Cardiovascular Risk Assessment- the U.S. Guidelines. Cardiovascular Risk Assessment in Primary Prevention. Springer Nature. 2021.
8. Eapen DJ, Faaborg-Andersen C, DeStefano RJ, Karagiannis AD, Quintana RA, Dhindsa D, Chaudhuri M, Searles CD, **Sperling LS**. Defining and Optimizing Vascular Health. The Vasculome: From Many, One. Elsevier / Academic Press. 2022.
9. Khetan AK, **Sperling L**, Josephson RA. Exercise Rehabilitation and Exercise for Prevention. American College of Cardiology Self-Assessment Program 10 Update, 2021.
10. Shen J, Eapen DJ, Wong ND, Deedwania P, **Sperling L**. Diabetes and Metabolic Syndrome. American College of Cardiology Self-Assessment Program 10 Update , 2021.
11. Agrawal A, Thobani A, Garcia M, Fatade Y, Tummala LS, **Sperling L**, Isiadinso I. NAFLD and Cardiovascular Risk- At a Crossroads. Chapter 26 in Need to Know NAFLD: The Complete Guide to Non-Alcoholic Fatty Liver Disease for Clinicians, 2022

d. Other publications:

1. Miller J, **Sperling LS,** Nell C, Agahtehrani A, Weintraub W. Premature coronary artery disease: 15 year follow-up in patients under the age of 40. *J Am Coll Cardiol* 2001;37(2A):504A.
2. Tirrito SJ, **Sperling LS**, Vega D, Smith AL, Book WM. Aggressive lipid lowering does not prevent early transplant arteriopathy following cardiac transplantation (abstract presented at 8th World Congress on Heart Failure) 2002.
3. Badenhop D, Franklin B, **Sperling L**, Digenio R, Salmon R, Gordon N. Risk factor status on entry into contemporary phase 2 cardiac rehabilitation programs. *J Cardiopulm Rehab* 2001;21:321.
4. Gordon N, Franklin B, **Sperling L**, Badenhop D, Digenio A, Mitchell B, Salmon R. Stage of readiness to change multiple behaviors at entry to phase 2 cardiac rehabilitation programs. *J Cardiopulm Rehab* 2001;21:321.
5. Bonzheim K, Watson C, Fraanklin B, **Sperling L,** Badenhop D, Digenio A, English R, Gordon N. Need for continued cardiovascular disease risk reduction intervention after completion of a contemporary phase 2 cardiac rehabilitation program. *J Cardiopulm Rehab* 2001;21:321.
6. Haapaniemi SS, Franklin BA, **Sperling LS**, Badenhop DT, Salmon RD, English CD, Gordon NF. Clinical effectiveness of a phase 2 cardiac rehabiltation program in participants with and without arthritis (abstract presented at 2002 ACSM meeting).
7. Miller J, Fukai T, **Sperling L,** Landmesser U, Spiekerman S, Harrison D. Extracellular superoxide dismutase activity and protein expression in normal subjects and subjects with coronary artery disease. *Circulation* (Supplement II) 2001;104(17):294.
8. Galt JR. Krawczynska EG, Ingram F, Poole RA **Sperling LS**, Halkar RK. Optimization of simultaneous 201 Tl/99mTc BRU59-21 SPECT for myocardial viability determination. *J Nuc Med* 2002;43(5):183P.
9. Savona T, Salmon R, English C, **Sperling L**, Pickel S, Leighton R, Franklin B, Gordon N. Clinical effectiveness of a community-based cardiovascular risk reduction program in participants with versus without prediabetes. *J Cardiopulm Rehab* 2002;22:362.
10. Maynard T, **Sperling L,** Franklin B, Hall L, Salmon R, Gordon N. Effect of a phase 2 cardiac rehabilitation program on serum lipids and lipoproteins in patients with versus without known peripheral arterial disease. *J Cardiopulm Rehab* 2002;22:349.
11. Doughty M, **Sperling L**, Bishop-Lindsay KL, Salmon R, Mitchell B, Franklin B, Gordon N. Effect of educational status on clinical outcomes in participants in a contemporary phase 2 cardiac rehabilitation program. *J Cardiopulm Rehab* 2002;22:349.
12. **Sperling L**, Kallish S, Thiel J, Leighton R, Levinrad I, Salmon R, Franklin B, Gordon N. Clinical effectiveness of a community-based cardiovascular risk reduction program in participants with versus without the metabolic syndrome. *J Cardiopulm Rehab* 2002;22:362.
13. Haapaniemi S, Franklin B, Badenhop D, **Sperling L**, Salmon R, Gordon N. Clinical effectiveness of a phase 2 cardiac rehabilitation program in patients with versus without diabetes. *J Cardiopulm Rehab* 2002;22:362.
14. Larned J, Miller J, Mansour C, **Sperling L**. Clinical markers of cardiovascular risk (accepted as abstract for 10/03 AACVPR meeting).
15. Webb J, Hall L, Franklin B, **Sperling L**, Lewis A, Faircloth C, Levinrad I, Salmon R, Gordon N. Getting to goal: Is lifestyle intervention worth the effort in patients with an elevated blood glucose level? (presented at 10/03 AACVPR meeting).
16. Lewis A, Franklin B, Hall L, **Sperling L**, Faircloth C, Levinrad I, Salmon R, Gordon N. Getting to goal: Is lifestyle intervention worth the effort in patients with hypertension? (presented at 10/03 AACVPR meeting).
17. Franklin B, Hall L, Biggerstaff D, **Sperling L**, Pickel S, Kallish S, Thiel J, Mitchell B, Salmon R, Gordon N. Clinical effectiveness of a comprehensive cardiovascular risk reduction program in female vs. male participants (presented at 10/03 AACVPR meeting).
18. Hall L, Franklin B, Biggerstaff D, Pickel S, **Sperling L**, Thiel J, Kallish S, Mitchell B, Salmon R, Gordon N. Clinical effectiveness of a comprehensive cardiovascular risk reduction program in pre-menopausal vs. post-menopausal women (presented at 10/03 AACVPR meeting).
19. Morgan J, Schieber R, Swerdlow D, Roper M, Neff L, **Sperling L**. Myopericarditis following smallpox vaccination among civilians, United States, January-April 2003 (presented at IDSA meeting).
20. Baman T, Devireddy C, Cole J, **Sperling LS.** Coronary artery aneurysms are an independent predictor of high five-year mortality. *J Am Coll Cardiol* 2004:43(5A);282A.
21. Schieber RA, Morgan J, Roper M, Neff L, Chapman L, Iskander J, Mootrey G, **Sperling L**, Robinson,RM. Cardiac complications among civilians vaccinated against smallpox, U.S., 2003. *Circulation* (Supplement IV) 2003;108(17):751.
22. Esteves F, **Sperling L**, Miller J, Morris D, Schuster D, Halkar. PET/CT for comprehensive non-invasive assessment of the coronaries: a single stop test (accepted as abstract to Society of Molecular Imaging).2003
23. Gordon NF, **Sperling LS**, et al. Getting risk factors to goal: Lifestyle intervention is worth the effort in patients with hypertension, hyperlipidemia, and hyperglycemia. *J Am Coll Cardiol* 2004:43(5A);27A.
24. Miller J, McDaniel MC, **Sperling L**, STARR investigators. Inpatient cardiac risk factor management program can promote therapeutic lifestyle change. *J Am Coll Cardiol* 2004:43(5A);503A.
25. O’Neal RG, **Sperling LS**, Franklin BA, Salmon RD, Faircloth GC, Mitchell BS, Levinrad I, Gordon NF. Effectiveness of a tobacco cessation intervention, administered as a component of a comprehensive cardiovascular risk reduction program, in participants in different stages of readiness to quit smoking. *J of Cardiopulm Rehab* 2004;24(5):347.
26. Gordon NF, Salmon RD, Gordon TL, Bigggerstaff ED, Reid KS, Saxon WE, Faircloth GC, Levinrad I, Mitchell BS, Leighton RF, Verma A, **Sperling LS,** Hall LK, Bairey-Merz CN, Wenger NK, Franklin BA, Haskell WL. Clinical effectiveness of therapeutic lifestyle changes in pre-menopausal versus post-menopausal women. *Circulation* 2005;111:e65.
27. Gordon NF, Salmon RD, Levinrad I, Faircloth GC, Leighton RF, Berk MR, Hall LK, **Sperling LS**, Dafoe WA, Rubenfire M, Vogel D, Bairey Merz CN, Haskell WL, Franklin BA. Multicenter study of the clinical effectiveness of a contemporary cardiac rehabilitation program in elderly versus younger patients. *J Am Coll Cardiol* 2005;45(3A):187A.
28. Gordon NF, Salmon RF, Reid KS, Saxon WE, Faircloth GC, Levinrad I, Mitchell BS, Leighton RF, Verma A, Berk MR, **Sperling LS**, Haskell WL, Franklin BA. Clinical effectiveness of therapeutic lifestyle changes in African American versus Caucasians. *J Am Coll Cardiol* 2005;45(3A):422A.
29. Bavikati VV, **Sperling LS**, Salmon RD, Faircloth GC, Leighton RF, Franklin BA, Gordon NF. Clinical effectiveness of therapeutic lifestyle changes in patients with prehypertension (presented at national AACVPR meeting 10/06).
30. Bavikati VV, **Sperling LS**, Salmon RD, Faircloth GC, Gordon TL, Franklin BA, Gordon NF. Effect of gender and ethnicity on effectiveness of therapeutic lifestyle changes in patients with prehypertension. *J Am Coll Cardiol* 2007;49(9A):392A.
31. Jackson CF, Vaccarino V, Reid KJ, Grow P, Bavikati V, **Sperling LS**, et al. Association of cardiac rehabilitation and healthy lifestyle after acute myocardial infarction (presented at AHA Quality of Care and Outcomes Research in CV Disease and Stroke Conference 2007).
32. Georgiopoulou VV, Lindsay KL, Brown J, Hirsch B, **Sperling LS**. Metabolic abnormalities in adults with cystic fibrosis. *Chest* 2008;134(suppl).
33. Yehya A, Jacobs S, Mashman W, **Sperling LS**. Stress cardiomyopathy (Takotsubo) in a patient with presumptive Autoimmune Polyendocrine Synrome II. J Hosp Med. 2010;5(3) suppl 2.
34. Burroughs M, Patel D, Rodriguez D, Khan, **Sperling LS**. Comparing Coronary Artery Disease Risk Factors in Cubans and Cuban Americans. Presented at the Global Health Education Consotrium, April 2010, Cuernavaca, Mexico.
35. Bishop KL, Salmon R, Habib A, **Sperling L**, PinzonA, Rubenfire M, Reid K, Faircloth G, Wright B, Drimmer A, Franklin B, Gordon N. Effect of Cardiac Rehabilitation on Self-Reported Health Status in Patients Taking Antidepressants. Accepted to 2010 AACVPR meeting.
36. Habib A, Salmon R, Bishop KL, **Sperling L**, Pinzon A, Rubenfire M, Reid K, Faircloth G, Wright B, Drimmer A, Franklin B, Gordon N. Effect of Cardiac Rehabilitation on Coronary Heart Disease Risk Factors in Patients taking Antidepressants. Accepted to 2010 AACVPR meeting.
37. Chowdhury M, Abd T, Wirth D, **Sperling LS**. Incidence of bleeding events in patients on warfarin, aspirin, and/or clopidogrel in an anticoagulaiton clinic of a tertiary medical center. Presented at the 2010 AHA meeting
38. Bittner V, Bartolet M, Barraza R, Farkouh M, Goldberg S, Ramanathan K, Redmon J, **Sperling L**, Rutter M. Risk factor control in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI2D) Trial. presented at the 2010 AHA meeting
39. **Sperling L**. HIV, Inflammation, and Cardiovascular Disease, Global Antiviral Journal, 2010; 6(1):14-15.
40. Nieva RS, Safavynia SA, Bishop KL, **Sperling LS**. Use of omega-3 polyunsaturated fatty acids in patients enrolled in a cardiac rehabilitation program. (presented, AHA NPAM meeting, 3/11)
41. Nieva RS, Safavynia SA, Johnson C, Bishop KL, **Sperling LS**. Use of herbal supplements in patients enrolled in a cardiac rehabilitation program. (presented, ACC meeting, 4/11)
42. Achtchi A, Alvarez R, Nell C, Smiley W, **Sperling L**. Alternate day rosuvastatin dosing for statin intolerant patients. (presented, ACC meeting, 4/11)
43. Eapen D, Manocha P, Kassas I, **Sperling LS**, Quyyumi AA. Percent body fat is not an independent predictor of arterial stiffness in south asians unlike caucasians. (presented, ACC meeting 4/11)
44. Eapen D, **Sperling L**, Brigham K, Quyyumi A. Midaxillary subcutaneous fat is the best independent predictor of arterial stiffness in black woman as opposed to abdominal fat in white woman. (presented,Arteriosclerosis, Thombosis, and Vascular Biology, 2011)
45. Bittner V, Bertolet M, Farkouh M, Howard N, Lu J, **Sperling L**, Rutter M. Comprehensive risk factor control improves survival: The Bypass Angioplasty Revascularization Investigation 2 Diabetes. (accepted for oral presentation, AHA 11/11)
46. Eapen DJ, Manocha P, Patel R, Nanjundappa R, Veledar E, Wassel C, Voland J, Malayter D, Kassas I, Alradawi S, Kelli H, Poole J, Neuman R, **Sperling L**, Quyyumi A, Epstein S. Aggregate risk score based on markers of inflammation, immunity, and thrombosis is an independent predictor of adverse cardiovascular outcomes. (accepted for presentation AHA 11/11)
47. Manocha P, Nanjundappa RA, Eapen DJ, Kassas I, Sher S, Liu YX, Ahmed A, Kodura S, Raddawi S, **Sperling L**, Quyyumi A. Triglcerides are independently associated with diabetes among south asian females in the U.S. (presented at the World Congress of Heart Diseases, 7/11)
48. Ramjee V, Le A, **Sperling L**. Inflammatory and Lipid Markers pre- and post-LDL apheresis in patients with familial hypercholesterolemia (The INFLAME Study). (accepted for presentation, ACC 2012)
49. Ramjee V, Le A, **Sperling L**. The recovery of LDL after apheresis in patients with familial hypercholesterolemia: A need for more frequent treatment? (accepted for presentation, ACP 2012)
50. Corrigan F, Eapen D, Manocha P, Hammadah M, Al Kassem H, Vazquez J, Cunninghan L, Uphoff I, **Sperling L**, Alexander RW, Brigham K, Quyyumi A. Reduced bone mass predicts impaired arterial elasticity. (presented , ACC 2012)
51. Corrigan F, Eapen D, Moanocha M, Hammadah M, Kabbany MT, Vazquez J, Cunningham L, Uphoff I, **Sperling L**, Alexander RW, Brigham K, Quyyumi A. Body fat distribution as a predictor of arterial stiffness. (presented , ACC 2012)
52. Corrigan F, Eapen D, Manocha P, Hammadah M, Alradawi S, Vazquez J, Cunningham L, Uphoff I, **Sperling L**, Alexander RW, Brigham K, Quuyumi A. Low testosterone level is associated with impaired microvascular function in men. (presented , ACC 2012)
53. Eapen DJ, Manocha P, Patel R, Hammadah M, Kabbany MT, Veledar E, Wassel C, Alradawi S, Corrigan F, Al Kassem H, Nanjundappa R, Mantini N, Wilmot KA, Poole J, Neuman R, Malayter D, Sikora A, **Sperling L**, Quyyumi A, Epstein S. An aggregate of pathway-related biomarkers predict risk of acute myocardial infarction and death. (presented, ACC 2012)
54. Mantini NA, Eapen D, Corrigan F, Manocha P, Hammadah M, Vazquez J, Cunningham L, Uphoff I, **Sperling L**, Alexander RW, Brigham K, Quyyumi A. Obstructive sleep apnea is associated with increased severity of coronary artery disease and worse cardiovascular outcomes. (presented, ACC 2012)
55. Bhatia N, Patel A, Ramjee V, Epperson MF, Le NA, Vaughn L, Nell C, Baer J, Wilson PWF, **Sperling LS**. Cardiometabolic recovery kinetics post-apheresis in a model of accelerated atherosclerosis. (accepted for presentation, AHA BCVS meeting, 2012)
56. Parashar S, Spertus JA, Tang F, Bishop KL, Vaccarino V, Jackson CF, Boyden TF, **Sperling L**. Predictors of early and late enrollment in cardiac rehabilitation among those referred after acute myocardial infarction. (accepted for presentation, AHA meeting Nov. 2012)
57. Nanjundappa RPA, Eapen D, Kumar G, Manocha P, Patel R, Sher S, Al Kassem H, Hammadah M, Tahhan AS, Ghasemzadeh N, Farook N, Qadir MS, Emir V, **Sperling L**, Zafari AM, Samady H, Quyyumi AA. Mean platelet volume is an independent predictor of left ventricular systolic dysfunction and is associated with adverse cardiovascular outcomes. (accepted for presentation, AHA meeting Nov. 2012)
58. Corban MT, Eshtehardi P, Eapen DJ, Pankaj M, Al Kassem H, Le A, Pielak T, Thorball CW, **Sperling LS**, Quyyumi AA, Samady H. Elevated levels of soluble plasma urokinase plasminogen activator receptor is an independent predictor of coronary microvascular function. (accepted for presentation AHA 2012)
59. Corban MT, Eshtehardi P, Eapen DJ, Rasoul-Arzrumly E, Al Kassem H, Manocha P, Patel AD, Sikora S, **Sperling LS**, Quyyumi AA, Samady H. Elevated levels of fibrin degradation products are associated with intravascular ultrsound-defined features of plaque vulnerability in patients with coronary artery disease. (accepted for presentation, AHA 2012)
60. Corban MT, Eshtehardi P, Eapen DJ, Rasoul-Arzrumly E, Al Kassem H, Manocha P, Patel AD, Manocha P, Patel, AD, Sikora S, Mekonnen G, Hassanyar MR, **Sperling LS**, Quyyumi AA, Samady H. Elevated levels of fibrin degradation products is an independent predictor of intravascular ultrasound-defined features of plaque vulnerability in patients with coronary artery disease. (submitted for consideration, ACC 2013)
61. Ghasemzadeh N, Lam A, Reingold J, Margolis B, **Sperling LS**, Superko R. Potential use of coronary artery calcium scoring as a screening method for subclinical atherosclerosis in community firefighters. (submitted for consideration, ACC 2013)
62. Lam A, Ghasemzadeh N, Reingold J, Margolis B, **Sperling LS**, Superko R. Lack of association between Lipoprotein (a) with coronary artery calcium score in asymptomatic community firefighters. (submitted for consideration, ACC, 2013)
63. Weiss M, Eapen DJ, Veledar E, Kim J, Engberding N, BeDell P, Huey M, Williams BR, Lerakis S, **Sperling L**. Race and type of sport independently predict echocardiographic findings in Division I college athletes. (submitted for consideration, ACC, 2013)
64. Weiss M, Eapen DJ, Veledar E, Kim J, Engberding N, BeDell P, Huey M, Williams BR, Lerakis S, **Sperling L**. Prevalence of abnormal findings on preseason screening echocardiograms in NCAA Division I college athletes. (submitted for consideration, ACC, 2013)
65. Bhatia N, Ramjee V, Ghasemzadeh N, Guo Y, Li Q, Vaughn L, Nell C, Waller EE, Brigham K, Wilson PWF, Quyyumi A, Le NA, Sperling LS. Progenitor cell counts in familial hypercholesterolemic patients compared to healthy controls. (accepted for presentation, AHA BCVS, 2013)
66. Weiss M, Eapen DJ, Veledar E, Kim J, Engberding N, BeDell P, Huey M, Williams BR, Lerakis S, **Sperling L**. Race independently predicts echocardiographic findings in NCAA Division I College Athletes. (accepted for presentation, AHA, 2013)
67. Ghasemzadeh N, Al Kassem H, Eapen D, Khayata M, Tahhan As, Manocha P, Alzaraneh B, Nanjundappa R, Thorball CW, Patel R, Lerakis S, **Sperling L**, Pielak T, Sikora S, Epstein S, Quyyumi AA. A composite risk score of biomarkers of inflammation, thrombosis, and cell stress pathways significantly predicts risk of adverse cardiovascular events. (accepted for presentation, AHA,2013)
68. Khayata M, Ghasemzadeh N, Hritani A, Al Kassem H, Nguyen H, Eapen D, Alzaraneh B, Alanbari R, El-Khattabi M, Kaba AN, Manocha P, Patel R, Veledar A, Mavromatis K, **Sperling L**, Vaccarino V, Quyyumi AA. Prognostic Value of angina related health status in women with suspected coronary artery disease. (accepted for presentation, AHA, 2013).
69. Weiss M, Eapen DJ, Veledar E, Kim J, Engberding N, BeDell P, Huey M, Williams BR, Lerakis S, **Sperling L**. Type of sport independently predicts echocardiographic findings in NCAA Division I College Athletes. (accepted for presentation, 28th Annual AACVPR meeting, Nashville, TN 2013)
70. Kim JH, Gu D, Patton J, Binongo J, Shoop JL, Galante A, Williams BR, Quyyumi AA, **Sperling L** . Cardiac remodeling and Hypertension in elite NCAA Division I-American-style football players. (accepted for presentation, Georgia ACC meeting, 2013)
71. Patel S, Ghasemzadeh N, Patel R, Li Q, Eapen D, Khayata M, Malekzadegan M, Smith G, Barde R, Awad M, Reddy S, **Sperling L**, Waller E, Quyyumi A. Circulating progenitor cell levels are higher in patients with ST-segment elevation MI compared to other ACS presentations. (presented at 63rd ACC meeting, Washington, D.C., 2014)
72. Ghasemzadeh N, Kim J, Eapen D, Al Kassem H, Manocha P, Khayata M, Arafat D, Patel R, Kumar S, **Sperling L**, Gibson G, Quyyumi A. A distinct peripheral blood gene expression profile is associated with acute MI and predicts risk of cardiovascular death. (presented at 63rd ACC meeting, Washington, D.C., 2014)
73. Ghasemzadeh N, De Staercke C, Li Q, Eapen D, Khayata M, Malekzadegan M, Smith G, Alzaranah B, Mekonnen G, Alanbari R, **Sperling L**, Hooper C, Waller EK, Quyyumi A. Stromal cell-derived factor-1 and circulating progenitor cell levels as predictors of adverse cardiovascular outcomes in patients with coronary artery disease. (presented at 63rd ACC meeting, Washington, D.C., 2014)
74. Kim J, Al Mheid I, Malekzadegan M, Sher S, Shoop J, Galanter A, Williams B, **Sperling L**, Weinter R, Baggish A, Quyyumi A. Arterial stiffness in NCAA Division I American-style football players. (presented at 63rd ACC meeting, Washington, D.C., 2014)
75. Ghasemzadeh N, Brooks M, Vlachos H, Sikora S, **Sperling L**, Quyyumi AA, Epstein SE. A validated, modifiable, and actionable pathway-specific aggregate biomarker risk score predicts risk of CV outcomes in patients with CAD: Findings form the BARI-2D Trial. (accepted for oral presentation, AHA 2014, Chicago)
76. Shen J, Morris A, Bidulescu A, Dunbar S, Vaccarino V**, Sperling L**, Gibbons G, Quyyumi A. Associations between neighborhood characteristics and inflammation: The Morehouse and Emory Team up to Eliminate Health Disparities (META-Health) Study. (accepted for presentation, AHA 2014, Chicago)
77. Flueckiger P, Juraschek SP, Eades M, Khera A, Blaha M, **Sperling L**. Internal Medicine Housestaff perceptions of statins and ACC/ AHA Blood Cholesterol Guidelines. (accepted for presentation, AHA 2014, Chicago)
78. Kim JH, Sher S, Wang F, Berkstresser B, Shoop JL, Galante A, Al Mheid I, Ghasemzadeh N, Hutter AM, Williams BR, **Sperling L**, Weinter RB, Quyyumi AA, Baggish Al. The Impact of American-style Football Participation on Vascular Function. Presented at the Sports Summit, Indianapolis, IN, 2014
79. Shen J, Morris A, Hosny K, Vaccarino V**, Sperling L**, Gibbons G, Quyyumi A. Obesity affects circulating CD34+ cell number via the leptin pathway. (accepted for presentation, Europrevent 2015, Lisbon, Portugal).
80. Sandesara P, Lambert C, Knapper J, Wilson P, **Sperling L**. Familial Hypercholesterolemia: Hidden in Plain Sight- An algorithm for closing the gaps in the diagnosis and treatment. (under consideration for International Academy of Cardiology Annual Scientific Sessions 2015, Vancouver, Canada).
81. Shen J, Morris A, Al Mheid I, Vaccarino V, **Sperling L**, Gibbons G, Quyyumi A. Prediction of racial differences in subclinical vascular disease in African Americans and whites: Comparison of the Framingham and Atherosclerotic Risk scores (accepted for presentation at ACC 2015, San Diego)
82. Mahlof E, Koren M, Emery M, Doshi S, Liu T, Somaratne R, Wasserman S, **Sperling L**. Relationship of body weight and dosing of Evolocumab (EVO) for the treatment of hypercholesterolemia (accepted to ESC meeting 2015, London, England)
83. Sandesara PB, Eapen DJ, **Sperling L**, Salmon RD, Gordon NF. Multi-Center Study of ASCVD Risk Factor Status on entry to a Contemporary Phase 2 Cardiac Rehabilitation Program: Temporal Trends (accepted for presentation, AHA 2015)
84. Sandesara P, Lambert C, **Sperling L**. Estimated prevalence of Familial Hypercholesterolemia in the United States: Data from the NHANES Study. (accepted for presentation at the Annual ASPC meeting, Boca Raton, FL, 2015)
85. Schultz WM, Gordon N, Salmon R, Eapen DJ, **Sperling LS**. Statins do not attenuate improvements in fasting plasma glucose and multiple CHD risk factors during exercise-based cardiac rehabilitation (accepted for presentation at ACC 2016, Chicago)
86. Kelli HM, Awad M, Hammadah M, Haider M, Ahmed H, Topel M, Hayek S, Patel K, Gray B, Mohammed K, Pemu P, Lewis T, Dunbar S, **Sperling L**, Vaccarino V, Gibbons G, Quyyumi A. Education level is associated with cardiovascular risk factors, systemic inflammation, arterial stiffness and oxidative stress . (accepted for presentation at ACC 2016, Chicago)
87. Kelli HM, Ahmed H, Hammadah M, Topel M, Hayek S, Awad M, Patel K, Gray B, Mohammed K, Ko YA, **Sperling L**, Lewis TT, Martin G, Gibbons G, Quyyumi A. The association of living in food deserts with cardiovascular risk factors and subclinical vascular disease. (accepted for presentation at ACC 2016, Chicago)
88. Kelli HM, Haider MN, Hammadah M, Awad M, Dunbar S, Lewis T, **Sperling L**, Vaccarino V, Gibbons G, Quyyumi AA. Lower income is associated with cardiovascular risk factors, systemic inflammation, arterial stiffness and oxidative stress. (accepted for presentation at the World Congress of Cardiology 2016, Mexico City, Mexico)
89. Kim JH, Ko YA, Hedley J, MacNamara J, Awad M, Taylor W, Healy S, Aida H, Le NA, Wilson PW, White M, **Sperling L**, Wilson JS, Baggish AL.. The impact of age and completion of a moderate distance running race on cardiac function: results from the PEACH (Profiling the Effects of Aging on Exercise-induced Changes in cardiac mechanics) study. (accepted for presentation at ACC 2016, Chicago)
90. Arnold SV, Inzucchi SE, McGuire DK, **Sperling LS,** Wong ND, Kosiborod M. Quality of care in the initial patient cohort of the Diabetes Collaborative Registry. (submitted for consideration, ADA meeting 2016)
91. Arnold SV, Inzucchi SE, McGuire DK, **Sperling LS**, Wong ND, Kosiborod M. Baseline characteristics of the Diabetes Collaborative Registry. (submitted for consideration , ADA meeting 2016).
92. Arnold SV, Inzucchi SE, Maddox TM, Tang F, McGuire DK, Mehta SN, Goyal A, **Sperling LS**, Einhorn D, Wong ND, Kosiborod M. Defining the potential “real world” impact of EMPA-REG Outcomes trial on improving cardiovascular outcomes of patients in the Diabetes Collaborative Registry (DCR). (submitted for consideration to 2016 EASD meeting).
93. Kosiborod M, Arnold SV, McGuire DK, Tang F, Mehta SN, Goyal A, **Sperling LS**, Maddox TM, Einhorn D, Wong ND, Hammar N, Fenici P, Sheehan JJ, Inzucchi SE. Personalization of glycemic management among patients in the Diabetes Collaborative Registry (DCR). (submitted for consideration to 2016 EASD meeting).
94. Emmons A, Flueckiger P, **Sperling L**. Patient perceptions of the risks / benefits of statins. (submitted for consideration, AHA 2016)
95. Kelli HM, Corrigan FE, Heinl RE, Dhindsa DS, Hammadah M, Al Mheid I, Awad M, Patel K, Mohammed K, Gray B, Hayek SS, Ko YA, Vaccarino V, Ziegler TR, Alexander W, **Sperling LS**, Brigham K, Martin GS, Quyyumi. Body fat distribution is associated with oxidative stress. (submitted for consideration, AHA 2016)
96. Kelli HM, Hammadah M, Hayek SS, Awad M, Corrigan FE, Heinl RE, Dhindsa Ds, Patel K, Mohammed K, Gray B, Ko YA, Vaccarino V, **Sperling LS**, Quyyumi. Neighborhood income rather than food access is associated with adverse cardiovascular outcomes in food deserts. (submitted for consideration, AHA 2016)
97. Arnold SV, Inzucchi SE, McGuire DK, Tang F, Mehta SN, Goyal A, **Sperling LS**, Maddox TM, Einhorn D, Wong ND, Hammar N, Fenici P, Sheehan JS, Kosiborod M. Assessing the personalization of glycemic management strategies through the Diabetes Collaborative Registry (DCR). (submitted for consideration, AHA 2016)
98. Gradidge P, Constaninou D, Salmon R, Schultz W, **Sperling L**, Franklin B, Gordon N. Gender differences in improvements in multiple cardiovascular disease risk factors during exercise-based cardiac rehabilitation in patients receiving statin therapy. ( submitted for consideration, AHA 2016)
99. Kelli HM, Corrigan FE, Heinl RE, Dhindsa DS, Hammadah M, Tahhan AS, Sandesara P, Alghamdi T, Al Meid I, Ko Y, Ziegler T, **Sperling LS**, Brigham K, Jones D, Vaccarino V, Martin GS, Quyyumi AA. Changes in body fat distribution is associated with oxidative stress. (accepted for presentation, ACC 2017)
100. Tahhan AS, Sandesara P, Kelli HM, Allard-Ratick M, Kindya B, Hammadah M, Topel M, Almuwaqqat Z, Stahl E, Heinl R, Hesaroieh I, Naqui H, Mahar E, Waller EK, Vaccarino V, Ziegler TR, **Sperling LS**, Brigham K, Martin GS, Quyyumi AA. Association between progenitor cells and vascular function. (accepted for presentation, ACC 2017)
101. Almuwaqqat Z, Tahhan As, Sandesara PB, Stahl E, Heinl R, Hayek SS, Kelli HM, Hammadah M, Topel M, Alkhoder A, Gafeer MM, Chivukula K, Aida H, Allard-Ratick M, Kindya B, Abdelhadi N, Hesaroieth I, Mahar E, Waller EK, **Sperling L**, Quyyumi A. Circulating progenitor cell levels and outcomes in acute myocardial infarction. (accepted for presentation, ACC 2017)
102. Khambhati J, Sandesara P, Tahhan AS, Topel M, Corrigan F, Kelli HM, Stahl E, Allard-ratick M, Alkhoder A, Aida H, Gafeer MM, Hesaroieh I, Mahar E, Waller E, Vaccarino V, Zeigler TR, **Sperling L**, Brigham K, Martin G, Quyyumi A. Central obesity predicts circulating progenitor cell levels. (accepted for presentation, ACC 2017)
103. Sandesara P, Tahhan AS, Khambhati J, Stahl E, Hayek S, Hammadah M, Kelli HM, Topel M, Alkhoder A, Chivkuka K, Aida H, Gafeer MM, Abdelhadi N, Hesaroieh I, Naqui H, Mahar E, Waller E, **Sperling L**, Quyyumi A. Association between circulating progenitor cells and outcomes in patients with coronary artery disease. (accepted for presentation, ACC 2017)
104. Shin E, Ochuko P, Bhatt K, Howard B, McGorisk G, Delaney L, Langdon K, Khosravanipour M, Nambi AA, Grahovec A, Morris DC, **Sperling LS**, Shaw LJ, Castellano PZ, Goyal A. Electronic health record-based overestimation of failure to prescribe statins in patients with coronary artery disease in a large academic multispecialty clinic practice. (accepted for oral presentation, AHA QCOR 2017)
105. Arnold S, Inzucchi S, Tang F, McGuire D, Mehta SN, Goyal A, Maddox T, **Sperling L**, Einhorn D, Wong N, Kosiborod M. Using the Diabetes Collaborative Registry to Estimate the potential real-world impact of the LEADER trial on improving CV Outcomes in patients with Diabetes at High CV Risk. (accepted for presentation, ACC 2017)
106. Sandesara P, Tahhan AS, Hajjari J, Khambhati J, Lee S, Hayek S, Hammadah M, Mohammad-Kelli H, Topel M, Alkhoder A, Chivukula K, Aida H, Gafeer M, **Sperling L**, Quyyumi A. Association between peripheral artery disease and measures of oxidative stress. (accepted for presentation, ESC 2017)
107. Lee S, Khambhati J, Sandesara P, O’Neal W, Tahhan S, Hayek S, Hammadah M, Mohammad-Kelli M, Topel M, Alkhodar A, Aida H, Chivukupa K, **Sperling L**, Quyyumi A. High-sensitivity troponin I predicts the risk of adverse outcomes in patients with chronic kidney disease. (accepted for presentation, ESC 2017)
108. Sandesara P, Tahhan AS, Khambhati J, Lee S, ,Hayek S, Hammadah M, Mohammad-Kelli H, Topel M, Alkhoder A, Aida H, Hesaroieh I, Mahar E, Waller E, **Sperling L**, Quyyumi A. Association between progenitor cells and measures of vascular function. (accepted for presentation, ESC 2017)
109. Sandesara P, Tahhan AS, Ko Y, Hayek S, Khambhati J, Lee S, Alkhoder A, Aida H, **Sperling L**, Quyyumi A. Using a decision tree analysis to risk stratify patients with coronary artery disease. (accepted for presentation, ESC 2017)
110. Sandesara PB, O’Neal WT, **Sperling LS**. Diastolic blood pressure and adverse outcomes in patients with Heart Failure with Preserved Ejectin Fraction: An Analysis from Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist Trial (TOPCAT), (submitted for consideration, ASPC Congress 2017)
111. Wong ND, Song Y, Arnold S, **Sperling L**, Cannon C, Inzucchi S, Kosiborod M. Composite Cardiovascular Risk Factor Target Achievement and its Indictors in US Adults with Diabetes; The Diabetes Collaborative Registry (accepted for presentation, ADA meeting 2018)
112. **Sperling L**, Raevschi E. Status of Cardiovascular Health in the Republic of **Moldova**. (submitted for consideration to CDC BRFSS Conference)
113. Sandesara P, O’Neal W, Kelli HM, Sathiyakumar V, MartinS, Blaha M, Blumenthal R, **Sperling L**. Prevalence of CV risk factors and prognostic significance of coronary artery calcium in individuals with LDL-C > 190 mg/dL: The MESA Study (presented at ACC 2018)
114. Arnold S, Seman L, Tang F, McGuire D, Mehta S, Goyal A, **Sperling L**, Kosiborod M. Real world opportunity of empagliflozin in CV risk factor modification: An NCDR Research to Practice project from the Diabetes Collaborative Registry. (presented at ACC 2018)
115. Sabbak N, Albadri A, Tahhan AS, Sandesara P, Alkhoder A, Hayek S, Kelli HM, Gafeer MM, Abdelhadi N, Kaseer B, Ko YA, Patel K, Choudhary F, Kumar S, Hajjari J, Patel A, Choudary M, Hasnain L, Enigneer V, Qadir S, Sidoti A**, Sperling L**, Mehta P, Quyyumi A. Circulating Urokinase Plasminogen Activator Receptor levels predict mortality in subjects with obstructive coronary artery disease. (presented at ACC 2018)
116. Glovaci D, Bluemke DA, Budhoff M, **Sperling L**, Gaita D, Chaffin MM, Trejo ME, Allison M, Wong N. Metabolically healthy and unhealthy obesity and changes in LV mass, volume, and function by cardiac MRI: Results from the MESA study (presented at ACC 2018)
117. Hajjari J, Tahhan AS, Alkhoder A, Kaseer B, NaserA, Almuwaqqat Z, Gafeer MM, Choudhary F, Patel K, Patel A, Jafri M, Choudhary M, Hasnain L, Qadir S, Sidoti A, Lankford A, Bhimani R, Ko YA, Vaccarino V, **Sperling L**, Jones D, Quyyumi A. Markers of Oxidative stress and peripheral artery disease (presented at ACC 2018).
118. Kelli HM, Liu C, Samman-Tahhan A, Alghamdi T, Ko YA, Choudhary F, Engineer V, Hammadah M, Sandesara P, Al Mheid I, O’Neal W, Vaccarino V, Ziegler T, **Sperling L**, Lampl M, Brigham K, Martin G, Quyyumi A. Ideal Cardiovascular Health Score and Oxidative Stress. (presented at AHA Epi/ Lifestyle , 2018 New Orleans)
119. Allard-Ratick MP, Khambhati J, Topel M, Sandesara PB, **Sperling LS**, Quyyumi AA. Elevated HDL-C is associated with Adverse Cardiovascular Outcomes (accepted for oral presentation, ESC 2018, Munich, Germany)
120. Mehta A, Pandey A, Ayers CR, Khera A, **Sperling L**, Szklo M, Gottesman R, Nasir K, Budoff MJ, Blaha MJ, Blumenthal RS, Joshi PH. Predictive Value of Coronary Artery Calcium for Coronary Events versus Strokes. (submitted to Northwestern CV Young Investigator Forum (NCYIF) for consideration)
121. Mehta A, Pandey A, Ayers CR, Khera A, **Sperling L,** Szklo M, Gottesman R, Nasir K, Budoff MJ, Blaha MJ, Blumenthal RS, Joshi PH. Impact of Gender and Ethnicity on the Predictive Value of Coronary Artery Calcium for Coronary Events vs. Strokes. (submitted for consideration, ACC Young Investigator Competition, 2018)
122. Mehta A, Pandey A, Ayers CR, Khera A, **Sperling L,** Szklo M, Gottesman R, Nasir K, Budoff MJ, Blaha MJ, Blumenthal RS, Joshi PH. Impact of Gender and Ethnicity on the Predictive Value of Coronary Artery Calcium for Coronary Events vs. Strokes. (submitted for consideration, AHA Epi meeting, 2019)
123. Mehta A, Liu C, Dhindsa DS, Ko YA, Kim JH, Sandesara PB, Tahhan AS, Topel ML, Kelli HM, Moazzami K, Bakhtadze B, Alkhoder A, Martin S, **Sperling LS,** Reiser J, Hayek SS, Quyyumi AA. Sex-differences in circulating Soluble Urokinase-type Plasminogen Activator Receptor (suPAR) levels and its impacto on the Prognostic Value of suPAR among Patients with Coronary Artery Disease. (accepted for presentation at ACC 2019, New Orleans, LA)
124. Dhindsa D, Sandesara P, Mehta A, Topel M, Allrad-Ratick M, O’Neal W, Khambhati J, Bakthadze B, Tahhan AS, Hayek S, **Sperling LS**, Quyyumi A. Association of High HDl in Patients with CAD: Impact of Race and Sex (accepted for presentation at ACC 2019, New Orleans, LA)
125. Madan N, Sohal S, Parapid B, **Sperling L,** Januzzi JL, Lalic K, Lundberg G, Butler J, Kosiborod M, Volgman AS. Sex-based differences in cardioprotective effects of SGLT-2 inhibitors in patients with T2DM. ( accepted for presentation at ESC 2019)
126. Volgman A, Madan N, Sohal S, **Sperling L**, Dembowski E, Lundberg G, Parapid B, Lalic K. SGLT2i Demonstrate Reduction in MACE and HF Admissions- An Up-to-Date Meta-analysis. (submitted for consideration to ESC 2019)
127. Dhindsa D, Sandesara PB, Liu C, Topel M, Mehta A, Allard-Ratick M**, Sperling L**, Quyyumi. HDL-C and All-cause mortality in a high-risk population: Impact of LDL-C. (presented at ESC meeting, Paris, France, 2019)
128. Mehta A, Ayers C, Blaha M, Blumenthal R, Hooda A, Khera A, Patel J, **Sperling LS**, Tsai M, Virani S, Shapiro MD, Vasquez N, Joshi P. Lp(a) and Coronary Artery Calcium Score Independently Predict CVD Risk in the MESA and Dallas Heart Study. (accepted for presentation, ACC 2020)
129. Patel J, Mehta A, Al Rafai M, Blaha MJ, Nasir K, McEvoy JW, Pandey A, Kanaya A, Kandula N, Virani S, Abbate A, Hundley WG, **Sperling L**, Joshi PH. Hypertension Guidelines and Coronary Artery Calcification among S. Asians: Mediators of Atherosclerosis in S. Asians Living in America (MASALA) and MESA. (accepted for presentation, ACC 2020)
130. Brown M, Mehta A, **Sperling L**. Skinny Fat: Metabolic Disease without the Metabolic Phenotype. (accepted for presentation, ACC 2020)
131. Knijnik LM, Fernandes M, Rivera M, Blumer V, Cardoso R, Goyal A, McDaniel M, Lieberman H, **Sperling L**, Cohen M. Antiplatelet Duration Strategies after PCI with Stenting: systematic Review and Meta-Analysis. (accepted for presentation, ACC 2020, JACC 2020;75(11)).
132. Ritchey MD, Maresh S, Jackson SL, McNeely J, Shaffer T, Keteyian SJ, Brawner CA, Whooley M, Stolp H, Wall HK, **Sperling LS**. Monitoring cardiac rehabilitation participation among eligible Medicare fee-for-service beneficiaries to track progress of a National Initiative, 2016-2018. (submitted for consideration, Academy Health Annual Research meeting and CMS Quality conference, 2020)
133. Mehta A, Meng Q, Desai S, D’Souza MS, Ho AH, Islam SJ, Dhindsa DS, Nayak A, Alkhoder AA, Hooda A, Varughese A, Ahmad SF, Mokhtari A, Hesaroieh I, **Sperling LS**, Ko YA, Waller EK, Quyyumi AA. Vascular Regenerative Capacity: A Window Into the Pathobiology of Obesity Paradox. (submitted for consideration, AHA 2020)
134. Okunrintemi V, Tibuakuu M, Virani SS, **Sperling LS**, Volgman AS, Gulati M, Cho L, Leuker TM, Blumenthal RS, Michos ED. Sex Differneces in the Age of Diagnosis of Cardiovascular Disease and Risk Factors Among U.S> Adults: Trends from 2017-2018: The Medical Expenditure Panel Survey (MEPS). (accepted for presentation, AHA 2020)
135. Ahmad MI, Mehta A, Almuuaqquat Z, Vatsa N, Schwartz A, Islam SJ, Dhindsa D, Nayak A, Rogers S, Shah S, Alkhoder A, Liu C, ko YA, **Sperling L**, Quyyumi A. Association of B-type Natriuretic Peptide Levels with Obesity Paradox in Patients with Coronary artery Disease. (submitted for consideration, AHA 2020)
136. Park S, Hong Y, Gillespie C, Merritt R, **Sperling L**. Temporal trends in non-invasive diagnostic tests for ischemic heart disease among U.S. adults, age 64 years or younger: results from the Marketscan Survey, 2010-2018. ( accepted for presentation, AHA 2020)
137. Hong Y, Park S, **Sperling L**, Gillespie C, Merritt R. Temporal trends in non-invasive diagnostic tests for ischemic heart disease among Medicare beneficiaries in the U.S., 2010-2017. (accepted for presentation, AHA 2020).
138. Knijnik LM, Maza MR, Fernandes M, Cardoso R, Goyal A, McDaniel M, Liberman H, **Sperling L**, Cohen M. Dual Antiplatelet Therapy for 1 to 3 Months is Superior to 12 Months After Coronary Stenting (submitted for consideration, ACC 2021)
139. Yadalam A, Almuwaqqat Z, Desai S, Beydoun N, Alkhoder A, Alras Z, Ko YA, Lewis T, Kim J, Shah A, **Sperling L**, Quyyumi A. Living in Socially Vulnerable Neighborhoods Predicts Future Cardiovascular Events in Patients with Coronary Artery Disease. Accepted for presentation, ACC, 2022.
140. Razavi A, Iftekhar Uddin SM, Dardari Z, Berman D, Budoff MJ, Miedema MD, Osei A, Obisesan AO, Nasir K, Rozanski A, Rumberger JA, Shaw LJ, **Sperling LS**, Whelton SP, Mortensen MB, Blaha M, Dzaye O. Coronary Artery Calcium for Risk Stratification of Sudden Cardiac Death: The Coronary Artery Calcium Consortium. accepted for presentation, ACC, 2022
141. Mehta A, Ahmad SF, Meng Q, Ho AH, Zuniga JV, Desai DR, Dindsa DS, Islam SJ, Almuwaqqat Z, Nayak A, Hooda A, Mokhtari A, **Sperling LS**, Ko YA, Waller EK, Quyyumi AA. Circulating Progenitor Cell Count: An Independent Biomarker of Adverse Outcomes in Coronary Artery Disease. accepted for presentation, ACC, 2022
142. Sekkarie A, Park S, Therrien N, Jackson S, Woodruff R, Attipoe-Dorcoo S, Yang P, **Sperling L**, Loustalot F, Thompson-Paul A. Trends of Lipid-Lowering Prescriptions by Statin Intensity-United States, Q3 2015-Q32021. Presented at the CDC EIS Conference, Chronic Disease and Emergency Preparedness Session, 2022.
143. Joy J, Haumschild R, **Sperling L**, Isiadinso I. Implementation of Specialty Clinical Pharmacist in a Preventive Cardiology Clinic. Accepted for presentation, American Society for Preventive Cardiology meeting, 2022).
144. Ford ND, DeSisto CL, Galang R, Kuklina E, **Sperling L**. Ko JY. Cardiac Arrest during Delivery Hospitalizations and Severe Hypertensive Disorders of Pregnancy, United States, 2017-2019. (accepted for presentation,AHA Hypertension meeting, 2022).
145. Razavi AC, Van Assen M, De Cecco CN, Dardari ZA, Berman DS, Budoff MJ, Miedema MD, Nasir K, Rozanaki A, Rumberger JA, Shaw LJ, **Sperling LS**, Whelton SP, Mortensen MB, Blaha MJ, Dzaye O. Discordance between Coronary Artery Calcium Area and Density Predicts Long-term Atherosclerotic Cardiovascular Disease Risk. (accepted for YIA presentation at SCCT meeting, 2022
146. Al-Kindi S, Motairek I, Nasir K, **Sperling L**, Farkouh M, Wright J, Dobre M, Rahman M, Rajagopalan S. Historical Neighborhood Redlining and Cardiovascular Risk in Patients with Chronic Kidney Disease: Results from Chronic Renal Insufficiency Cohort. (submitted to AHA 2022 for consideration)
147. Sekkarie A, Park S, Therrien NL, Jackson SL, Woodruff RC, Attipoe-Dorcoo S, Yang P, **Sperling L**, Loustalot F, Thompson-Paul AM. Trends in Lipid –Lowering Prescriptions by Statin Intensity- United States, 2017-2022. (submitted to AHA 2022 for consideration)
148. Cheung B, Block RC, Wong N, Eapen D, **Sperling LS**, McIntosh S. Accelerating the Diagnosis of Familial Hypercholesterolemia: A Mixed-methods Analysis of Patient-Physician Communication Needs. Accepted for presentation, AHA 2022
149. Varghese MS, Beatty A, **Sperling LS**, Fonarow GC, Keteyian SJ, McConeghy KW, Penko J, Song Y, Yeh R, Figueroa JF, Wu WC, Xu J, Kazi DS. Cardiac Rehabilitation and COVID-19: Nationwide Decline in Access and Participation Among Medicare Beneficiaries. (submitted to AHA 2022 for consideration)
150. Woodruff Rc, Campbell Ap, Loustalot F, Oster M, **Sperling L**, Taylor CA, Whitaker M, Havers FP, for the COVID-19 Associated Hospital Surveillance Network team (COVID-NET) Myocarditis during COVID-19 Associated Hospitalizations-14 US States, March 2020-May 2022. (submitted to AHA for consideration as LBCT, 2022)